Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi, … , Zahra Shahrokh, Ralph H. Schwall
Avi Ashkenazi, … , Zahra Shahrokh, Ralph H. Schwall
Published July 15, 1999
Citation Information: J Clin Invest. 1999;104(2):155-162. https://doi.org/10.1172/JCI6926.
View: Text | PDF
Article Article has an altmetric score of 12

Safety and antitumor activity of recombinant soluble Apo2 ligand

  • Text
  • PDF
Abstract

TNF and Fas ligand induce apoptosis in tumor cells; however, their severe toxicity toward normal tissues hampers their application to cancer therapy. Apo2 ligand (Apo2L, or TRAIL) is a related molecule that triggers tumor cell apoptosis. Apo2L mRNA is expressed in many tissues, suggesting that the ligand may be nontoxic to normal cells. To investigate Apo2L’s therapeutic potential, we generated in bacteria a potently active soluble version of the native human protein. Several normal cell types were resistant in vitro to apoptosis induction by Apo2L. Repeated intravenous injections of Apo2L in nonhuman primates did not cause detectable toxicity to tissues and organs examined. Apo2L exerted cytostatic or cytotoxic effects in vitro on 32 of 39 cell lines from colon, lung, breast, kidney, brain, and skin cancer. Treatment of athymic mice with Apo2L shortly after tumor xenograft injection markedly reduced tumor incidence. Apo2L treatment of mice bearing solid tumors induced tumor cell apoptosis, suppressed tumor progression, and improved survival. Apo2L cooperated synergistically with the chemotherapeutic drugs 5-fluorouracil or CPT-11, causing substantial tumor regression or complete tumor ablation. Thus, Apo2L may have potent anticancer activity without significant toxicity toward normal tissues.

Authors

Avi Ashkenazi, Roger C. Pai, Sharon Fong, Susan Leung, David A. Lawrence, Scot A. Marsters, Christine Blackie, Ling Chang, Amy E. McMurtrey, Andrea Hebert, Laura DeForge, Iphigenia L. Koumenis, Derf Lewis, Louise Harris, Jeanine Bussiere, Hartmut Koeppen, Zahra Shahrokh, Ralph H. Schwall

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 Total
Citations: 3 19 20 24 46 40 50 48 64 67 70 59 87 67 87 91 111 97 90 101 101 83 109 72 68 44 2 1 1721
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (1721)

Title and authors Publication Year
Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
Kawakatsu R, Tadagaki K, Yamasaki K, Kuwahara Y, Yoshida T
Diseases 2025
Advances in the study of death receptor 5
Qiao X, Guo S, Meng Z, Gan H, Wu Z, Sun Y, Liu S, Dou G, Gu R
Frontiers in Pharmacology 2025
Anticancer Mechanisms of Ginsenoside Compound K: A Review
Lee YP, Chan HT, Li TH, Chu L(, Lee SL, Chang YQ, Wang RY
Diseases 2025
Tumor-tropic Trojan horses: Using mesenchymal stem cells as cellular nanotheranostics
Rosu A, Ghaemi B, Bulte JW, Shakeri-Zadeh A
Theranostics 2024
Interferon-β Overexpression in Adipose Tissue-Derived Stem Cells Induces HepG2 and Macrophage Cell Death in Liver Tumor Organoids via Induction of TNF-Related Apoptosis-Inducing Ligand Expression
Yoon Y, Kim CW, Kim MY, Baik SK, Jung PY, Eom YW
International journal of molecular sciences 2024
Death-associated protein 3 in cancer—discrepant roles of DAP3 in tumours and molecular mechanisms
Song H, Liu H, Wang X, Yang Y, Zhao X, Jiang WG, Sui L, Song X
Frontiers in Oncology 2024
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Kawakatsu R, Tadagaki K, Yamasaki K, Yoshida T
Scientific Reports 2024
Strophanthidin Induces Apoptosis of Human Lung Adenocarcinoma Cells by Promoting TRAIL-DR5 Signaling
Tian X, Gu L, Zeng F, Liu X, Zhou Y, Dou Y, Han J, Zhao Y, Zhang Y, Luo Q, Wang F
Molecules (Basel, Switzerland) 2024
Heparan sulfate promotes TRAIL-induced tumor cell apoptosis.
Luo Y, Hao H, Wang Z, Ong CY, Dutcher R, Xu Y, Liu J, Pedersen LC, Xu D
eLife 2024
TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling.
Guerrache A, Micheau O
Cells 2024
Bacteriophage-based particles carrying the TNF-related apoptosis-inducing ligand (TRAIL) gene for targeted delivery in hepatocellular carcinoma.
Sittiju P, Wudtiwai B, Chongchai A, Hajitou A, Kongtawelert P, Pothacharoen P, Suwan K
Nanoscale 2024
MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer.
Kim S, Lee KW, Yoo Y, Park SH, Lee JW, Jeon S, Illia S, Joshi P, Park HW, Lo HE, Seo J, Kim Y, Chang M, Lee TJ, Seo JB, Kim SH, Croce CM, Kim I, Suh SS, Jeon YJ
Animal Cells and Systems 2024
Spatial distribution of tumor-associated macrophages in an orthotopic prostate cancer mouse model.
Grayson KA, Greenlee JD, Himmel LE, Hapach LA, Reinhart-King CA, King MR
Pathology oncology research : POR 2024
Advances in the targeted theragnostics of osteomyelitis caused by Staphylococcus aureus.
Abdulrehman T, Qadri S, Haik Y, Sultan A, Skariah S, Kumar S, Mendoza Z, Yadav KK, Titus A, Khader S
Archives of Microbiology 2024
Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells
De Wilt L, Sobocki BK, Jansen G, Tabeian H, de Jong S, Peters GJ, Kruyt F
2024
The Role of TRAIL Signaling in Cancer: Searching for New Therapeutic Strategies
Luo C, He S, Shi F, Zhou J, Shang L
Biology 2024
Chemical synthetic approaches to mimic the TRAIL: promising cancer therapeutics.
Masum AA, Aoki S, Rahman MM, Hisamatsu Y
RSC medicinal chemistry 2024
Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma.
Grisendi G, Dall'Ora M, Casari G, Spattini G, Farshchian M, Melandri A, Masicale V, Lepore F, Banchelli F, Costantini RC, D'Esposito A, Chiavelli C, Spano C, Spallanzani A, Petrachi T, Veronesi E, Ferracin M, Roncarati R, Vinet J, Magistri P, Catellani B, Candini O, Marra C, Eccher A, Bonetti LR, Horwtiz EM, Di Benedetto F, Dominici M
Cell reports. Medicine 2024
E3 ubiquitin ligase gene BIRC3 modulates TNF-induced cell death pathways and promotes aberrant proliferation in rheumatoid arthritis fibroblast-like synoviocytes.
Meng Q, Wei K, Shan Y
Frontiers in immunology 2024
Tumor necrosis factor superfamily signaling: life and death in cancer
Ababneh O, Nishizaki D, Kato S, Kurzrock R
Cancer Metastasis Reviews 2024
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
Jung P, Glaser SP, Han J, Popa A, Pisarsky L, Feng N, Geyer A, Haderk F, Alpar D, Bristow C, Schmittner S, Traexler PE, Mahendra M, Poehn B, Gandhi P, Fiorelli R, Awate S, Budano N, Martin F, Albrecht C, Drobits-Handl B, Anand SS, Kasturirangan S, Trapani F, Schweifer N, Marszalek JR, Tontsch-Grunt U, Pearson M, Heffernan TP, Kraut N, Vellano CP, García-Martínez JM
mAbs 2024
Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication
Goldmacher VS, Gershteyn IM, Kovtun Y
Antibody Therapeutics 2024
Therapeutic targeting of TRAIL death receptors
Di Cristofano F, George A, Tajiknia V, Ghandali M, Wu L, Zhang Y, Srinivasan P, Strandberg J, Hahn M, Sanchez Sevilla Uruchurtu A, Seyhan AA, Carneiro BA, Zhou L, Huntington KE, El-Deiry WS
Biochemical Society Transactions 2023
Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding
Riera-Domingo C, Leite-Gomes E, Charatsidou I, Zhao P, Carrá G, Cappellesso F, Mourao L, De Schepper M, Liu D, Serneels J, Alameh MG, Shuvaev VV, Geukens T, Isnaldi E, Prenen H, Weissman D, Muzykantov VR, Soenen S, Desmedt C, Scheele CL, Sablina A, Di Matteo M, Martín-Pérez R, Mazzone M
Science Advances 2023
Enhancer Clusters Drive Type I Interferon-Induced TRAIL Overexpression in Cancer, and Its Intracellular Protein Accumulation Fails to Induce Apoptosis.
Di Benedetto C, Khan T, Serrano-Saenz S, Rodriguez-Lemus A, Klomsiri C, Beutel TM, Thach A, Walczak H, Betancur P
Cancers 2023
RNA-seq and Single-Cell Transcriptome Analyses of TRAIL Receptors Gene Expression in Human Osteosarcoma Cells and Tissues.
Feng W, Lin H, Rothzerg E, Song D, Zhao W, Ning T, Wei Q, Zhao J, Wood D, Liu Y, Xu J
Cancer informatics 2023
The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer
Pimentel JM, Zhou JY, Wu GS
Cancers 2023
Current approaches in enhancing TRAIL therapies in glioblastoma.
Thang M, Mellows C, Mercer-Smith A, Nguyen P, Hingtgen S
2023
TNF superfamily control of tissue remodeling and fibrosis
Steele H, Cheng J, Willicut A, Dell G, Breckenridge J, Culberson E, Ghastine A, Tardif V, Herro R
Frontiers in immunology 2023
Anti-tumor Effects of IL-1β Induced TRAIL-Expressing hUCMSCs on Embelin Treated Breast Cancer Cell Lines.
Teng JW, Hung E, Wu JM, Liang YH, Chiu YH, Tyan YS, Wang HS
Asian Pacific Journal of Cancer Prevention 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Subbiah V, Chawla SP, Conley AP, Wilky BA, Tolcher A, Lakhani NJ, Berz D, Andrianov V, Crago W, Holcomb M, Hussain A, Veldstra C, Kalabus J, O'Neill B, Senne L, Rowell E, Heidt AB, Willis KM, Eckelman BP
Clinical cancer research 2023
Dose-related immunomodulatory effects of recombinant TRAIL in the tumor immune microenvironment.
Wang X, Wang L, Liu W, Liu X, Jia X, Feng X, Li F, Zhu R, Yu J, Zhang H, Wu H, Wu J, Wang C, Yu B, Yu X
Journal of experimental & clinical cancer research : CR 2023
TRAIL and its receptors in cardiac diseases.
Grisanti LA
Frontiers in physiology 2023
Anti-Cancer Effect of Neural Stem Cells Transfected with Carboxylesterase and sTRAIL Genes in Animals with Brain Lesions of Lung Cancer.
Kim JH, Ahn JS, Lee DS, Hong SH, Lee HJ
Pharmaceuticals (Basel, Switzerland) 2023
IL-1β stimulated human umbilical cord mesenchymal stem cells ameliorate rheumatoid arthritis via inducing apoptosis of fibroblast-like synoviocytes.
Chiu YH, Liang YH, Hwang JJ, Wang HS
Scientific Reports 2023
Heparan sulfate promotes TRAIL-induced tumor cell apoptosis.
Luo Y, Hao H, Wang Z, Ong C, Dutcher R, Xu Y, Liu J, Pedersen LC, Xu D
bioRxiv : the preprint server for biology 2023
Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.
El Yousfi Y, Mora-Molina R, López-Rivas A, Yerbes R
Cells 2023
Generation of magnetic biohybrid microrobots based on MSC.sTRAIL for targeted stem cell delivery and treatment of cancer.
Gundersen RA, Chu T, Abolfathi K, Dogan SG, Blair PE, Nago N, Hamblin M, Brooke GN, Zwacka RM, Hoshiar AK, Mohr A
Cancer Nanotechnology 2023
Emerging role of mesenchymal stromal cells in gynecologic cancer therapy.
Song Y, Liu H, Pan S, Xiang X, Ye M, Zhu X
Stem Cell Research & Therapy 2023
The tumor suppressive effect and apoptotic mechanism of TRAIL gene-containing recombinant NDV in TRAIL-resistant colorectal cancer HT-29 cells and TRAIL-nonresistant HCT116 cells, with each cell bearing a mouse model.
Jung BK, An YH, Jang SH, Ryu G, Jung SB, Kim S, Kim CS, Jang H
Cancer Medicine 2023
Mathematical modeling predicts pathways to successful implementation of combination TRAIL-producing oncolytic virus and PAC-1 to treat granulosa cell tumors of the ovary.
Le Sauteur-Robitaille J, Crosley P, Hitt M, Jenner AL, Craig M
Cancer biology & therapy 2023
Autoinhibitory structure of preligand association state implicates a new strategy to attain effective DR5 receptor activation
Du G, Zhao L, Zheng Y, Belfetmi A, Cai T, Xu B, Heyninck K, Van Den Heede K, Buyse MA, Fontana P, Bowman M, Lin LL, Wu H, Chou JJ
Cell Research 2023
Construction and Validation of a Ferroptosis-Related Prognostic Signature for Melanoma Based on Single-Cell RNA Sequencing
Y Liu, Y Shou, R Zhu, Z Qiu, Q Zhang, J Xu
Frontiers in Cell and Developmental Biology 2022
Receptor Specificity Engineering of TNF Superfamily Ligands
F Suo, X Zhou, R Setroikromo, W Quax
Pharmaceutics 2022
Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A
Narayan S, Raza A, Mahmud I, Koo N, Garrett TJ, Law ME, Law BK, Sharma AK
iScience 2022
Recent Progress on Heparin–Protamine Particles for Biomedical Application
Hata Y, Miyazaki H, Ishihara M, Nakamura S
Polymers 2022
Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.
Moser R, Annis J, Nikolova O, Whatcott C, Gurley K, Mendez E, Moran-Jones K, Dorrell C, Sears RC, Kuo C, Han H, Biankin A, Grandori C, Von Hoff DD, Kemp CJ
Cancer research 2022
Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries.
Montinaro A, Walczak H
Cell Death and Differentiation 2022
Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist
A Soto-Gamez, Y Wang, X Zhou, L Seras, W Quax, M Demaria
Cancer Letters 2022
Kaempferol: A potential agent in the prevention of colorectal cancer
Nejabati HR, Roshangar L
Physiological Reports 2022
Limonoids From the Genus Melia (Meliaceae): Phytochemistry, Synthesis, Bioactivities, Pharmacokinetics, and Toxicology.
Fan W, Fan L, Wang Z, Yang L
Frontiers in pharmacology 2022
Identification of UAP1L1 as a critical factor for prostate cancer and underlying molecular mechanism in tumorigenicity.
Wu XC, Yu YZ, Zuo YZ, Song XL, Zhou ZE, Xiao Y, Luo DS, Yan WG, Zhao SC
Journal of Translational Medicine 2022
The Ongoing Journey of a Shigella Bioconjugate Vaccine.
Martin P, Alaimo C
Human vaccines 2022
Site-Specific Integration of TRAIL in iPSC-Derived Mesenchymal Stem Cells for Targeted Cancer Therapy.
Wang Z, Chen H, Wang P, Zhou M, Li G, Hu Z, Hu Q, Zhao J, Liu X, Wu L, Liang D
Stem Cells Translational Medicine 2022
Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity.
Yagolovich AV, Artykov AA, Isakova AA, Vorontsova YV, Dolgikh DA, Kirpichnikov MP, Gasparian ME
International journal of molecular sciences 2022
Proscillaridin A Sensitizes Human Colon Cancer Cells to TRAIL-Induced Cell Death.
Semba M, Takamatsu S, Komazawa-Sakon S, Miyoshi E, Nishiyama C, Nakano H, Moriwaki K
International journal of molecular sciences 2022
Role of phloretin as a sensitizer to TRAIL-induced apoptosis in colon cancer.
Kim JL, Lee DH, Pan CH, Park SJ, Oh SC, Lee SY
Oncology Letters 2022
Endogenous TRAIL-R4 critically impacts apoptotic and non-apoptotic TRAIL-induced signaling in cancer cells.
Rambow AC, Aschenbach I, Hagelund S, Tawfik D, Gundlach JP, Weiße S, Maass N, Trauzold A
Frontiers in Cell and Developmental Biology 2022
Inhibition of induced-hepatic cancer in vivo through IQGAP1-shRNA gene therapy and modulation of TRAIL-induced apoptosis pathway.
Zoheir KMA, Abd-Rabou AA, Darwish AM, Abdelhafez MA, Mahrous KF
Frontiers in Oncology 2022
Limiting glutamine utilization activates a GCN2/TRAIL-R2/Caspase-8 apoptotic pathway in glutamine-addicted tumor cells.
Yerbes R, Mora-Molina R, Fernández-Farrán FJ, Hiraldo L, López-Rivas A, Palacios C
Cell Death and Disease 2022
EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma.
Su K, Yuan Q, Hou H, Ke C, Huang C, Li S, Sun J, Yuan X, Lin Y, Chen Y, Xin H, Liang X, Du Z, Yuan Z
Journal of Molecular Medicine 2022
TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems.
Alizadeh Zeinabad H, Szegezdi E
Cancers 2022
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
Ben Khaled N, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN
Cancers 2022
Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma.
Piechna K, Żołyniak A, Jabłońska E, Noyszewska-Kania M, Szydłowski M, Żerek B, Kulecka M, Rumieńczyk I, Mikula M, Juszczyński P
Frontiers in Oncology 2022
Exosomal delivery of TRAIL and miR-335 for the treatment of hepatocellular carcinoma (Review)
Thapa N, Chwae YJ, Yoo KH, Won TB, Kang D, Choi D, Kim J
International journal of molecular medicine 2022
Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy
Kundu M, Greer YE, Dine JL, Lipkowitz S
Cells 2022
TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake
B Toffoli, F Tonon, V Tisato, G Zauli, P Secchiero, B Fabris, S Bernardi
Cell Death and Disease 2021
Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo
D Winterberg, L Lenk, M Oßwald, F Vogiatzi, CL Gehlert, FS Frielitz, K Klausz, T Rösner, T Valerius, A Trauzold, M Peipp, C Kellner, DM Schewe
Journal of Clinical Medicine 2021
Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
NK Moorthy, O Seifert, S Eisler, S Weirich, RE Kontermann, M Rehm, G Fullstone
Molecules (Basel, Switzerland) 2021
S1P signaling, its interactions and cross-talks with other partners and therapeutic importance in colorectal cancer
RS Sattar, MP Sumi, Nimisha, Apurva, A Kumar, AK Sharma, E Ahmad, A Ali, B Mahajan, SS Saluja
Cellular Signalling 2021
Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage
C Ternet, C Kiel
Cell Communication and Signaling 2021
A Dual Role for Death Receptor 5 in Regulating Cardiac Fibroblast Function
MA Tanner, LA Grisanti
Frontiers in Cardiovascular Medicine 2021
Intravenously Infused Stem Cells for Cancer Treatment
AR Mercer-Smith, IA Findlay, HN Bomba, SD Hingtgen
Stem Cell Reviews and Reports 2021
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer
SA Nalawade, P Shafer, P Bajgain, MK McKenna, A Ali, L Kelly, J Joubert, S Gottschalk, N Watanabe, A Leen, R Parihar, JF Valdes, V Hoyos
Journal for ImmunoTherapy of Cancer 2021
Overcoming TRAIL Resistance for Glioblastoma Treatment
L Deng, X Zhai, P Liang, H Cui
Biomolecules 2021
Therapeutics Targeting the Core Apoptotic Machinery
C Hamilton, JP Fox, DB Longley, CA Higgins
Cancers 2021
Stem cells for the treatment of glioblastoma: a 20-year perspective
AA Calinescu, MK Kauss, Z Sultan, WN Al-Holou, SK OShea
CNS Oncology 2021
Pharmacological Properties of Plant-Derived Natural Products and Implications for Human Health
GE Barreto, A Sahebkar
2021
Pharmacological Properties of Plant-Derived Natural Products and Implications for Human Health
GE Barreto, A Sahebkar
2021
Tumor necrosis factor‑related apoptosis‑inducing ligand is a novel transcriptional target of runt‑related transcription factor 1.
Yoshida T, Yamasaki K, Tadagaki K, Kuwahara Y, Matsumoto A, Sofovic AE, Kondo N, Sakai T, Okuda T
International journal of oncology 2021
BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
Ishii Y, Kolluri KK, Pennycuick A, Zhang X, Nigro E, Alrifai D, Borg E, Falzon M, Shah K, Kumar N, Janes SM
The Journal of biological chemistry 2021
Modes of Regulated Cell Death in Cancer
E Koren, Y Fuchs
Cancer Discovery 2021
Application of Emerging Plant-Derived Nanoparticles as a Novel Approach for Nano-Drug Delivery Systems
P Sarvarian, P Samadi, E Gholipour, KS Asenjan, M Hojjat-Farsangi, R Motavalli, FM Khiavi, M Yousefi
Immunological Investigations 2021
Immunoediting role for major vault protein in apoptotic signaling induced by bacterial N -acyl homoserine lactones
J Rayo, R Gregor, NT Jacob, R Dandela, L Dubinsky, A Yashkin, A Aranovich, M Thangaraj, O Ernst, E Barash, S Malitsky, BI Florea, BP Krom, EA Wiemer, VA Kickhoefer, LH Rome, JC Mathison, GF Kaufmann, HS Overkleeft, BF Cravatt, T Zor, KD Janda, RJ Ulevitch, VV Kravchenko, MM Meijler
Proceedings of the National Academy of Sciences 2021
BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
Y Ishii, KK Kolluri, A Pennycuick, X Zhang, E Nigro, D Alrifai, E Borg, M Falzon, K Shah, N Kumar, SM Janes
The Journal of biological chemistry 2021
Trichostatin A and Zebularine along with E-cadherin re-expression enhance tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cell cycle arrest in human breast adenocarcinoma cells
SH Wong, CM Fang, HS Loh, SC Ngai
2021
Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress
KA Grayson, JM Hope, W Wang, CA Reinhart-King, MR King
Molecular cancer therapeutics 2021
TRIM21, a New Component of the TRAIL-Induced Endogenous Necrosome Complex
MS Eugénio, F Faurez, GH Kara-Ali, M Lagarrigue, P Uhart, MC Bonnet, I Gallais, E Com, C Pineau, M Samson, JL Seyec, MT Dimanche-Boitrel
Frontiers in Molecular Biosciences 2021
Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells
A Yagolovich, A Kuskov, P Kulikov, L Kurbanova, D Bagrov, A Artykov, M Gasparian, S Sizova, V Oleinikov, A Gileva, M Kirpichnikov, D Dolgikh, E Markvicheva
Pharmaceutics 2021
Chemo-Sensitization of CD133+ Cancer Stem Cell Enhances the Effect of Mesenchymal Stem Cell Expressing TRAIL in Non-Small Cell Lung Cancer Cell Lines
KS Fakiruddin, MN Lim, N Nordin, R Rosli, S Abdullah
Biology : open access journal 2021
Vanillin oxime inhibits lung cancer cell proliferation and activates apoptosis through JNK/ERK-CHOP pathway
J Shen, Z Su
The Korean Journal of Physiology & Pharmacology 2021
The non‐peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis
G Knoll, M Ehrenschwender
FEBS Open Bio 2021
Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy
D Singh, M Tewari, S Singh, G Narayan
Future Oncology 2021
Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC
S Liu, EV Polsdofer, L Zhou, S Ruan, H Lyu, D Hou, H Liu, AD Thor, Z He, B Liu
Molecular Therapy — Oncolytics 2021
Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis
OH Voss, D Arango, JC Tossey, MA Calero, AI Doseff
Cell Death and Disease 2021
First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer
S Wang, H Zhu, Y Li, J Ding, F Wang, L Ding, X Wang, J Zhao, Y Zhang, Y Yao, T Zhou, N Li, A Wu, Z Yang
Journal for ImmunoTherapy of Cancer 2021
Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers
A Montinaro, IA Zubiaur, J Saggau, AL Kretz, RM Ferreira, O Hassan, E Kitzig, I Müller, MA El-Bahrawy, S von Karstedt, D Kulms, G Liccardi, J Lemke, H Walczak
Cell Death and Differentiation 2021
Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma
C Wu, M You, D Nguyen, M Wangpaichitr, YY Li, LG Feun, MT Kuo, N Savaraj
International journal of molecular sciences 2021
Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer
HJ Vaughan, CG Zamboni, NP Radant, P Bhardwaj, ER Lechtich, LF Hassan, K Shah, JJ Green
Molecular Therapy — Oncolytics 2021
Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes
KA Grayson, N Jyotsana, N Ortiz-Otero, MR King, IV Lebedeva
PloS one 2021
Arginine-tocopherol bioconjugated lipid vesicles for selective pTRAIL delivery and subsequent apoptosis induction in glioblastoma cells
V Ravula, YL Lo, YT Wu, CW Chang, SV Patri, LF Wang
Materials science & engineering. C, Materials for biological applications 2021
TRAIL‐Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582)
H Hou, K Su, C Huang, Q Yuan, S Li, J Sun, Y Lin, Z Du, C Ke, Z Yuan
Advanced Healthcare Materials 2021
The Anti-Tumor Effect of Lactococcus lactis Bacteria-Secreting Human Soluble TRAIL Can Be Enhanced by Metformin Both In Vitro and In Vivo in a Mouse Model of Human Colorectal Cancer
K Kaczmarek, J Więckiewicz, K Węglarczyk, M Siedlar, J Baran
Cancers 2021
TRAIL-receptor 2—a novel negative regulator of p53
A Willms, H Schupp, M Poelker, A Adawy, JF Debus, T Hartwig, T Krichel, J Fritsch, S Singh, H Walczak, S von Karstedt, H Schäfer, A Trauzold
Cell Death and Disease 2021
Say no to drugs: Bioactive macromolecular therapeutics without conventional drugs
M Rütter, N Milošević, A David
Journal of Controlled Release 2021
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro
P Crosley, A Farkkila, AL Jenner, C Burlot, O Cardinal, KG Potts, K Agopsowicz, M Pihlajoki, M Heikinheimo, M Craig, Y Fu, MM Hitt
International journal of molecular sciences 2021
Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers
W Jiang, Y Yang, AR Mercer-Smith, A Valdivia, JR Bago, AS Woodell, AA Buckley, MH Marand, L Qian, CK Anders, SD Hingtgen
Science Advances 2021
Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects
JU Choi, J Kim, SW Chung, NK Lee, J Park, S Kweon, YS Cho, HR Kim, SM Lim, JW Park, KC Lee, Y Byun
Journal of Controlled Release 2021
Paving the Road Toward Exploiting the Therapeutic Effects of Ginsenosides: An Emphasis on Autophagy and Endoplasmic Reticulum Stress.
Ashrafizadeh M, Tavakol S, Mohammadinejad R, Ahmadi Z, Yaribeygi H, Jamialahmadi T, Johnston TP, Sahebkar A
Advances in experimental medicine and biology 2021
Mesenchymal stem cells as professional actors in gastrointestinal cancer therapy: From Naïve to genetically modified.
Nasrollahzadeh Sabet M, Movahedi Asl M, Kazemi Esfeh M, Nasrabadi N, Shakarami M, Alani B, Alimolaie A, Azhdari S, Cheraghi E
Iranian Journal of Basic Medical Sciences 2021
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199.
Wang BT, Kothambawala T, Wang L, Matthew TJ, Calhoun SE, Saini AK, Kotturi MF, Hernandez G, Humke EW, Peterson MS, Sinclair AM, Keyt BA
Molecular cancer therapeutics 2021
Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress.
Grayson KA, Hope JM, Wang W, Reinhart-King CA, King MR
Molecular cancer therapeutics 2021
Stress Management: Death Receptor Signalling and Cross-Talks with the Unfolded Protein Response in Cancer
E Lafont
Cancers 2020
Assessing the Current State of Lung Cancer Chemoprevention: A Comprehensive Overview
AU, A Bhalerao, CM Mikelis, L Cucullo, NA German
Cancers 2020
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
S von Karstedt, H Walczak
Cell Death Discovery 2020
Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
C Sordo-Bahamonde, S Lorenzo-Herrero, ÁR Payer, S Gonzalez, A López-Soto
International journal of molecular sciences 2020
Insight into the divergent role of TRAIL in non‐neoplastic neurological diseases
S Gao, Y Fang, S Tu, H Chen, A Shao
Journal of Cellular and Molecular Medicine 2020
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
W Mu, Q Chu, Y Liu, N Zhang
Nano-Micro Letters 2020
PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR
J Lv, T Guo, X Qu, X Che, C Li, S Wang, J Gong, P Wu, Y Liu, Y Liu, L Xu
Frontiers in Oncology 2020
TRAIL therapy and prospective developments for cancer treatment
B Thapa, R KC, H Uludağ
Journal of Controlled Release 2020
Reduction in MLKL-mediated endosomal trafficking enhances the TRAIL-DR4/5 signal to increase cancer cell death
SY Park, HH Park, SY Park, SM Hong, S Yoon, MJ Morgan, YS Kim
Cell Death and Disease 2020
Cancer Immunology: A Translational Medicine Context
N Rezaei
2020
The multifaceted role of TRAIL signaling in cancer and immunity
LC Alves, N Corazza, O Micheau, P Krebs
The FEBS journal 2020
Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist
JM García-Martínez, S Wang, C Weishaeupl, A Wernitznig, P Chetta, C Pinto, J Ho, D Dutcher, PN Gorman, R Kroe-Barrett, J Rinnenthal, C Giragossian, MA Impagnatiello, I Tirapu, F Hilberg, N Kraut, M Pearson, KP Kuenkele
Molecular cancer therapeutics 2020
Heat Shock Proteins in Inflammatory Diseases
AA Asea, P Kaur
2020
Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models
HS Tuli
2020
Personalized‐induced neural stem cell therapy: Generation, transplant, and safety in a large animal model
HN Bomba, KT Sheets, A Valdivia, S Khagi, L Ruterbories, CL Mariani, LB Borst, DA Tokarz, SD Hingtgen
Bioengineering & Translational Medicine 2020
Periplocin mediates TRAIL-induced apoptosis and cell cycle arrest in human myxofibrosarcoma cells via the ERK/p38/JNK pathway
B Lohberger, E Bernhart, N Stuendl, D Glaenzer, A Leithner, B Rinner, R Bauer, N Kretschmer
Phytomedicine : international journal of phytotherapy and phytopharmacology 2020
TRAIL of Hope Meeting Resistance in Cancer
D Deng, K Shah
Trends in Cancer 2020
Micelle-in-Liposomes for Sustained Delivery of Anticancer Agents That Promote Potent TRAIL-Induced Cancer Cell Apoptosis
Z Zhang, SB Patel, MR King
Molecules (Basel, Switzerland) 2020
Oxidative stress-driven DR5 upregulation restores TRAIL/Apo2L sensitivity induced by iron oxide nanoparticles in colorectal cancer
Y Shi, J Wang, J Liu, G Lin, F Xie, X Pang, Y Pei, Y Cheng, Y Zhang, Z Lin, Z Yin, X Wang, G Niu, X Chen, G Liu
Biomaterials 2020
TRAIL-conjugated silver nanoparticles sensitize glioblastoma cells to TRAIL by regulating CHK1 in the DNA repair pathway
I Sur-Erdem, K Muslu, N Pınarbası, M Altunbek, F Seker-Polat, A Cingöz, SO Aydın, M Kahraman, M Culha, I Solaroglu, T Bagcı-Önder
Neurological Research 2020
DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models
MC Johnston, JA Nicoll, KM Redmond, P Smyth, MK Greene, WJ McDaid, DK Chan, N Crawford, KJ Stott, JP Fox, NL Straubinger, S Roche, M Clynes, RM Straubinger, DB Longley, CJ Scott
Journal of Controlled Release 2020
The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model
J He, Y An, J Qi, L Cui, K Yang, M Liu, B Qu, S Yan, J Yin, X Jing, H Dong, Q Yu, D Li, Y Wu
Journal of Medical Virology 2020
A simplified method for the efficient purification and refolding of recombinant human TRAIL
Z Zhang, SB Hahn, TM Cao, MR King
Biotechnology Progress 2020
A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells
F Hartung, T Krüwel, X Shi, K Pfizenmaier, R Kontermann, P Chames, F Alves, LA Pardo
Frontiers in pharmacology 2020
Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand
N Vunnam, S Szymonski, P Hirsova, GJ Gores, JN Sachs, BJ Hackel
Biochemistry 2020
Mcl‐1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells
Z Sarif, B Tolksdorf, H Fechner, J Eberle
Molecular Carcinogenesis 2020
Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile
AV Yagolovich, AA Artykov, TA Karmakova, MS Vorontsova, AA Pankratov, AA Andreev-Andrievsky, DA Dolgikh, MP Kirpichnikov, ME Gasparian
Translational oncology 2020
The MUDENG Augmentation: A Genesis in Anti-Cancer Therapy?
M Muthu, S Chun, J Gopal, GS Park, A Nile, J Shin, J Shin, TH Kim, JW Oh
International journal of molecular sciences 2020
Pichia fermentans originates apoptosis in human oral squamous cell carcinoma by over-expressing BAX and CASP 9 genes
HB Shamloo, A Shahabi, Z Aghazadeh, AY Khosroushahi
Cytotechnology 2020
Suppression of TRPM7 enhances TRAIL‐induced apoptosis in triple‐negative breast cancer cells
C Song, S Choi, KB Oh, T Sim
Journal of Cellular Physiology 2020
Strategies for treating oesophageal diseases with stem cells
Y Gao, SZ Jin
World journal of stem cells 2020
Doxorubicin hydrochloride enhanced antitumour effect of CEA‐regulated oncolytic virotherapy in live cancer cells and a mouse model
B Xiao, C Ying, Y Chen, F Huang, B Wang, H Fang, W Guo, T Liu, X Zhou, B Huang, X Liu, Y Wang
Journal of Cellular and Molecular Medicine 2020
Fabrication and Characterization of Tumor Nano-Lysate as a Preventative Vaccine for Breast Cancer
JA Dombroski, N Jyotsana, DW Crews, Z Zhang, MR King
Langmuir 2020
Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy
JD Yoo, SM Bae, J Seo, IS Jeon, SM Vadevoo, SY Kim, IS Kim, B Lee, S Kim
Scientific Reports 2020
Akkermansia muciniphila Aspartic Protease Amuc_1434* Inhibits Human Colorectal Cancer LS174T Cell Viability via TRAIL-Mediated Apoptosis Pathway
X Meng, J Zhang, H Wu, D Yu, X Fang
International journal of molecular sciences 2020
TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer
D Singh, CB Prasad, D Biswas, M Tewari, AG Kar, MA Ansari, S Singh, G Narayan
Pathology 2020
Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP
MI Elmallah, S Cogo, AA Constantinescu, S Elifio-Esposito, MS Abdelfattah, O Micheau
Cells 2020
Targeting of keloid with TRAIL and TRAIL-R2/DR5
P Sun, Z Hu, B Pan, X Lu
Journal of Dermatological Treatment 2020
Andrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death receptor 4.
Bi R, Deng Y, Tang C, Xuan L, Xu B, Du Y, Wang C, Wei W
Oncology reports 2020
Personalized-induced neural stem cell therapy: Generation, transplant, and safety in a large animal model.
Bomba HN, Sheets KT, Valdivia A, Khagi S, Ruterbories L, Mariani CL, Borst LB, Tokarz DA, Hingtgen SD
Bioengineering & Translational Medicine 2020
Hispidulin Enhances TRAIL-Mediated Apoptosis via CaMKKβ/AMPK/USP51 Axis-Mediated Bim Stabilization
SM Woo, SU Seo, SH Kim, JO Nam, S Kim, JW Park, K Min, TK Kwon
Cancers 2019
Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
Lim, Greer, Lipkowitz, Takebe
Cancers 2019
Cellular demolition: Proteins as molecular players of programmed cell death
YK Dhuriya, D Sharma, AA Naik
International Journal of Biological Macromolecules 2019
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
A Stamatopoulos, T Stamatopoulos, Z Gamie, E Kenanidis, RD Ribeiro, KS Rankin, C Gerrand, K Dalgarno, E Tsiridis
Journal of Bone Oncology 2019
Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation
MA Tanner, TP Thomas, LA Grisanti
Journal of Molecular and Cellular Cardiology 2019
Human Embryonic Stem Cells Acquire Responsiveness to TRAIL upon Exposure to Cisplatin
L Pešková, V Vinarský, T Bárta, A Hampl
Stem Cells International 2019
A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
A Satta, G Grazia, F Caroli, B Frigerio, MD Nicola, F Raspagliesi, D Mezzanzanica, N Zaffaroni, AM Gianni, A Anichini, M Figini
Frontiers in immunology 2019
Destined to Die: Apoptosis and Pediatric Cancers
Choo, Loh, Chen
Cancers 2019
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
R Jan, GS Chaudhry
Advanced pharmaceutical bulletin 2019
Regulation of death receptor signaling by the autophagy protein TP53INP2
S Ivanova, M Polajnar, AJ NarbonaPerez, MI HernandezAlvarez, P Frager, K Slobodnyuk, N Plana, AR Nebreda, M Palacin, RR Gomis, C Behrends, A Zorzano
The EMBO Journal 2019
Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells
N Mungra, S Jordaan, P Hlongwane, K Naran, S Chetty, S Barth
Oncotarget 2019
Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma
JJ Noonan, M Jarzabek, FA Lincoln, BL Cavanagh, AR Pariag, V Juric, LS Young, KL Ligon, H Jahns, D Zheleva, JH Prehn, M Rehm, AT Byrne, BM Murphy
Cancers 2019
Hantavirus Inhibits TRAIL-Mediated Killing of Infected Cells by Downregulating Death Receptor 5
C Solà-Riera, S Gupta, KT Maleki, P González-Rodriguez, D Saidi, CL Zimmer, S Vangeti, L Rivino, YS Leo, DC Lye, PA MacAry, C Ahlm, A Smed-Sörensen, B Joseph, NK Björkström, HG Ljunggren, J Klingström
Cell Reports 2019
Mechanisms and biomarkers of liver regeneration after drug-induced liver injury
Clemens MM, McGill MR, Apte U
Advances in pharmacology (San Diego, Calif.) 2019
Acetaminophen Hepatotoxicity - A Mitochondrial Perspective
Ramachandran A, Jaeschke H
Advances in pharmacology (San Diego, Calif.) 2019
Biomarkers of Drug-induced Liver Injury
McGill MR, Jaeschke H
Advances in pharmacology (San Diego, Calif.) 2019
PIM kinases mediate resistance of glioblastoma cells to TRAIL by a p62/SQSTM1-dependent mechanism
S Serrano-Saenz, C Palacios, D Delgado-Bellido, L López-Jiménez, A Garcia-Diaz, Y Soto-Serrano, JI Casal, RA Bartolomé, JL Fernández-Luna, A López-Rivas, FJ Oliver
Cell Death and Disease 2019
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer
C Spano, G Grisendi, G Golinelli, F Rossignoli, M Prapa, M Bestagno, O Candini, T Petrachi, A Recchia, F Miselli, G Rovesti, G Orsi, A Maiorana, P Manni, E Veronesi, MS Piccinno, A Murgia, M Pinelli, EM Horwitz, S Cascinu, P Conte, M Dominici
Scientific Reports 2019
Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization
A Dubuisson, C Favreau, E Fourmaux, S Lareure, R Rodrigues-Saraiva, C Pellat-Deceunynck, SE Alaoui, O Micheau
Cell Death and Disease 2019
Death receptor 5 is activated by fucosylation in colon cancer cells
B Zhang, IA van Roosmalen, CR Reis, R Setroikromo, WJ Quax
The FEBS journal 2019
Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD
R Fadeev, A Chekanov, M Solovieva, O Bezborodova, E Nemtsova, N Dolgikh, I Fadeeva, A Senotov, M Kobyakova, Y Evstratova, R Yakubovskaya, V Akatov
International journal of molecular sciences 2019
Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling
L Pan, TM Fu, W Zhao, L Zhao, W Chen, C Qiu, W Liu, Z Liu, A Piai, Q Fu, S Chen, H Wu, JJ Chou
Cell 2019
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
C Dostert, M Grusdat, E Letellier, D Brenner
Physiological reviews 2019
Insight into the role of TRAIL in liver diseases
W Jiang, DB Wu, SY Fu, EQ Chen, H Tang, TY Zhou
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2019
The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection
L Miarka, C Hauser, O Helm, D Holdhof, S Beckinger, JH Egberts, JP Gundlach, L Lenk, S Rahn, W Mikulits, A Trauzold, S Sebens
Cancers 2019
Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells
B Zhang, B Liu, D Chen, R Setroikromo, HJ Haisma, WJ Quax
Cancers 2019
TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells
E Díaz-Rodríguez, J Pérez-Peña, C Ríos-Luci, J Arribas, A Ocaña, A Pandiella
Cancer Letters 2019
TRAIL ‐expressing recombinant Lactococcus lactis induces apoptosis in human colon adenocarcinoma SW 480 and HCT 116 cells
E Bohlul, F Hasanlou, AH Taromchi, S Nadri
Journal of Applied Microbiology 2019
Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells
A Willms, H Schittek, S Rahn, J Sosna, U Mert, D Adam, A Trauzold, A Krieg
PloS one 2019
Natural products against cancer: Review on phytochemicals from marine sources in preventing cancer
AF Wali, S Majid, S Rasool, SB Shehada, SK Abdulkareem, A Firdous, S Beigh, S Shakeel, S Mushtaq, I Akbar, H Madhkali, MU Rehman
Saudi Pharmaceutical Journal 2019
TRAILblazing Strategies for Cancer Treatment
AL Kretz, A Trauzold, A Hillenbrand, U Knippschild, D Henne-Bruns, S von Karstedt, J Lemke
Cancers 2019
Combined effects of XAF1 and TRAIL on the apoptosis of lung adenocarcinoma cells
F Zhang, D Chen, W Yang, S Duan, Y Chen
Experimental and therapeutic medicine 2019
Engineered human mesenchymal stem cells for neuroblastoma therapeutics
V Nieddu, R Piredda, D Bexell, J Barton, J Anderson, N Sebire, K Kolluri, S Janes, E Karteris, A Sala
Oncology reports 2019
TRAIL Induces Nuclear Translocation and Chromatin Localization of TRAIL Death Receptors
U Mert, A Adawy, E Scharff, P Teichmann, A Willms, V Haselmann, C Colmorgen, J Lemke, S von Karstedt, J Fritsch, A Trauzold
Cancers 2019
Zebularine and trichostatin A sensitized human breast adenocarcinoma cells towards tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis
WY Kong, ZY Yee, CW Mai, CM Fang, S Abdullah, SC Ngai
Heliyon 2019
TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis
R Baskar, HG Fienberg, Z Khair, P Favaro, S Kimmey, DR Green, GP Nolan, S Plevritis, SC Bendall
2019
Tumour necrosis factor‐related apoptosis‐inducing ligand induces apoptosis in canine hemangiosarcoma cells in vitro
M Goto, K Owaki, A Hirata, T Yanai, H Sakai
Veterinary and Comparative Oncology 2019
Loss of MCL1 function sensitizes the MDA‐MB‐231 breast cancer cells to rh‐TRAIL by increasing DR4 levels
A Blasio, G Pratelli, R DragoFerrante, C Saliba, S Baldacchino, G Grech, G Tesoriere, C Scerri, R Vento, RD Fiore
Journal of Cellular Physiology 2019
Prediction of genes and protein-protein interaction networking for miR-221-5p using bioinformatics analysis
Shanmugapriya, N Othman, S Sasidharan
Gene Reports 2019
E3 ubiquitin ligases and deubiquitinases as modulators of TRAIL-mediated extrinsic apoptotic signaling pathway
Seon Min Woo, Taeg Kyu Kwon
BMB Reports 2019
Monocyte-Macrophage Differentiation Suppresses the Expression of Proapoptotic Receptors to Apo2L/TRAIL and Increases Resistance to TRAIL-Induced Apoptosis
YV Evstratova, MI Kobyakova, VV Novikova, AS Senotov, VS Akatov, RS Fadeev
Biophysics 2019
Trimer form of tumor necrosis factor-related apoptosis inducing ligand induces apoptosis in canine cell lines derived from mammary tumors
M GOTO, A HIRATA, M MURAKAMI, H SAKAI
Journal of Veterinary Medical Science 2019
Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy
L Han, S Dai, Z Li, C Zhang, S Wei, R Zhao, H Zhang, L Zhao, B Shan
Journal of Experimental & Clinical Cancer Research 2019
TRAIL-based gene delivery and therapeutic strategies
H Zhong, H Wang, J Li, Y Huang
Acta Pharmacologica Sinica 2019
TRAIL‐Inspired Multivalent Dextran Conjugates Efficiently Induce Apoptosis upon DR5 Receptor Clustering
H Schneider, D Yanakieva, A Macarrón, L Deweid, B Becker, S Englert, O Avrutina, H Kolmar
Chembiochem : a European journal of chemical biology 2019
Trained Macrophage Bioreactor for Penetrating Delivery of Fused Antitumor Protein
Y Zhang, Y Zhang, Q Guo, Z Guo, X Chen, L Liu, C Li, Q Chen, , Y Lu, T Sun, Y Huang, C Jiang
ACS Applied Materials & Interfaces 2019
Double-Edged Lipid Nanoparticles Combining Liposome-Bound TRAIL and Encapsulated Doxorubicin Showing an Extraordinary Synergistic Pro-Apoptotic Potential
DD Miguel, A Gallego-Lleyda, M Martinez-Ara, J Plou, A Anel, L Martinez-Lostao
Cancers 2019
Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients
T Heilmann, F Vondung, C Borzikowsky, S Szymczak, S Krüger, I Alkatout, A Wenners, M Bauer, W Klapper, C Röcken, N Maass, S von Karstedt, C Schem, A Trauzold
Journal of Molecular Medicine 2019
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway
M Wang, ME Law, BJ Davis, E Yaaghubi, AF Ghilardi, RB Ferreira, CW Chiang, OA Guryanova, D Kopinke, CD Heldermon, RK Castellano, BK Law
Cell Death Discovery 2019
Delivery of TRAIL-expressing plasmid DNA to cancer cells in vitro and in vivo using aminoglycoside-derived polymers
S Goklany, P Lu, S Godeshala, A Hall, E Garrett-Mayer, C Voelkel-Johnson, K Rege
Journal of Materials Chemistry B 2019
Targeted Inhibition of ULK1 Promotes Apoptosis and Suppresses Tumor Growth and Metastasis in Neuroblastoma
CM Dower, N Bhat, MT Gebru, L Chen, CA Wills, BA Miller, HG Wang
Molecular cancer therapeutics 2018
A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma
E Oh, JW Hong, OJ Kwon, CO Yun
Scientific Reports 2018
Involvement of AMP-activated protein kinase and Death Receptor 5 in TRAIL-Berberine-induced apoptosis of cancer cells
R Ke, K Vishnoi, N Viswakarma, S Santha, S Das, A Rana, B Rana
Scientific Reports 2018
Downregulation of TRAIL-Receptor 1 Increases TGFβ Type II Receptor Expression and TGFβ Signalling Via MicroRNA-370-3p in Pancreatic Cancer Cells
D Radke, Q Ling, R Häsler, G Alp, H Ungefroren, A Trauzold
Cancers 2018
Attenuation of autophagy flux by 6-shogaol sensitizes human liver cancer cells to TRAIL-induced apoptosis via p53 and ROS
U Nazim, SY Park
International journal of molecular medicine 2018
Divergent Roles for TRAIL in Lung Diseases
AT Braithwaite, HM Marriott, A Lawrie
Frontiers in Medicine 2018
Peptides/Proteins Encoded by Non-coding RNA: A Novel Resource Bank for Drug Targets and Biomarkers
S Zhu, J Wang, Y He, N Meng, GR Yan
Frontiers in pharmacology 2018
Glutamine metabolism regulates FLIP expression and sensitivity to TRAIL in triple-negative breast cancer cells
M Mauro-Lizcano, A López-Rivas
Cell Death and Disease 2018
3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5
Y Chen, L Wei, X Zhang, X Liu, Y Chen, S Zhang, L Zhou, Q Li, Q Pan, S Zhao, H Liu
Oncology reports 2018
TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase
E Brin, K Wu, E Dagostino, MM Kuo, Y He, WJ Shia, LC Chen, M Stempniak, R Hickey, R Almassy, R Showalter, J Thomson
Oncotarget 2018
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
M Timaner, N Letko-Khait, R Kotsofruk, M Benguigui, O Beyar-Katz, C Rachman-Tzemah, Z Raviv, T Bronshtein, M Machluf, Y Shaked
Cancer research 2018
Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma
C Trejo-Solís, N Serrano-Garcia, Á Escamilla-Ramírez, R Castillo-Rodríguez, D Jimenez-Farfan, G Palencia, M Calvillo, M Alvarez-Lemus, A Flores-Nájera, A Cruz-Salgado, J Sotelo
International journal of molecular sciences 2018
Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells
KK Kolluri, C Alifrangis, N Kumar, Y Ishii, S Price, M Michaut, S Williams, S Barthorpe, H Lightfoot, S Busacca, A Sharkey, Z Yuan, EK Sage, S Vallath, JL Quesne, DA Tice, D Alrifai, S von Karstedt, A Montinaro, N Guppy, DA Waller, A Nakas, R Good, A Holmes, H Walczak, DA Fennell, M Garnett, F Iorio, L Wessels, U McDermott, SM Janes
eLife 2018
Developing TRAIL/TRAIL death receptor-based cancer therapies
X Yuan, A Gajan, Q Chu, H Xiong, K Wu, S Wu
Cancer and Metastasis Reviews 2018
TRAIL pathway targeting therapeutics
MD Ralff, WS El-Deiry
Expert Review of Precision Medicine and Drug Development 2018
Structural principles of tumor necrosis factor superfamily signaling
ÉS Vanamee, DL Faustman
Science signaling 2018
Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy
AL Kretz, S von Karstedt, A Hillenbrand, D Henne-Bruns, U Knippschild, A Trauzold, J Lemke
Cancers 2018
CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors
C Reinshagen, D Bhere, SH Choi, S Hutten, I Nesterenko, H Wakimoto, EL Roux, A Rizvi, W Du, C Minicucci, K Shah
Science Translational Medicine 2018
Relationship between TRAIL and Left Ventricular Ejection Fraction in Patients with ST-Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention
E Teringova, M Kozel, J Knot, V Kocka, K Benesova, P Tousek
BioMed Research International 2018
Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin:
KA Turner, JM Manouchehri, M Kalafatis
Melanoma Research 2018
Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages
M Kih, EJ Lee, NK Lee, YK Kim, KE Lee, C Jeong, Y Yang, DH Kim, IS Kim
Biomaterials 2018
Mcl-1 and Bcl-xL sequestration of Bak confers differential resistance to BH3-only proteins
C Hockings, AE Alsop, SC Fennell, EF Lee, WD Fairlie, G Dewson, RM Kluck
Cell Death and Differentiation 2018
Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells
RM Fancy, H Kim, T Napier, DJ Buchsbaum, KR Zinn, Y Song
Journal of Cellular Biochemistry 2018
Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps
L Danish, D Imig, F Allgöwer, P Scheurich, N Pollak, YH Hsieh
PloS one 2018
CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3
X Jin, L Cai, C Wang, X Deng, S Yi, Z Lei, Q Xiao, H Xu, H Luo, J Sun
Cell Death and Disease 2018
The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells
K Legler, C Hauser, JH Egberts, A Willms, C Heneweer, S Boretius, C Röcken, CC Glüer, T Becker, M Kluge, O Hill, C Gieffers, H Fricke, H Kalthoff, J Lemke, A Trauzold
Cell Death and Disease 2018
Interleukin-4 Enhances the Sensitivity of Human Monocytes to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Through Upregulation of Death Receptor 4
S Zhang, Z Li, W Huang
Journal of Interferon & Cytokine Research 2018
Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells
J Liu, Q Gao, T Xie, Y Liu, L Luo, C Xu, L Shen, F Wan, T Lei, F Ye
Clinical and Experimental Medicine 2018
Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors
S Sirtl, G Knoll, DT Trinh, I Lang, D Siegmund, S Gross, B Schuler-Thurner, P Neubert, J Jantsch, H Wajant, M Ehrenschwender
Oncogene 2018
Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-Type Cell Death
AA Masum, Y Hisamatsu, K Yokoi, S Aoki
Bioinorganic Chemistry and Applications 2018
Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells
M Hutt, S Fellermeier-Kopf, O Seifert, LC Schmitt, K Pfizenmaier, RE Kontermann
Oncotarget 2018
Trichosanthin enhances sensitivity of non-small cell lung cancer (NSCLC) TRAIL-resistance cells
C You, Y Sun, S Zhang, G Tang, N Zhang, C Li, X Tian, S Ma, Y Luo, W Sun, F Wang, X Liu, Y Xiao, Y Gong, J Zhang, C Xie
International journal of biological sciences 2018
Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations
ME Melendez, RJ Silva-Oliveira, AL Vicente, LM Arantes, AC de Carvalho, AL Epstein, RM Reis, AL Carvalho
Oncotarget 2018
Ciprofloxacin Enhances TRAIL-Induced Apoptosis in Lung Cancer Cells by Upregulating the Expression and Protein Stability of Death Receptors through CHOP Expression
E Lim, Y Yoon, J Heo, T Lee, YH Kim
International journal of molecular sciences 2018
Ferrocene-Containing Impiridone (ONC201) Hybrids: Synthesis, DFT Modelling, In Vitro Evaluation, and Structure–Activity Relationships
P Bárány, RS Oláh, I Kovács, T Czuczi, CL Szabó, A Takács, E Lajkó, O Láng, L Kőhidai, G Schlosser, S Bősze, G Mező, F Hudecz, A Csámpai
Molecules (Basel, Switzerland) 2018
Targeted nonviral gene therapy in prostate cancer
N Altwaijry, S Somani, C Dufès
International Journal of Nanomedicine 2018
Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism
FA Lincoln, D Imig, C Boccellato, V Juric, J Noonan, RE Kontermann, F Allgöwer, BM Murphy, M Rehm
Cell Death and Disease 2018
Design and synthesis of a luminescent iridium complex-peptide hybrid (IPH) that detects cancer cells and induces their apoptosis
AA Masum, K Yokoi, Y Hisamatsu, K Naito, B Shashni, S Aoki
Bioorganic & Medicinal Chemistry 2018
Early Drug Development: Bringing a Preclinical Candidate to the Clinic
FG Giordanetto
2018
15d-PGJ2 is a new hope for controlling tumor growth
Qingli Bie, Haixin Dong, Chengqiang Jin, Hao Zhang, Bin Zhang
American journal of translational research 2018
Chimeric Mice With Humanized Livers Demonstrate Human-Specific Hepatotoxicity Caused by a Therapeutic Antibody Against TRAIL-Receptor 2/Death Receptor 5
K Nihira, K Nan-ya, M Kakuni, Y Ono, Y Yoshikawa, T Ota, M Hiura, K Yoshinari
Toxicological Sciences 2018
C-27-carboxylated oleanane triterpenoids up-regulate TRAIL DISC assembly via p38 MAPK and CHOP-mediated DR5 expression in human glioblastoma cells
HS Byun, W Zhou, IW Park, K Kang, SR Lee, X Piao, JB Park, TK Kwon, MK Na, GM Hur
Biochemical Pharmacology 2018
Recent Advances in Anti-cancer Protein/Peptide Delivery
X Liu, F Wu, Y Ji, L Yin
Bioconjugate Chemistry 2018
Zoledronik asit uygulamasının meme kanseri hücre hattı (mcf 7) kanser kök hücrelerinin üzerine otofaji gen seviyesindeki etkilerinin araştırılması
F Oltulu, A Uysal, H Rouhrazi, KD Kılıç, DÇ Kocatürk, G Öktem
2018
Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL‑induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species
U Nazim, H Yin, SY Park
Molecular medicine reports 2018
Cytokeratin 8/18 protects breast cancer cell lines from TRAIL-induced apoptosis
WP Bozza, Y Zhang, B Zhang
Oncotarget 2018
Luteolin sensitizes human liver cancer cells to TRAIL‑induced apoptosis via autophagy and JNK‑mediated death receptor 5 upregulation
U Nazim, SY Park
International journal of oncology 2018
β-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors
C You, S Zhang, Y Sun, S Zhang, G Tang, F Tang, X Liu, Y Xiao, J Zhang, Y Gong, C Xie
International journal of oncology 2018
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
A Dubuisson, O Micheau
Antibodies 2017
Yin Yang 1 (YY1): Regulation of Survivin and Its Role In Invasion and Metastasis
NR Galloway, KF Ball, TR Stiff, NR Wall
Critical Reviews in Oncogenesis 2017
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
V Liapis, A Zysk, M DeNichilo, I Zinonos, S Hay, V Panagopoulos, A Shoubridge, C Difelice, V Ponomarev, W Ingman, GJ Atkins, DM Findlay, AC Zannettino, A Evdokiou
Cancer Medicine 2017
Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells
X Zhang, X Zhang, S Hu, M Zheng, J Zhang, J Zhao, X Zhang, B Yan, L Jia, J Zhao, K Wu, A Yang, R Zhang
Nucleic Acids Research 2017
A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
LY Dimberg, CG Towers, K Behbakht, TJ Hotz, J Kim, S Fosmire, CC Porter, AC Tan, A Thorburn, HL Ford
Molecular cancer research : MCR 2017
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
S von Karstedt, A Montinaro, H Walczak
Nature Reviews Cancer 2017
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
X Ouyang, M Shi, F Jie, Y Bai, P Shen, Z Yu, X Wang, C Huang, M Tao, Z Wang, C Xie, Q Wu, Y Shu, B Han, F Zhang, Y Zhang, C Hu, X Ma, Y Liang, A Wang, B Lu, Y Shi, J Chen, Z Zhuang, J Wang, J Huang, C Wang, C Bai, X Zhou, Q Li, F Chen, H Yu, J Feng
Investigational New Drugs 2017
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors
A Forero, JC Bendell, P Kumar, L Janisch, M Rosen, Q Wang, C Copigneaux, M Desai, G Senaldi, ML Maitland
Investigational New Drugs 2017
The linear ubiquitin chain assembly complex regulates TRAIL‐induced gene activation and cell death
E Lafont, C KantariMimoun, P Draber, DD Miguel, T Hartwig, M Reichert, S Kupka, Y Shimizu, L Taraborrelli, M Spit, MR Sprick, H Walczak
The EMBO Journal 2017
TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer.
Wei B, Liang J, Hu J, Mi Y, Ruan J, Zhang J, Wang Z, Hu Q, Jiang H, Ding Q
Medical science monitor : international medical journal of experimental and clinical research 2017
Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer
C Geismann, F Grohmann, A Dreher, R Häsler, P Rosenstiel, K Legler, C Hauser, JH Egberts, B Sipos, S Schreiber, A Linkermann, Z Hassan, G Schneider, H Schäfer, A Arlt
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2017
Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma towards TRAIL by Natural Product Toosendanin
X Li, M You, Y Liu, L Ma, P Jin, R Zhou, ZX Zhang, B Hua, X Ji, X Cheng, F Yin, Y Chen, W Yin
Scientific Reports 2017
TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation
CR Reis, PH Chen, N Bendris, SL Schmid
Proceedings of the National Academy of Sciences 2017
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2
T Hartwig, A Montinaro, S Karstedt, A Sevko, S Surinova, A Chakravarthy, L Taraborrelli, P Draber, E Lafont, FA Vargas, MA El-Bahrawy, SA Quezada, H Walczak
Molecular Cell 2017
Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP
BR Seo, K Min, SM Woo, M Choe, KS Choi, YK Lee, G Yoon, TK Kwon
Antioxidants & Redox Signaling 2017
Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway:
X Guo, Y Meng, X Sheng, Y Guan, F Zhang, Z Han, Y Kang, G Tai, Y Zhou, H Cheng
Anti-Cancer Drugs 2017
Analysis of TNF-related apoptosis-inducing ligand and receptors and implications in thymus biology and myasthenia gravis
I Kanatli, B Akkaya, H Uysal, S Kahraman, AD Sanlioglu
Neuromuscular Disorders 2017
Ibulocydine sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis via calpain-mediated Bax cleavage
SS Park, E Jwa, SH Shin, EJ Ju, I Park, JH Pak, JJ Hwang, DH Cho, BM Kim, SB Kim, JS Lee, SY Song, SY Jeong, EK Choi
The International Journal of Biochemistry & Cell Biology 2017
Imaging and Focal Therapy of Early Prostate Cancer
TJ Polascik
Imaging and Focal Therapy of Early Prostate Cancer 2017
Renaissance of protein crystallization and precipitation in biopharmaceuticals purification
R Santos, AL Carvalho, AC Roque
Biotechnology Advances 2017
sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
Y Huang, X Li, H Sha, L Zhang, X Bian, X Han, B Liu
Scientific Reports 2017
An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T-cell activation in inflammatory arthritis
IT Chyuan, HF Tsai, HJ Liao, CS Wu, PN Hsu
Cellular and Molecular Immunology 2017
Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein
I Marini, M Siegemund, M Hutt, RE Kontermann, K Pfizenmaier
Frontiers in immunology 2017
MDR1A deficiency restrains tumor growth in murine colitis-associated carcinogenesis
EM Hennenberg, A Eyking, H Reis, E Cario, J Karhausen
PloS one 2017
MDL-12330A potentiates TRAIL-induced apoptosis in gastric cancer cells through CHOP-mediated DR5 upregulation
SC Lim, SI Han
The Korean Journal of Physiology & Pharmacology 2017
Biodegradable and bioreducible poly(beta-amino ester) nanoparticles for intracellular delivery to treat brain cancer
Y Rui, G Quiñones, JJ Green
AIChE Journal 2017
Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells: CaM B INDING T o DR5-M EDIATED DISC I N B REAST C ANCER C ELLS
RM Fancy, H Kim, T Zhou, KR Zinn, DJ Buchsbaum, Y Song
Journal of Cellular Biochemistry 2017
TRAIL–NP hybrids for cancer therapy: a review
H Belkahla, G Herlem, F Picaud, T Gharbi, M Hémadi, S Ammar, O Micheau
Nanoscale 2017
Partial p53-dependence of anisomycin-induced apoptosis in PC12 cells
R Schipp, J Varga, J Bátor, M Vecsernyés, Z Árvai, M Pap, J Szeberényi
Molecular and Cellular Biochemistry 2017
miR-133a Promotes TRAIL Resistance in Glioblastoma via Suppressing Death Receptor 5 and Activating NF-κB Signaling
S Wang, L Feng, B Hu, Y Lu, W Wang, W Guo, C Suen, B Jiao, J Pang, W Fu, J Zhang
Molecular Therapy - Nucleic Acids 2017
Fn14·TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog
TB Prigozhina, F Szafer, A Aronin, K Tzdaka, S Amsili, E Makdasi, N Shani, MD Elhalel
Cancer Letters 2017
Cellular Injury in Liver Diseases
WX Ding, XM Yin
Cellular Injury in Liver Diseases 2017
Immunoproapoptotic molecule scFv-Fdt-tBid modified mesenchymal stem cells for prostate cancer dual-targeted therapy
F Yan, X Li, N Li, R Zhang, Q Wang, Y Ru, X Hao, J Ni, H Wang, G Wu
Cancer Letters 2017
Human menstrual blood-derived mesenchymal stem cells as a cellular vehicle for malignant glioma gene therapy
X Wang, B Xiang, Y Ding, L Chen, H Zou, X Mou, C Xiang
Oncotarget 2017
Journey of TRAIL from bench to bedside and its potential role in immuno-oncology
GE Naoum, DJ Buchsbaum, F Tawadros, A Farooqi, WO Arafat
Oncology Reviews 2017
Multifunctional Nucleus-targeting Nanoparticles with Ultra-high Gene Transfection Efficiency for In Vivo Gene Therapy
L Li, X Li, Y Wu, L Song, X Yang, T He, N Wang, S Yang, Y Zeng, Q Wu, Z Qian, Y Wei, C Gong
Theranostics 2017
Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells: CaM B INDING T o DR5-M EDIATED DISC I N B REAST C ANCER C ELLS
RM Fancy, H Kim, T Zhou, KR Zinn, DJ Buchsbaum, Y Song
Journal of Cellular Biochemistry 2017
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects
H Tenshin, J Teramachi, A Oda, R Amachi, M Hiasa, A Bat-Erdene, K Watanabe, M Iwasa, T Harada, S Fujii, K Kagawa, K Sogabe, S Nakamura, H Miki, K Kurahashi, S Yoshida, K Aihara, I Endo, E Tanaka, T Matsumoto, M Abe
Blood Advances 2017
TRAIL, Fas Ligand, TNF and TLR3 in Cancer
O Micheau
TRAIL, Fas Ligand, TNF and TLR3 in Cancer 2017
Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL
A Elia, R Henry-Grant, C Adiseshiah, C Marboeuf, RJ Buckley, MJ Clemens, S Mudan, S Pyronnet
Cell Death and Disease 2017
cFLIP critically modulates apoptotic resistance in epithelial-to-mesenchymal transition
C Padmanabhan, EJ Rellinger, J Zhu, H An, LG Woodbury, DH Chung, AG Waterson, CW Lindsley, AL Means, RD Beauchamp
Oncotarget 2017
The effect of cisplatin on cytotoxicity of anticancer cytokine TRAIL and its receptor-selective mutant variant DR5-B1
ME Gasparian, ML Bychkov, AV Yagolovich, MP Kirpichnikov, DA Dolgikh
Doklady Biochemistry and Biophysics 2017
Up-regulation of 5-lipoxygenase by inhibition of cathepsin G enhances TRAIL-induced apoptosis through down-regulation of survivin
SM Woo, KJ Min, SU Seo, S Kim, JW Park, DK Song, HS Lee, SH Kim, TK Kwon
Oncotarget 2017
Overexpression of miR-101 promotes TRAIL-induced mitochondrial apoptosis in papillary thyroid carcinoma by targeting c-met and MCL-1
J Zhu, Z Li
Oncotarget 2017
TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data
Z Gamie, K Kapriniotis, D Papanikolaou, E Haagensen, RD Ribeiro, K Dalgarno, A Krippner-Heidenreich, C Gerrand, E Tsiridis, KS Rankin
Cancer Letters 2017
Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy
X Wu, S Wang, M Li, A Wang, Y Zhou, P Li, Y Wang
Nanoscale 2017
Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi-1 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP
X Kong, J Luo, T Xu, Y Zhou, Z Pan, Y Xie, L Zhao, Y Lu, X Han, Z Li, L Liu
Oncology reports 2017
SPAG6 regulates cell apoptosis through the TRAIL signal pathway in myelodysplastic syndromes
X Li, B Yang, L Wang, L Chen, X Luo, L Liu
Oncology reports 2017
Ginkgetin inhibits proliferation of human leukemia cells via the TNF-α signaling pathway
LL Pan, WJ Wu, GF Zheng, XY Han, JS He, Z Cai
Zeitschrift für Naturforschung C 2017
TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer
B Wei, J Liang, J Hu, Y Mi, J Ruan, J Zhang, Z Wang, Q Hu, H Jiang, Q Ding
Medical science monitor : international medical journal of experimental and clinical research 2017
Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery: Novel targets for sensitizing breast cancer cells
B Thapa, RB KC, H Uludağ
International Journal of Cancer 2017
Multifunctional Nucleus-targeting Nanoparticles with Ultra-high Gene Transfection Efficiency for In Vivo Gene Therapy
L Li, X Li, Y Wu, L Song, X Yang, T He, N Wang, S Yang, Y Zeng, Q Wu, Z Qian, Y Wei, C Gong
Theranostics 2017
Chaetospirolactone reverses the apoptotic resistance towards TRAIL in pancreatic cancer
W Hu, X Jia, Y Gao, Q Zhang
Biochemical and Biophysical Research Communications 2017
Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5
Y Zhao, B Tian, Y Wang, H Ding
Medical science monitor : international medical journal of experimental and clinical research 2017
Paving TRAIL’s Path with Ubiquitin
E Lafont, T Hartwig, H Walczak
Trends in Biochemical Sciences 2017
TRAIL-induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor
Z Nahacka, J Svadlenka, M Peterka, M Ksandrova, S Benesova, J Neuzil, L Andera
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2017
Combination of oncolytic adenovirus and luteolin exerts synergistic antitumor effects in colorectal cancer cells and a mouse model
B Xiao, Y Qin, C Ying, B Ma, B Wang, F Long, R Wang, L Fang, Y Wang
Molecular medicine reports 2017
Ophiopogonin B sensitizes TRAIL-induced apoptosis through activation of autophagy flux and downregulates cellular FLICE-like inhibitory protein
U Nazim, JK Jeong, SY Park
Oncotarget 2017
Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine
O OrtegaRivera, JL Quintanar, SD ToroArreola, ï½ngel AlpucheSolis, M EsparzaAraiza, E Salinas
Oncology Letters 2017
Generation of a novel TRAIL mutant by proline to arginine substitution based on codon bias and its antitumor effects
A Zhu, X Wang, M Huang, C Chen, J Yan, Q Xu, L Wei, X Huang, H Zhu, C Yi
Molecular medicine reports 2017
RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND SELECTIVELY INDUCES APOPTOSIS IN MALIGNANT MELANOMA
M Kalafatis, KA Turner, DJ Lindner, M Kalafatis
International Journal of Cancer and Oncology 2017
TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors.
Yang X, Li Z, Wu Q, Chen S, Yi C, Gong C
Drug Delivery 2017
Partial p53-dependence of anisomycin-induced apoptosis in PC12 cells.
Schipp R, Varga J, Bátor J, Vecsernyés M, Árvai Z, Pap M, Szeberényi J
Molecular and Cellular Biochemistry 2017
Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5.
Zhao Y, Tian B, Wang Y, Ding H
Medical science monitor : international medical journal of experimental and clinical research 2017
Activation of autophagy flux by metformin downregulates cellular FLICE–like inhibitory protein and enhances TRAIL- induced apoptosis
UM Nazim, JH Moon, JH Lee, YJ Lee, JW Seol, SK Eo, JH Lee, SY Park
Oncotarget 2016
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
D Hendriks, Y He, I Koopmans, VR Wiersma, RJ van Ginkel, DF Samplonius, W Helfrich, E Bremer
OncoImmunology 2016
Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis
P Hirsova, SH Ibrabim, GJ Gores, H Malhi
Journal of lipid research 2016
The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy
B Lohberger, B Steinecker-Frohnwieser, N Stuendl, H Kaltenegger, A Leithner, B Rinner, V Trajkovic
PloS one 2016
Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in�vivo
K Harati, S Emmelmann, B Behr, O Goertz, T Hirsch, N Kapalschinski, J Kolbenschlag, I Stricker, A Tannapfel, M Lehnhardt, A Daigeler
Oncology Letters 2016
Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer
U Mert, AD Sanlioglu
Cellular and Molecular Life Sciences 2016
A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression
K Piras-Straub, K Khairzada, P Kocabayoglu, A Paul, G Gerken, K Herzer
Cancer Medicine 2016
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease
S Bernardi, F Bossi, B Toffoli, B Fabris
BioMed Research International 2016
Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey
CL de Zafra, A Ashkenazi, WC Darbonne, M Cheu, K Totpal, S Ortega, H Flores, MD Walker, B Kabakoff, BL Lum, BJ Mounho-Zamora, SA Marsters, NO Dybdal
Cell Death and Disease 2016
Redox signaling and oxidative stress: cross talk with TNF-related apoptosis inducing ligand activity
R Voltan, P Secchiero, F Casciano, D Milani, G Zauli, V Tisato
The International Journal of Biochemistry & Cell Biology 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl
JL Dine, CC OSullivan, D Voeller, YE Greer, KJ Chavez, CM Conway, S Sinclair, B Stone, L Amiri-Kordestani, AS Merchant, SM Hewitt, SM Steinberg, SM Swain, S Lipkowitz
Breast Cancer Research and Treatment 2016
Genetic engineering of mesenchymal stromal cells for cancer therapy: turning partners in crime into Trojan horses
H Niess, MN Thomas, TS Schiergens, A Kleespies, KW Jauch, C Bruns, J Werner, PJ Nelson, MK Angele
Innovative Surgical Sciences 2016
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
S Baig, I Seevasant, J Mohamad, A Mukheem, HZ Huri, T Kamarul
Cell Death and Disease 2016
Co-delivery of chemotherapeutics and proteins for synergistic therapy
C He, Z Tang, H Tian, X Chen
Advanced Drug Delivery Reviews 2016
TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy
ZQ Yuan, KK Kolluri, KH Gowers, SM Janes
Journal of Extracellular Vesicles 2016
Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5
JW Eng, TA Mace, R Sharma, DY Twum, P Peng, JF Gibbs, R Pitoniak, CB Reed, SI Abrams, EA Repasky, BL Hylander
Journal for ImmunoTherapy of Cancer 2016
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
KG Fleten, VA Flørenes, L Prasmickaite, O Hill, J Sykora, GM Mælandsmo, B Engesæter
Cell Death Discovery 2016
USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability
M Jeong, EW Lee, D Seong, J Seo, JH Kim, S Grootjans, SY Kim, P Vandenabeele, J Song
Oncogene 2016
Guiding TRAIL to cancer cells through Kv10.1 potassium channel overcomes resistance to doxorubicin
F Hartung, LA Pardo
European Biophysics Journal 2016
TRAIL restores DCA/metformin-mediated cell death in hypoxia
SE Hong, CS Kim, S An, HA Kim, SG Hwang, JY Song, JK Lee, J Hong, JI Kim, WC Noh, HO Jin, IC Park
Biochemical and Biophysical Research Communications 2016
Combinatorial treatment with anacardic acid followed by TRAIL augments induction of apoptosis in TRAIL resistant cancer cells by the regulation of p53, MAPK and NFκβ pathways
MH Raj, B Yashaswini, J Rössler, BP Salimath
Apoptosis 2016
ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2  kinases
CL Kline, AP van Heuvel, JE Allen, VV Prabhu, DT Dicker, WS El-Deiry
Science signaling 2016
Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer
PT Yin, S Shah, NJ Pasquale, OB Garbuzenko, T Minko, KB Lee
Biomaterials 2016
Lipid- and polyion complex-based micelles as agonist platforms for TNFR superfamily receptors
RN Gilbreth, S Novarra, L Wetzel, S Florinas, H Cabral, K Kataoka, J Rios-Doria, RJ Christie, M Baca
Journal of Controlled Release 2016
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL
M Iaboni, V Russo, R Fontanella, G Roscigno, D Fiore, E Donnarumma, CL Esposito, C Quintavalle, PH Giangrande, V Franciscis, G Condorelli
Molecular Therapy — Nucleic Acids 2016
Resveratrol Enhances Apoptosis in Endometriotic Stromal Cells
A Taguchi, K Koga, K Kawana, T Makabe, F Sue, M Miyashita, M Yoshida, Y Urata, G Izumi, M Tkamura, M Harada, T Hirata, Y Hirota, O Wada-Hiraike, T Fujii, Y Osuga
American Journal of Reproductive Immunology 2016
Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells
MA Han, DH Lee, SM Woo, BR Seo, K Min, S Kim, JW Park, SH Kim, YH Choi, TK Kwon
Scientific Reports 2016
Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1
DI Radke, H Ungefroren, O Helm, S Voigt, G Alp, H Braun, S Hübner, J Dilchert, S Sebens, D Adam, H Kalthoff, A Trauzold
Cellular Signalling 2016
Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma: Osteoprotegerin
FA de Voogd, RB Gearry, CJ Mulder, AS Day
Journal of Gastroenterology and Hepatology 2016
TRAIL-CM4 fusion protein shows in vitro antibacterial activity and a stronger antitumor activity than solo TRAIL protein
M Sang, J Zhang, B Li, Y Chen
Protein Expression and Purification 2016
Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation
L Chen, Y Meng, Q Sun, Z Zhang, X Guo, X Sheng, G Tai, H Cheng, Y Zhou
Cell Death and Disease 2016
Protein engineering strategies with potential applications for altering clinically relevant cellular pathways at the protein level
L Regan, MR Hinrichsen, C Oi
Expert Review of Proteomics 2016
Ethanolic extract of Descurainia sophia seeds sensitizes A549 human lung cancer cells to TRAIL cytotoxicity by upregulating death receptors
JS Park, CJ Lim, OS Bang, NS Kim
BMC complementary and alternative medicine 2016
Selective activation of TNFR1 and NF-κB inhibition by a novel biyouyanagin analogue promotes apoptosis in acute leukemia cells
CG Savva, S Totokotsopoulos, KC Nicolaou, CM Neophytou, AI Constantinou
BMC Cancer 2016
Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation
L Chen, Y Meng, X Guo, X Sheng, G Tai, F Zhang, H Cheng, Y Zhou
Apoptosis 2016
Opposing roles of TGF-β and EGF in the regulation of TRAIL-induced apoptosis in human breast epithelial cells
A Cano-González, A López-Rivas
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2016
Fully human monoclonal antibodies to TRAIL-R1 enhance TRAIL-induced apoptosis via activation of caspase-8 pathway
Z Hao, X Han, X Sun, M Shen, J Huang, Y Li, T Ozawa, D Pang, S Jin, H Kishi, A Muraguchi, A Jin
Biochemical and Biophysical Research Communications 2016
Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer
AK Singh, SS Chauhan, SK Singh, VV Verma, A Singh, RK Arya, S Maheshwari, MS Akhtar, J Sarkar, VM Rangnekar, PM Chauhan, D Datta
Carcinogenesis 2016
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy
J Wang, H Wang, LY Wang, D Cai, Z Duan, Y Zhang, P Chen, JX Zou, J Xu, X Chen, HJ Kung, HW Chen
Cell Death and Differentiation 2016
Onto better TRAILs for cancer treatment
D Miguel, J Lemke, A Anel, H Walczak, L Martinez-Lostao
Cell Death and Differentiation 2016
An Apoptosis-Inducing Peptidic Heptad That Efficiently Clusters Death Receptor 5
B Valldorf, H Fittler, L Deweid, A Ebenig, S Dickgiesser, C Sellmann, J Becker, S Zielonka, M Empting, O Avrutina, H Kolmar
Angewandte Chemie (International ed. in English) 2016
Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer
R Zhang, X Zhang, B Ma, B Xiao, F Huang, P Huang, C Ying, T Liu, Y Wang
Cancer Gene Therapy 2016
TRAIL causes deletions at the HPRT and TK1 loci of clonogenically competent cells
MA Miles, TM Shekhar, NE Hall, CJ Hawkins
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2016
Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application
V Taucher, H Mangge, J Haybaeck
Cellular Oncology 2016
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
T Ciuleanu, I Bazin, D Lungulescu, L Miron, I Bondarenko, A Deptala, M Rodriguez-Torres, B Giantonio, NL Fox, P Wissel, J Egger, M Ding, RN Kalyani, R Humphreys, M Gribbin, W Sun
Annals of Oncology 2016
Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL
B Jancekova, E Ondrouskova, L Knopfova, J Smarda, P Benes
Tumor Biology 2016
Fed-batch production of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in soluble form in Escherichia coli and its purification and characterization
P Li, Q Gu, X Wu
Protein Expression and Purification 2016
Non-viral nucleic acid containing nanoparticles as cancer therapeutics
KL Kozielski, Y Rui, JJ Green
Expert Opinion on Drug Delivery 2016
Gingival Mesenchymal Stem/Progenitor Cells: A Unique Tissue Engineering Gem
KM El-Sayed, CE Dörfer
Stem Cells International 2016
Role of nanotechnology and gene delivery systems in TRAIL based therapies
GE Naoum, F Tawadros, AA Farooqi, MZ Qureshi, S Tabassum, DJ Buchsbaum, W Arafat
ecancermedicalscience 2016
Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs
Y Huang, X Yang, T Xu, Q Kong, Y Zhang, Y Shen, Y Wei, G Wang, KJ Chang
International journal of oncology 2016
Adipose‑derived mesenchymal stem cell‑facilitated TRAIL expression in melanoma treatment in�vitro
H Jing, D Duan, H Zhou, Q Hu, T Lei
Molecular medicine reports 2016
Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY
RM Fancy, L Wang, Q Zeng, H Wang, T Zhou, DJ Buchsbaum, Y Song
The Journal of biological chemistry 2016
Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies
G Pistritto, D Trisciuoglio, C Ceci, A Garufi, G D'Orazi
Aging 2016
Snake Venom synergized Cytotoxic Effect of Natural Killer Cells on NCI H358 Human Lung Cancer Cell Growth through Induction of Apoptosis
JW Oh, HS Song
The Acupuncture 2016
Antitumor and radiosensitization effect of 12C6+ heavy-ion irradiation mediated by radiation-inducible gene therapy
H Liu, CF Jin, SF Ge, LJ Wu
Nuclear Science and Techniques 2016
Ein Apoptose-induzierendes Heptamer, das effizient den Todesrezeptor 5 bündelt
B Valldorf, H Fittler, L Deweid, A Ebenig, S Dickgiesser, C Sellmann, J Becker, S Zielonka, M Empting, O Avrutina, H Kolmar
Angewandte Chemie 2016
Encyclopedia of Signaling Molecules
S Choi
Encyclopedia of Signaling Molecules 2016
Genetically modified mesenchymal stromal cells in cancer therapy
EK Sage, RM Thakrar, SM Janes
Cytotherapy 2016
Protective effects of a polymethoxy flavonoids-rich Citrus aurantium peel extract on liver fibrosis induced by bile duct ligation in mice
SW Lim, DR Lee, BK Choi, HS Kim, SH Yang, JW Suh, KS Kim
Asian Pacific Journal of Tropical Medicine 2016
Tumor suppressor BLU promotes TRAIL-induced apoptosis by downregulating NF-κB signaling in nasopharyngeal carcinoma
J Zhou, Z Huang, Z Wang, S Liu, A Grandien, I Ernberg, Z He, X Zhang
Oncotarget 2016
The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation
AM el Zawily, BM Toosi, T Freywald, VV Indukuri, FJ Vizeacoumar, SC Leary, A Freywald
Oncotarget 2016
Inhibition of never in mitosis A (NIMA)-related kinase-4 reduces survivin expression and sensitizes cancer cells to TRAIL-induced cell death
SJ Park, DS Jo, SY Jo, DW Shin, S Shim, YK Jo, JH Shin, YJ Ha, SY Jeong, JJ Hwang, YS Kim, YA Suh, JW Chang, JC Kim, DH Cho
Oncotarget 2016
Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane
Y Su, K Tatzel, X Wang, B Belt, P Binder, L Kuroki, MA Powell, DG Mutch, WG Hawkinsand, D Spitzer
Oncotarget 2016
Involvement of DR4/JNK pathway-mediated autophagy in acquired TRAIL resistance in HepG2 cells
SC Lim, HJ Jeon, KH Kee, MJ Lee, R Hong, SI Han
International journal of oncology 2016
A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression
K Piras-Straub, K Khairzada, P Kocabayoglu, A Paul, G Gerken, K Herzer
Cancer Medicine 2016
The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer.
Cousin FJ, Jouan-Lanhouet S, Théret N, Brenner C, Jouan E, Le Moigne-Muller G, Dimanche-Boitrel MT, Jan G
Oncotarget 2016
Targeting the extrinsic apoptosis pathway in cancer: lessons learned and future directions
Avi Ashkenazi
Journal of Clinical Investigation 2015
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
MH Tuthill, A Montinaro, J Zinngrebe, K Prieske, P Draber, S Prieske, T Newsom-Davis, S Karstedt, J Graves, H Walczak
Oncogene 2015
Vascular-targeted TNFα improves tumor blood vessel function and enhances antitumor immunity and chemotherapy in colorectal cancer
L Lu, ZJ Li, LF Li, WK Wu, J Shen, L Zhang, RL Chan, L Yu, YW Liu, SX Ren, KM Chan, CH Cho
Journal of Controlled Release 2015
HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells
DH Lee, KS Sung, DL Bartlett, YT Kwon, YJ Lee
Cellular Signalling 2015
Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-Troglitazone-induced Apoptosis in Prostate Cancer Cells Involve AMP-activated Protein Kinase
S Santha, N Viswakarma, S Das, A Rana, B Rana
The Journal of biological chemistry 2015
Protein Glycosylation in Cancer
SR Stowell, T Ju, RD Cummings
Annual review of pathology 2015
Therapeutic applications of TRAIL receptor agonists in cancer and beyond
GP Amarante-Mendes, TS Griffith
Pharmacology & Therapeutics 2015
TRAIL Modulates the Immune System and Protects against the Development of Diabetes
F Bossi, S Bernardi, G Zauli, P Secchiero, B Fabris
Journal of Immunology Research 2015
The double trouble of metabolic diseases: the diabetes-cancer link
S Tudzarova, MA Osman
Molecular biology of the cell 2015
Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression
E Strekalova, D Malin, DM Good, VL Cryns
Clinical cancer research 2015
Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy
X Dai, J Zhang, F Arfuso, A Chinnathambi, ME Zayed, SA Alharbi, AP Kumar, KS Ahn, G Sethi
Experimental biology and medicine (Maywood, N.J.) 2015
Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis
S von Karstedt, A Conti, M Nobis, A Montinaro, T Hartwig, J Lemke, K Legler, F Annewanter, AD Campbell, L Taraborrelli, A Grosse-Wilde, JF Coy, MA El-Bahrawy, F Bergmann, R Koschny, J Werner, TM Ganten, T Schweiger, K Hoetzenecker, I Kenessey, B Hegedüs, M Bergmann, C Hauser, JH Egberts, T Becker, C Röcken, H Kalthoff, A Trauzold, KI Anderson, OJ Sansom, H Walczak
Cancer Cell 2015
Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity
L O'Leary, AM van der Sloot, CR Reis, S Deegan, AE Ryan, SP Dhami, LS Murillo, RH Cool, PC de Sampaio, K Thompson, G Murphy, WJ Quax, L Serrano, A Samali, E Szegezdi
Oncogene 2015
Tumor necrosis factor-related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotype
J Gao, D Wang, D Liu, M Liu, Y Ge, M Jiang, Y Liu, D Zheng
Molecular biology of the cell 2015
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
R Trivedi, DP Mishra
Frontiers in Oncology 2015
Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors
Y Oh, M Swierczewska, TH Kim, SM Lim, HN Eom, JH Park, DH Na, K Kim, KC Lee, MG Pomper, S Lee
Journal of Controlled Release 2015
Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model
BL Hylander, A Sen, SH Beachy, R Pitoniak, S Ullas, JF Gibbs, J Qiu, JD Prey, GJ Fetterly, EA Repasky
Journal of Controlled Release 2015
Intranasal delivery of stem cells as therapy for central nervous system disease
Y Li, L Feng, GX Zhang, C Ma
Experimental and Molecular Pathology 2015
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
Y Liu, OE Hawkins, AE Vilgelm, JS Pawlikowski, JA Ecsedy, JA Sosman, MC Kelley, A Richmond
Clinical cancer research 2015
Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β2-adrenergic receptor activation
JW Eng, CB Reed, KM Kokolus, R Pitoniak, A Utley, MJ Bucsek, WW Ma, EA Repasky, BL Hylander
Nature Communications 2015
Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display
PM Nair, H Flores, A Gogineni, S Marsters, DA Lawrence, RF Kelley, H Ngu, M Sagolla, L Komuves, R Bourgon, J Settleman, A Ashkenazi
Proceedings of the National Academy of Sciences 2015
Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas: Adipose MSC with TRAIL Target Sarcomas
G Grisendi, C Spano, N D'souza, V Rasini, E Veronesi, M Prapa, T Petrachi, S Piccinno, F Rossignoli, JS Burns, S Fiorcari, D Granchi, N Baldini, EM Horwitz, V Guarneri, P Conte, P Paolucci, M Dominici
Stem Cells 2015
Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis
P Hirsova, GJ Gores
CMGH Cellular and Molecular Gastroenterology and Hepatology 2015
Safety and tolerability of TRAIL receptor agonists in cancer treatment
S Fulda
European Journal of Clinical Pharmacology 2015
Icaritin Sensitizes Human Glioblastoma Cells to TRAIL-Induced Apoptosis
H Han, B Xu, P Hou, C Jiang, L Liu, M Tang, X Yang, Y Zhang, Y Liu
Cell Biochemistry and Biophysics 2015
A novel adenoviral vector carrying an all-in-one Tet-On system with an autoregulatory loop for tight, inducible transgene expression
H Chen, D Wang, R Xia, Q Mao, H Xia
BMC Biotechnology 2015
Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator
SM Loya, X Zhang
Gene Therapy 2015
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
KP Papadopoulos, R Isaacs, S Bilic, K Kentsch, HA Huet, M Hofmann, D Rasco, N Kundamal, Z Tang, J Cooksey, A Mahipal
Cancer Chemotherapy and Pharmacology 2015
Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells: Oncolytic adenoviruses for MSC delivery to pancreatic cancer
K Hammer, A Kazcorowski, L Liu, M Behr, P Schemmer, I Herr, DM Nettelbeck
International Journal of Cancer 2015
PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy
YS Youn, HJ Byeon, I Kim, JS Choi, ES Lee, BS Shin
International Journal of Nanomedicine 2015
Anti-estrogen‑resistant breast cancer cells are sensitive to cisplatin plus TRAIL treatment
S Yin, A Rishi, K Reddy
Oncology reports 2015
Mesenchymal stromal cell delivery of full-length tumor necrosis factor–related apoptosis-inducing ligand is superior to soluble type for cancer therapy
ZQ Yuan, KK Kolluri, EK Sage, KH Gowers, SM Janes
Cytotherapy 2015
A Humanized Leucine Zipper-TRAIL Hybrid Induces Apoptosis of Tumors both In Vitro and In Vivo
D Rozanov, P Spellman, A Savinov, AY Strongin, C Yan
PloS one 2015
Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis
S Philipp, J Sosna, J Plenge, H Kalthoff, D Adam
Cell Communication and Signaling 2015
Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells
GA Alexiou, KI Tsamis, E Vartholomatos, E Peponi, E Tzima, I Tasiou, E Lykoudis, P Tsekeris, AP Kyritsis
Journal of Neuro-Oncology 2015
Proteomic tools for the characterization of cell death mechanisms in drug discovery
VG Anania, JR Lill
PROTEOMICS – CLINICAL APPLICATIONS 2015
Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells
R Tanaka, M Tomosugi, M Horinaka, Y Sowa, T Sakai, AR Amin
PloS one 2015
Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines
CC Chang, CP Kuan, JY Lin, JS Lai, TF Ho
Chemical Research in Toxicology 2015
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein
J Zhitao, L Long, L Jia, B Yunchao, W Anhua
Tumor Biology 2015
TRAIL and TRAIL receptors in patients with laryngeal cancer: TRAIL Receptors in Laryngeal Carcinoma
E Erkul, Z Kucukodaci, D Pinar, A Gungor, MA Babayigit, O Kurt, H Cincik
Head & Neck 2015
Targeting TRAIL in the treatment of cancer: new developments
B Lim, JE Allen, VV Prabhu, MK Talekar, NK Finnberg, WS El-Deiry
Expert Opinion on Therapeutic Targets 2015
Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib
PJ Neeson, AK Hsu, YR Chen, HM Halse, J Loh, R Cordy, K Fielding, J Davis, J Noske, AJ Davenport, CA Lindqvist-Gigg, R Humphreys, T Tai, HM Prince, JA Trapani, MJ Smyth, DS Ritchie
OncoImmunology 2015
State of the art paper Does aspirin-induced oxidative stress cause asthma exacerbation?
D Kacprzak, R Pawliczak
Archives of Medical Science : AMS 2015
Elevated pressure enhanced TRAIL-induced apoptosis in hepatocellular carcinoma cells via ERK1/2-inactivation
E Hong, E Lee, J Kim, D Kwon, Y Lim
Cellular & Molecular Biology Letters 2015
DED or alive: assembly and regulation of the death effector domain complexes
JS Riley, A Malik, C Holohan, DB Longley
Cell Death and Disease 2015
Foods and Dietary Supplements in the Prevention and Treatment of Disease in Older Adults
G Ntaios
Foods and Dietary Supplements in the Prevention and Treatment of Disease in Older Adults 2015
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
CY Cheah, D Belada, MA Fanale, A Janikova, MS Czucman, IW Flinn, AV Kapp, A Ashkenazi, S Kelley, GL Bray, S Holden, JF Seymour
The Lancet Haematology 2015
Oncotoxic proteins in cancer therapy: Mechanisms of action
YN Lezhnin, YE Kravchenko, EI Frolova, PM Chumakov, SP Chumakov
Molecular Biology 2015
Activation of surrogate death receptor signaling triggers peroxynitrite-dependent execution of cisplatin-resistant cancer cells
S Seah, IC Low, JL Hirpara, K Sachaphibulkij, G Kroemer, C Brenner, S Pervaiz
Cell Death and Disease 2015
Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma
K Wang, FM Kievit, M Jeon, JR Silber, RG Ellenbogen, M Zhang
Advanced Healthcare Materials 2015
Periplasmic Expression of TNF Related Apoptosis Inducing Ligand (TRAIL) in E.coli
Omid Tavallaei, Mojgan Bandehpour, Nastaran Nafissi-Varcheh, Bahram Kazemi
IRAN J PHARM RES 2015
Detection of Anticancer and Apoptotic Effect of the Produced IgYs against the Three Extracellular Domain of Human DR5 Protein
Shaghayegh Amirijavid, Mehrdad Hashemi
Iranian journal of cancer prevention 2015
Mutations enhancing selectivity of antitumor cytokine TRAIL to DR5 receptor increase its cytotoxicity against tumor cells
ME Gasparian, ML Bychkov, AV Yagolovich, DA Dolgikh, MP Kirpichnikov
Biochemistry (Moscow) 2015
Suppression of casein kinase 2 sensitizes tumor cells to antitumor TRAIL therapy by regulating the phosphorylation and localization of p65 in prostate cancer
X Gang, Y Wang, Y Wang, Y Zhao, L Ding, J Zhao, L Sun, G Wang
Oncology reports 2015
The Role of Selected Flavonols in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor–1 (TRAIL-R1) Expression on Activated RAW 264.7 Macrophages
M Warat, T Sadowski, E Szliszka, W Król, Z Czuba
Molecules (Basel, Switzerland) 2015
TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2
T Tamada, D Shinmi, M Ikeda, Y Yonezawa, S Kataoka, R Kuroki, E Mori, K Motoki
Scientific Reports 2015
Partial Protection of PC12 Cells from Cellular Stress by Low-Dose Sodium Nitroprusside Pre-treatment
J Varga, J Bátor, G Nádasdi, Z Árvai, R Schipp, J Szeberényi
Cellular and Molecular Neurobiology 2015
Genistein enhances TRAIL-induced cancer cell death via inactivation of autophagic flux
U Nazim, SY Park
Oncology reports 2015
First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
JE Allen, R Crowder, WS El-Deiry, SY Sun
PloS one 2015
Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death
S Raimondo, F Naselli, S Fontana, F Monteleone, AL Dico, L Saieva, G Zito, A Flugy, M Manno, MA di Bella, GD Leo, R Alessandro
Oncotarget 2015
TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells
R Sriraksa, T Limpaiboon
Asian Pacific Journal of Cancer Prevention 2015
Anticancer activity of NOB1-targeted shRNA combination with TRAIL in epithelial ovarian cancer cells
Yang Lin, Tianmin Xu, Hong Teng, Manhua Cui
International journal of clinical and experimental pathology 2015
TRAIL-Expressing Gingival-Derived Mesenchymal Stem Cells Inhibit Tumorigenesis of Tongue Squamous Cell Carcinoma
L Xia, R Peng, W Leng, R Jia, X Zeng, X Yang, M Fan
Journal of dental research 2015
MSCs: Is this the future therapeutic for cancer?
A Kakouri
Acta Medica International 2015
Resistance of Cancer Cells to CTL-Mediated Immunotherapy
B Bonavida, S Chouaib
2015
Proteases in Apoptosis: Pathways, Protocols and Translational Advances
K Bose
2015
FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells
SM Woo, BR Seo, K Min, TK Kwon
Oncotarget 2015
Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells
KJ Jung, K Min, JH Bae, TK Kwon
Oncotarget 2015
Induction of cellular prion protein (PrPc) under hypoxia inhibits apoptosis caused by TRAIL treatment
JY Park, JK Jeong, JH Lee, JH Moon, SW Kim, YJ Lee, SY Park
Oncotarget 2015
TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model
H Fritsche, T Heilmann, RJ Tower, C Hauser, A von Au, D El-Sheikh, GM Campbell, G Alp, D Schewe, S Hübner, S Tiwari, D Kownatzki, S Boretius, D Adam, W Jonat, T Becker, CC Glüer, M Zöller, H Kalthoff, C Schem, A Trauzold
Oncotarget 2015
Brazilian Red Propolis Induces Apoptosis-Like Cell Death and Decreases Migration Potential in Bladder Cancer Cells
KR Begnini, PM de Leon, H Thurow, E Schultze, VF Campos, FM Rodrigues, S Borsuk, OA Dellagostin, L Savegnago, M Roesch-Ely, S Moura, FF Padilha, T Collares, JA Henriques, FK Seixas
Evidence-Based Complementary and Alternative Medicine 2014
Relationship between tumour necrosis factor-related apoptosis inducing ligand (TRAIL) and vascular endothelial growth factor in human multiple myeloma patients: Relationship between TRAIL and VEGF in MM patients
L Bolkun, D Lemancewicz, J Piszcz, M Moniuszko, U Bolkun-Skornicka, M Szkiladz, E Jablonska, J Kloczko, J Dzieciol
Hematological Oncology 2014
Roles of ligands from the TNF superfamily in B cell development, function, and regulation
WA Figgett, FB Vincent, D Saulep-Easton, F Mackay
Seminars in Immunology 2014
Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System
D Sarhan, P D'Arcy, A Lundqvist
International journal of molecular sciences 2014
The Interruption of PKC-ι Signaling and TRAIL Combination Therapy Against Glioblastoma Cells
AN McCray, S Desai, M Acevedo-Duncan
Neurochemical Research 2014
Delaying mitotic exit downregulates FLIP expression and strongly sensitizes tumor cells to TRAIL
T Sánchez-Pérez, RH Medema, A López-Rivas
Oncogene 2014
TRAIL receptor deficiency sensitizes mice to dextran sodium sulphate-induced colitis and colitis-associated carcinogenesis
J Zhu, L Chen, J Shi, S Liu, Y Liu, D Zheng
Immunology 2014
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab
J Tabernero, SP Chawla, H Kindler, K Reckamp, EG Chiorean, NS Azad, AC Lockhart, CP Hsu, NF Baker, F Galimi, P Beltran, J Baselga
Targeted Oncology 2014
Targeting the apoptosis pathway in hematologic malignancies
S Zaman, R Wang, V Gandhi
Leukemia & Lymphoma 2014
Evaluation of therapeutic effects of natural killer (NK) cell-based immunotherapy in mice using in vivo apoptosis bioimaging with a caspase-3 sensor
HW Lee, TD Singh, SW Lee, JH Ha, A Rehemtulla, BC Ahn, YH Jeon, J Lee
The FASEB Journal 2014
Regulation of the Extrinsic Apoptotic Pathway by MicroRNA-21 in Alcoholic Liver Injury
H Francis, K McDaniel, Y Han, X Liu, L Kennedy, F Yang, J McCarra, T Zhou, S Glaser, J Venter, L Huang, P Levine, JM Lai, CG Liu, G Alpini, F Meng
The Journal of biological chemistry 2014
Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway
AR Jazirehi, SK Kurdistani, JS Economou
Journal of immunology (Baltimore, Md. : 1950) 2014
Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging
Y Xie, Z Xie
Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging 2014
Identification of novel molecular regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening
SV Garimella, K Gehlhaus, JL Dine, JJ Pitt, M Grandin, S Chakka, MM Nau, NJ Caplen, S Lipkowitz
Breast Cancer Research 2014
Getting TRAIL back on track for cancer therapy
J Lemke, S Karstedt, J Zinngrebe, H Walczak
Cell Death and Differentiation 2014
Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice
XG Wang, T Jandl, E Dadachova, E Revskaya
Therapeutic Delivery 2014
Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L)
K Min, BR Seo, YC Bae, YH Yoo, TK Kwon
Cell Death and Disease 2014
Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma
EK Sage, KK Kolluri, K McNulty, SD Lourenco, TL Kalber, KL Ordidge, D Davies, YC Lee, A Giangreco, SM Janes
Thorax 2014
Ion channels and apoptosis in cancer
CD Bortner, JA Cidlowski
Philosophical Transactions of the Royal Society B: Biological Sciences 2014
Inhibition of eIF2α dephosphorylation enhances TRAIL-induced apoptosis in hepatoma cells
Y Teng, M Gao, J Wang, Q Kong, H Hua, T Luo, Y Jiang
Cell Death and Disease 2014
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3
G Garg, J Gibbs, B Belt, MA Powell, DG Mutch, P Goedegebuure, L Collins, D Piwnica-Worms, WG Hawkins, D Spitzer
BMC Cancer 2014
Influence of the Implantation Site on the Sensitivity of Patient Pancreatic Tumor Xenografts to Apo2L/TRAIL Therapy:
R Sharma, S Buitrago, R Pitoniak, JF Gibbs, L Curtin, M Seshadri, EA Repasky, BL Hylander
Pancreas 2014
Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis
ÁC Murphy, B Weyhenmeyer, J Noonan, SM Kilbride, S Schimansky, KP Loh, D Kögel, AG Letai, JH Prehn, BM Murphy
Apoptosis 2014
Exercise-induced lung cancer regression: Mechanistic findings from a mouse model: Exercise and Lung Cancer
KA Higgins, D Park, GY Lee, WJ Curran, X Deng
Cancer 2014
The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma
IA van Roosmalen, CR Reis, R Setroikromo, S Yuvaraj, JV Joseph, PG Tepper, FA Kruyt, WJ Quax
SpringerPlus 2014
Multi-layered nanoparticles for combination gene and drug delivery to tumors
A Ediriwickrema, J Zhou, Y Deng, WM Saltzman
Biomaterials 2014
Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2
U Bertsch, C Röder, H Kalthoff, A Trauzold
Cell Death and Disease 2014
Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells
M Horinaka, T Yoshida, M Tomosugi, S Yasuda, Y Sowa, T Sakai
Scientific Reports 2014
Combination of TRAIL with Bortezomib Shifted Apoptotic Signaling from DR4 to DR5 Death Receptor by Selective Internalization and Degradation of DR4
ML Bychkov, ME Gasparian, DA Dolgikh, MP Kirpichnikov, SA Rizza
PloS one 2014
A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells
E Kobayashi, H Kishi, T Ozawa, H Hamana, H Nakagawa, A Jin, Z Lin, A Muraguchi
Biochemical and Biophysical Research Communications 2014
Sensitization of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Resistant Primary Prostate Cancer Cells by Isoegomaketone from Perilla frutescens
JH Lee, HD Cho, IY Jeong, MK Lee, KI Seo
Journal of Natural Products 2014
Anti-breast cancer activity of Fine Black ginseng (Panax ginseng Meyer) and ginsenoside Rg5
SJ Kim, AK Kim
Journal of Ginseng Research 2014
Kurarinone Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells
W Zhou, A Cao, L Wang, D Wu
Cell Biochemistry and Biophysics 2014
DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer
R Yu, SM Albarenque, RH Cool, WJ Quax, A Mohr, RM Zwacka
Cancer biology & therapy 2014
RIP1 modulates death receptor mediated apoptosis and autophagy in macrophages
Z Yao, P Zhang, H Guo, J Shi, S Liu, Y Liu, D Zheng
Molecular Oncology 2014
Potential Application of Temozolomide in Mesenchymal Stem Cell-Based TRAIL Gene Therapy Against Malignant Glioma
SM Kim, JS Woo, CH Jeong, CH Ryu, JD Jang, SS Jeun
Stem Cells Translational Medicine 2014
Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies
JR Foster, G Lund, S Sapelnikova, DL Tyrrell, NM Kneteman
Xenobiotica 2014
Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma:
G Pasello, L Urso, M Silic-Benussi, M Schiavon, I Cavallari, G Marulli, N Nannini, F Rea, V Ciminale, A Favaretto
Journal of Thoracic Oncology 2014
Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model
HJ Byeon, SH Choi, JS Choi, TH Kim, ES Lee, KC Lee, YS Youn
Biomedicine & Pharmacotherapy 2014
ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing phosphorylation of survivin Thr34
MH Park, SY Kim, YJ Kim, YH Chung
Biochemical and Biophysical Research Communications 2014
Cancer therapeutics: Targeting the apoptotic pathway
KH Khan, M Blanco-Codesido, LR Molife
Critical Reviews in Oncology/Hematology 2014
Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter
C Yan, M Yang, Z Li, S Li, X Hu, D Fan, Y Zhang, J Wang, D Xiong
Biomaterials 2014
Pharmacophore Reassignment for Induction of the Immunosurveillance Cytokine TRAIL
NT Jacob, JW Lockner, VV Kravchenko, KD Janda
Angewandte Chemie 2014
GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial
J Jiang, X Liu, L Deng, P Zhang, G Wang, S Wang, H Liu, Y Su
European Journal of Pharmacology 2014
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
J Pawel, JH Harvey, DR Spigel, M Dediu, M Reck, CL Cebotaru, RC Humphreys, MJ Gribbin, NL Fox, DR Camidge
Clinical Lung Cancer 2014
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression
XW Meng, BD Koh, JS Zhang, KS Flatten, PA Schneider, DD Billadeau, AD Hess, BD Smith, JE Karp, SH Kaufmann
The Journal of biological chemistry 2014
Autophagy facilitates the development of resistance to the tumor necrosis factor superfamily member TRAIL in breast cancer
S Lv, X Wang, N Zhang, M Sun, W Qi, Y Li, Q Yang
International journal of oncology 2014
Pathobiology of Human Disease
S Akilesh
Pathobiology of Human Disease 2014
Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells
HO Jin, YH Lee, JA Park, HN Lee, JH Kim, JY Kim, BR Kim, SE Hong, HA Kim, EK Kim, WC Noh, JI Kim, YH Chang, SI Hong, YJ Hong, IC Park, JK Lee
Journal of Cancer Research and Clinical Oncology 2014
Sandwich-Type Au-PEI/DNA/PEI-Dexa Nanocomplex for Nucleus-Targeted Gene Delivery in Vitro and in Vivo
Z Chen, L Zhang, Y He, Y Li
ACS Applied Materials & Interfaces 2014
Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
JD Graves, JJ Kordich, TH Huang, J Piasecki, TL Bush, T Sullivan, IN Foltz, W Chang, H Douangpanya, T Dang, JW O’Neill, R Mallari, X Zhao, DG Branstetter, JM Rossi, AM Long, X Huang, PM Holland
Cancer Cell 2014
Anisomycin, an Inhibitor of Protein Synthesis, Overcomes TRAIL Resistance in Human Hepatocarcinoma Cells via Caspases Activation and Bid Downregulation
CY Jin, C Park, SH Hong, YH Choi
Journal of Life Science 2014
Caspase-8 as a regulator of tumor cell motility
R P Graf, N Keller, S Barbero, D Stupack
Current molecular medicine 2014
Caspase-8 as a Regulator of Tumor Cell Motility
Ryon P. Graf, Nadine Keller, Simone Barbero, Dwayne Stupack
Current molecular medicine 2014
Effects of TNF Secreting HEK Cells on B Lymphocytes' Apoptosis in Human Chronic Lymphocytic Leukemias
A Valizadeh, A Ahmadzadeh, A Teimoori, A Khodadadi, G Saki
Asian Pacific Journal of Cancer Prevention 2014
RIP1 modulates death receptor mediated apoptosis and autophagy in macrophages
Z Yao, P Zhang, H Guo, J Shi, S Liu, Y Liu, D Zheng
Molecular Oncology 2014
TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer
K Zhu, W Fang, Y Chen, S Lin, X Chen
Oncology reports 2014
Production of functional native human interleukin-2 in tobacco chloroplasts.
Zhang XH, Keating P, Wang XW, Huang YH, Martin J, Hartmann JX, Liu A
Molecular Biotechnology 2014
Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells.
Jin HO, Lee YH, Park JA, Lee HN, Kim JH, Kim JY, Kim B, Hong SE, Kim HA, Kim EK, Noh WC, Kim JI, Chang YH, Hong SI, Hong YJ, Park IC, Lee JK
Journal of Cancer Research and Clinical Oncology 2014
Plant Sterols as Anticancer Nutrients: Evidence for Their Role in Breast Cancer
B Grattan
Nutrients 2013
Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy
F Qiu, M Hu, B Tang, X Liu, H Zhuang, J Yang, ZC Hua
Scientific Reports 2013
Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury
T Adachi, N Sugiyama, T Gondai, H Yagita, T Yokoyama
ACTA HISTOCHEMICA ET CYTOCHEMICA 2013
Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus mAb
M Kouno, C Lin, NM Schechter, D Siegel, X Yang, JT Seykora, JR Stanley
Journal of Investigative Dermatology 2013
Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family
K Azijli, B Weyhenmeyer, GJ Peters, S Jong, FA Kruyt
Cell Death and Differentiation 2013
Small-Molecule IAP Antagonists Sensitize Cancer Cells to TRAIL-Induced Apoptosis: Roles of XIAP and cIAPs
D Finlay, M Vamos, M Gonzalez-Lopez, RJ Ardecky, SR Ganji, H Yuan, Y Su, TR Cooley, CT Hauser, K Welsh, JC Reed, ND Cosford, K Vuori
Molecular cancer therapeutics 2013
Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth
A Aronin, S Amsili, TB Prigozhina, K Tzdaka, J Rachmilewitz, N Shani, ML Tykocinski, MD Elhalel
PloS one 2013
The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer
N Zhang, X Wang, Q Huo, X Li, H Wang, P Schneider, G Hu, Q Yang
The Journal of biological chemistry 2013
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
JE Allen, G Krigsfeld, PA Mayes, L Patel, DT Dicker, AS Patel, NG Dolloff, E Messaris, KA Scata, W Wang, JY Zhou, GS Wu, WS El-Deiry
Science Translational Medicine 2013
Functional roles of tumor necrosis factor-related apoptosis-inducing ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-κB pathway to induce metastatic potential
K Takahashi, K Takeda, I Saiki, T Irimura, Y Hayakawa
Cancer Science 2013
Facilitating Cytokine-Mediated Cancer Cell Death by Proteobacterial N -Acylhomoserine Lactones
V Kravchenko, AL Garner, J Mathison, A Seit-Nebi, J Yu, IP Gileva, R Ulevitch, KD Janda
ACS chemical biology 2013
Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand
NS Azahri, MM Kavurma
Cellular and Molecular Life Sciences 2013
Real-time detection of cellular death receptor-4 activation by fluorescence resonance energy transfer
Z Dereli-Korkut, H Gandhok, LG Zeng, S Waqas, X Jiang, S Wang
Biotechnology and Bioengineering 2013
Fluid shear stress sensitizes cancer cells to receptor-mediated apoptosis via trimeric death receptors
MJ Mitchell, MR King
New Journal of Physics 2013
Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects
R Yu, L Deedigan, SM Albarenque, A Mohr, RM Zwacka
Cell Death and Disease 2013
The Synergistic Apoptotic Interaction of Indole-3-Carbinol and Genistein with TRAIL on Endometrial Cancer Cells
B Parajuli, SJ Shin, SH Kwon, SD Cha, HG Lee, I Bae, CH Cho
Journal of Korean Medical Science 2013
TRAIL on trial: preclinical advances in cancer therapy
DW Stuckey, K Shah
Trends in Molecular Medicine 2013
Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer
W Zhu, H Zhang, Y Shi, M Song, B Zhu, L Wei
Cancer biology & therapy 2013
Persistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine
P Sridevi, MK Nhiayi, RL Setten, JY Wang
PloS one 2013
Down-regulation of RIP1 by 2-deoxy-D-glucose sensitizes breast cancer cells to TRAIL-induced apoptosis
YY Huang, H Liu, Y Li, LJ Pu, CC Jiang, JC Xu, ZW Jiang
European Journal of Pharmacology 2013
Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins
L Yang, Q Wang, D Li, Y Zhou, X Zheng, H Sun, J Yan, L Zhang, Y Lin, X Wang
Apoptosis 2013
Resistance of cancer cells to the TRAIL-induced apoptosis in confluent cultures
RS Fadeev, AV Chekanov, NV Dolgikh, VS Akatov
Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology 2013
PMN and anti-tumor immunity—The case of bladder cancer immunotherapy
EL Brincks, MC Risk, TS Griffith
Seminars in Cancer Biology 2013
Fabrication of tumor necrosis factor-related apoptosis inducing ligand (TRAIL)/ALG modified CaCO3 as drug carriers with the function of tumor selective recognition
W Cui, Y Cui, J Zhao, J Li
Journal of Materials Chemistry B 2013
Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib
K Wahl, M Siegemund, F Lehner, F Vondran, A Nüssler, F Länger, T Krech, R Kontermann, MP Manns, K Schulze-Osthoff, K Pfizenmaier, H Bantel
Hepatology 2013
Functional roles of tumor necrosis factor-related apoptosis-inducing ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-κB pathway to induce metastatic potential
K Takahashi, K Takeda, I Saiki, T Irimura, Y Hayakawa
Cancer Science 2013
Targeting apoptosis pathways in glioblastoma
G Eisele, M Weller
Cancer Letters 2013
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells
A Giacomini, M Righi, L Cleris, SL Locatelli, S Mitola, MG Daidone, AM Gianni, C Carlo-Stella
Angiogenesis 2013
Tissue decellularization by activation of programmed cell death
PE Bourgine, BE Pippenger, A Todorov, L Tchang, I Martin
Biomaterials 2013
Cytotherapies in multiple myeloma: a complementary approach to current treatments?
S Ciavarella, A Caselli, A Savonarola, AV Tamma, M Tucci, F Silvestris
Expert Opinion on Biological Therapy 2013
Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation
MJ Yoon, YJ Kang, IY Kim, EH Kim, JA Lee, JH Lim, TK Kwon, KS Choi
Carcinogenesis 2013
Inhibition of vacuolar ATPase attenuates the TRAIL-induced activation of caspase-8 and modulates the trafficking of TRAIL receptosomes
V Horova, N Hradilova, I Jelinkova, M Koc, J Svadlenka, J Brazina, M Klima, J Slavik, AH Vaculova, L Andera
FEBS Journal 2013
Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins
S Park, DH Cho, L Andera, N Suh, I Kim
Molecular and Cellular Biochemistry 2013
The TRAIL of oncogenes to apoptosis: Oncogenes, TRAIL and Apoptosis for Cancer Therapy
E Oikonomou, A Pintzas
BioFactors 2013
Stem Cell Therapeutics for Cancer: Shah/Stem Cell Therapeutics for Cancer
A Pessina, A Bonomi, E Parati, R Pallini, G Alessandri
Stem Cell Therapeutics for Cancer: Shah/Stem Cell Therapeutics for Cancer 2013
Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
LQ Pan, HB Wang, J Lai, YC Xu, C Zhang, SQ Chen
Biomaterials 2013
Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis
T He, S Haapa-Paananen, VO Kaminskyy, P Kohonen, V Fey, B Zhivotovsky, O Kallioniemi, M Perälä
Oncogene 2013
Targeting apoptosis pathways in cancer stem cells
M Signore, L Ricci-Vitiani, RD Maria
Cancer Letters 2013
Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer
HJ Byeon, SH Choi, JS Choi, I Kim, BS Shin, ES Lee, ES Park, KC Lee, YS Youn
Acta Biomaterialia 2013
A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
ZA Wainberg, WA Messersmith, PF Peddi, AV Kapp, A Ashkenazi, S Royer-Joo, CC Portera, MF Kozloff
Clinical Colorectal Cancer 2013
Aortic valvular interstitial cells apoptosis and calcification is mediated by TNF-related apoptosis-inducing ligand
A Galeone, G Brunetti, A Oranger, G Greco, AD Benedetto, G Mori, S Colucci, A Zallone, D Paparella, M Grano
International Journal of Cardiology 2013
Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and 1 H MR spectroscopy: MRI/MRS of Breast Tumor Xenografts
G Zhai, H Kim, D Sarver, S Samuel, L Whitworth, H Umphrey, DK Oelschlager, TM Beasley, KR Zinn
Journal of Magnetic Resonance Imaging 2013
Polyphenols Isolated from Propolis Augment TRAIL-Induced Apoptosis in Cancer Cells
E Szliszka, W Krol
Evidence-Based Complementary and Alternative Medicine 2013
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
J Lemke, S Karstedt, MA el Hay, A Conti, F Arce, A Montinaro, K Papenfuss, MA El-Bahrawy, H Walczak
Cell Death and Differentiation 2013
Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
A Meijer, FA Kruyt, AG van der Zee, H Hollema, P Le, KA Hoor, GM Groothuis, WJ Quax, EG de Vries, S Jong
British Journal of Cancer 2013
Ethanolic Extract of Polish Propolis: Chemical Composition and TRAIL-R2 Death Receptor Targeting Apoptotic Activity against Prostate Cancer Cells
E Szliszka, A Sokół-Łętowska, AZ Kucharska, D Jaworska, ZP Czuba, W Król
Evidence-Based Complementary and Alternative Medicine 2013
Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis
B Bonavida, A Jazirehi, MI Vega, S Huerta-Yepez, S Baritaki
Forum on immunopathological diseases and therapeutics 2013
Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27
G Mellier, D Liu, G Bellot, AL Holme, S Pervaiz
Cell Death and Disease 2013
Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker
A Krieg, S Mersch, N Wolf, NH Stoecklein, PE Verde, JS 2nd, S Heikaus, HE Gabbert, WT Knoefel, C Mahotka
BMC Cancer 2013
Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways
M Dijk, A Halpin-McCormick, T Sessler, A Samali, E Szegezdi
Cell Death and Disease 2013
Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy
Y Zheng, H Chen, X Zeng, Z Liu, X Xiao, Y Zhu, D Gu, L Mei
Nanoscale research letters 2013
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer
B Lim, A Scicchitano, C Beachler, N Gusani, N Sarwani, Z Yang, K Staveley-O’Carroll, A Ashkenazi, C Portera, WS El-Deiry
Cancer biology & therapy 2013
Manipulating the apoptotic pathway: potential therapeutics for cancer patients
DJ Bates, LD Lewis
British Journal of Clinical Pharmacology 2013
Death receptors as targets in cancer
O Micheau, S Shirley, F Dufour
British Journal of Pharmacology 2013
Down-Modulation of Expression, or Dephosphorylation, of IG20/MADD in Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Resistant Thyroid Cancer Cells Makes Them Susceptible to Treatment with This Ligand
LC Li, S Jayarama, T Pilli, L Qian, F Pacini, BS Prabhakar
Thyroid 2013
Targeted Therapies in Oncology, Second Edition
JY Blay, A Dufresne, O Derbel, I Ray-Coquard
Targeted Therapies in Oncology, Second Edition 2013
Identification of death receptors DR4 and DR5 in HTB-12 astrocytoma cell lines and determination of TRAIL sensitivity
E Riddick, S Evans, J Rousch, E Gwebu, HN Banerjee
Journal of Solid Tumors 2013
Azadirone, a Limonoid Tetranortriterpene, Induces Death Receptors and Sensitizes Human Cancer Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) through a p53 Protein-independent Mechanism: EVIDENCE FOR THE ROLE OF THE ROS-ERK-CHOP-DEATH RECEPTOR PATHWAY
SC Gupta, SK Francis, MS Nair, YY Mo, BB Aggarwal
The Journal of biological chemistry 2013
Increased Serum S-TRAIL Level in Newly Diagnosed Stage-IV Lung Adenocarcinoma but not Squamous Cell Carcinoma is Correlated with Age and Smoking
A Kargi, A Bisgin, AD Yalcin, AB Kargi, E Sahin, S Gumuslu
Asian Pacific Journal of Cancer Prevention 2013
Claudin-7 suppresses the cytotoxicity of TRAIL-expressing mesenchymal stem cells in H460 human non-small cell lung cancer cells
P Xia, W Wang, Y Bai
Apoptosis 2013
Production of Functional Native Human Interleukin-2 in Tobacco Chloroplasts
XH Zhang, P Keating, XW Wang, YH Huang, J Martin, JX Hartmann, A Liu
Molecular Biotechnology 2013
The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases
R Liu, X Ma, H Wang, Y Xi, M Qian, W Yang, D Luo, L Fan, X Xia, J Zhou, L Meng, S Wang, D Ma, L Xi
Journal of Molecular Medicine 2013
Antibody-Free LC-MS/MS Quantification of rhTRAIL in Human and Mouse Serum
D Wilffert, CR Reis, J Hermans, N Govorukhina, T Tomar, S Jong, WJ Quax, NC van de Merbel, R Bischoff
Analytical Chemistry 2013
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance
AR Jazirehi, D Arle
American Journal of Clinical and Experimental Immunology 2013
AXL mediates TRAIL resistance in esophageal adenocarcinoma
J Hong, A Belkhiri
Neoplasia (New York, N.Y.) 2013
Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
H Walczak
Cold Spring Harbor perspectives in biology 2013
Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5
X Di, G Zhang, Y Zhang, K Takeda, LA Rosado, B Zhang
Oncotarget 2013
TRAIL induces apoptosis in oral squamous carcinoma cells: a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5
J Chen, CM Mikelis, Y Zhang, JS Gutkind, B Zhang
Oncotarget 2013
Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance
SA Maxwell, S Mousavi-Fard
Experimental biology and medicine (Maywood, N.J.) 2013
Persistent Inhibition of ABL Tyrosine Kinase Causes Enhanced Apoptotic Response to TRAIL and Disrupts the Pro-Apoptotic Effect of Chloroquine
P Sridevi, MK Nhiayi, RL Setten, JY Wang, A Villunger
PloS one 2013
Fn14•Trail Effectively Inhibits Hepatocellular Carcinoma Growth
A Aronin, S Amsili, TB Prigozhina, K Tzdaka, J Rachmilewitz, N Shani, ML Tykocinski, MD Elhalel, T Takehara
PloS one 2013
Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma
C KARLISCH, K HARATI, A Chromik, D BULUT, L Klein-Hitpass, O GOERTZ, T HIRSCH, M LEHNHARDT, W UHL, A DAIGELER
International journal of oncology 2013
Peroxisome proliferator-activated receptor γ ligand troglitazone and TRAIL synergistically induce apoptosis
M Koyama, Y Sowa, M Horinaka, AE Goda, J Fujiwara, T Sakai
Oncology reports 2013
Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy
KI Pishas, SJ Neuhaus, MT Clayer, A Adwal, MP Brown, A Evdokiou, DF Callen, PM Neilsen
Oncology reports 2013
CAPE promotes TRAIL-induced apoptosis through the upregulation of TRAIL receptors via activation of p38 and suppression of JNK in SK-Hep1 hepatocellular carcinoma cells
EY Kim, JH Ryu, AK Kim
International journal of oncology 2013
Ibuprofen enhances TRAIL-induced apoptosis through DR5 upregulation
M Todo, M Horinaka, M Tomosugi, R Tanaka, H Ikawa, Y Sowa, H Ishikawa, H Fujiwara, E Otsuji, T Sakai
Oncology reports 2013
Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes
J Pospisilova, O Vit, L Lorkova, M Klanova, J Zivny, P Klener, J Petrak
International journal of molecular medicine 2013
Analysis of oncology research from 2001 to 2010: A scientometric perspective
H Shao, QI YU, X Bo, Z Duan
Oncology reports 2013
Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8
M Shinnoh, M Horinaka, T Yasuda, S Yoshikawa, M Morita, T Yamada, T Miki, T Sakai
International journal of oncology 2013
Emetine enhances the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of pancreatic cancer cells by downregulation of myeloid cell leukemia sequence-1 protein
Y Han, S Park, AW Kinyua, L Andera, KW Kim, I Kim
Oncology reports 2013
Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells
X Liu, J Wang, H Wang, S Liu, YE LIANG, Z Lv, Q Zhou, W Ding
Oncology reports 2013
Cancer Targeted Drug Delivery
YH Bae, RJ Mrsny, K Park
2013
Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy
B Bonavida
2013
Role of Capsaicin in Oxidative Stress and Cancer
SK Srivastava
2013
TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.
Chen JJ, Mikelis CM, Zhang Y, Gutkind JS, Zhang B
Oncotarget 2013
Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.
Park S, Cho DH, Andera L, Suh N, Kim I
Molecular and Cellular Biochemistry 2013
The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases.
Liu R, Ma X, Wang H, Xi Y, Qian M, Yang W, Luo D, Fan L, Xia X, Zhou J, Meng L, Wang S, Ma D, Xi L
Journal of Molecular Medicine 2013
The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cells
BI Koh, Y Kang
EMBO reports 2012
Epirubicin potentiates recombinant adeno-associated virus type 2/5-mediated TRAIL expression in fibroblast-like synoviocytes and augments the antiarthritic effects of rAAV2/5-TRAIL
J Shi, Z Diao, J Zhou, J Zhu, H Yuan, X You, Y Liu, D Zheng
Arthritis & Rheumatism 2012
TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what’s new?
A Neve, A Corrado, FP Cantatore
Clinical and Experimental Medicine 2012
TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation
S Jouan-Lanhouet, MI Arshad, C Piquet-Pellorce, C Martin-Chouly, GL Moigne-Muller, FV Herreweghe, N Takahashi, O Sergent, D Lagadic-Gossmann, P Vandenabeele, M Samson, MT Dimanche-Boitrel
Cell Death and Differentiation 2012
Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth
BR James, A Tomanek-Chalkley, EJ Askeland, T Kucaba, TS Griffith, LA Norian
Journal of immunology (Baltimore, Md. : 1950) 2012
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to TRAIL-Induced Apoptosis
S Mamaghani, CD Simpson, PM Cao, M Cheung, S Chow, B Bandarchi, AD Schimmer, DW Hedley
PloS one 2012
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist
V Subbiah, RE Brown, J Buryanek, J Trent, A Ashkenazi, R Herbst, R Kurzrock
Molecular cancer therapeutics 2012
Significance of serum tumor necrosis factor-related apoptosis-inducing ligand as a prognostic biomarker for renal cell carcinoma
D Toiyama, N Takaha, M Shinnoh, T Ueda, Y Kimura, T Nakamura, F Hongo, K Mikami, K Kamoi, A Kawauchi, T Miki
Molecular and Clinical Oncology 2012
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
LY Dimberg, CK Anderson, R Camidge, K Behbakht, A Thorburn, HL Ford
Oncogene 2012
Apigenin Sensitizes Huh-7 Human Hepatocellular Carcinoma Cells to TRAIL-induced Apoptosis
EY Kim, AK Kim
Biomolecules and Therapeutics 2012
Effect of Smac on TRAIL-induced apoptosis of prostate cancer cell line PC-3 and the molecular mechanism
M Wang, T Huang, F Zeng, G Jiang, L Wang, L Zheng, Q Tong
Journal of Huazhong University of Science and Technology [Medical Sciences] 2012
Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer
C Stolfi, F Pallone, G Monteleone
International journal of molecular sciences 2012
Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL*
E Szegezdi, AM van der Sloot, D Mahalingam, L O'Leary, RH Cool, IG Muñoz, G Montoya, WJ Quax, S Jong, A Samali, L Serrano
Molecular & cellular proteomics : MCP 2012
The Transmembrane Domains of TNF-Related Apoptosis-Inducing Ligand (TRAIL) Receptors 1 and 2 Co-Regulate Apoptotic Signaling Capacity
S Neumann, T Bidon, M Branschädel, A Krippner-Heidenreich, P Scheurich, M Doszczak
PloS one 2012
Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer
L Guo, L Fan, J Ren, Z Pang, Y Ren, J Li, Z Wen, Y Qian, L Zhang, H Ma, X Jiang
International Journal of Nanomedicine 2012
Mesenchymal Stem Cell-Based Tumor-Targeted Gene Therapy in Gastrointestinal Cancer
Q Bao, Y Zhao, H Niess, C Conrad, B Schwarz, KW Jauch, R Huss, PJ Nelson, CJ Bruns
Stem Cells and Development 2012
Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo
S Vitovski, AD Chantry, MA Lawson, PI Croucher
PloS one 2012
PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting
TH Kim, YG Jo, HH Jiang, SM Lim, YS Youn, S Lee, X Chen, Y Byun, KC Lee
Journal of Controlled Release 2012
Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation
C Qiao, M Hu, L Guo, M Lv, Z Lin, J Geng, X Lang, X Li, Y Li, Y Ma, J Feng, B Shen
BMC Immunology 2012
Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice
L Zheng, Z Weilun, J Minghong, Z Yaxi, L Shilian, L Yanxin, Z Dexian
BMC Cancer 2012
Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells
K Kajitani, Y Tanaka, K Arihiro, T Kataoka, H Ohdan
Breast Cancer Research and Treatment 2012
An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation
BS Lee, SU Kang, HS Hwang, YS Kim, ES Sung, YS Shin, YC Lim, CH Kim
Cancer Letters 2012
In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells
S Ciavarella, G Grisendi, M Dominici, M Tucci, O Brunetti, F Dammacco, F Silvestris
British Journal of Haematology 2012
Isoobtusilactone A Sensitizes Human Hepatoma Hep G2 Cells to TRAIL-Induced Apoptosis via ROS and CHOP-Mediated Up-regulation of DR5
CY Chen, SJ Yiin, JL Hsu, WC Wang, SC Lin, CL Chern
Journal of Agricultural and Food Chemistry 2012
Apoptosis-Modulating Drugs for Improved Cancer Therapy
M Ocker, M Höpfner
European Surgical Research 2012
Novel targeted agents for the treatment of advanced breast cancer
M la Vega, E Díaz-Cantón, RH Alvarez
Future Medicinal Chemistry 2012
The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: what is next?
AC Bellail, C Hao
Expert Review of Anticancer Therapy 2012
Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy
Y Cai, X Liu, W Huang, K Zhang, X Liu
Acta Biochimica et Biophysica Sinica 2012
Mesenchymal Stem Cells as a Novel Carrier for Targeted Delivery of Gene in Cancer Therapy Based on Nonviral Transfection
YL Hu, B Huang, TY Zhang, PH Miao, GP Tang, Y Tabata, JQ Gao
Molecular Pharmaceutics 2012
The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells
HY Tseng, LH Chen, Y Ye, KH Tay, CC Jiang, ST Guo, L Jin, P Hersey, XD Zhang
Carcinogenesis 2012
Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth
NS Wilson, A Yang, B Yang, S Couto, H Stern, A Gogineni, R Pitti, S Marsters, RM Weimer, M Singh, A Ashkenazi
Cancer Cell 2012
Calyculin A causes sensitization to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by ROS-mediated down-regulation of cellular FLICE-inhibiting protein (c-FLIP) and by enhancing death receptor 4 mRNA stabilization
SM Woo, K Min, TK Kwon
Apoptosis 2012
Antibody–cytokine fusion proteins
RE Kontermann
Archives of Biochemistry and Biophysics 2012
Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?
LH Wilt, J Kroon, G Jansen, S Jong, GJ Peters, FA Kruyt
Critical Reviews in Oncology/Hematology 2012
Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
J Molinsky, M Klanova, M Koc, L Beranova, L Andera, Z Ludvikova, M Bohmova, Z Gasova, M Strnad, R Ivanek, M Trneny, E Necas, J Zivny, P Klener
Leukemia & Lymphoma 2012
Antitumor effect of human TRAIL on adenoid cystic carcinoma using magnetic nanoparticle–mediated gene expression
L Miao, K Zhang, C Qiao, X Jin, C Zheng, B Yang, H Sun
Nanomedicine: Nanotechnology, Biology and Medicine 2012
The three Rs along the TRAIL: Resistance, re-sensitization and reactive oxygen species (ROS)
G Mellier, S Pervaiz
Free Radical Research 2012
Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors
X Zhang, T Inukai, K Hirose, K Akahane, I Kuroda, H Honna-Oshiro, K Kagami, K Goi, K Nakamura, M Kobayashi, M Endo, H Yagita, H Kurosawa, AT Look, H Honda, T Inaba, S Nakazawa, K Sugita
Leukemia 2012
Translating TRAIL-receptor targeting agents to the clinic
MW Hollander, JA Gietema, S Jong, AM Walenkamp, AK Reyners, CN Oldenhuis, EG de Vries
Cancer Letters 2012
Synergetic toxicity of DATR, a recombinant soluble human TRAIL mutant, in combination with traditional chemotherapeutics in rats
Y Zou, X Zhang, Y Mao, M Huang, B Yuan, Z Chu, G Lu
Regulatory Toxicology and Pharmacology 2012
Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner
DO Moon, Y Asami, H Long, JH Jang, EY Bae, BY Kim, YH Choi, CH Kang, JS Ahn, GY Kim
Toxicology in Vitro 2012
TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosis
Z Diao, J Shi, J Zhu, H Yuan, Q Ru, S Liu, Y Liu, D Zheng
Cancer Immunology, Immunotherapy 2012
PRMT5 suppresses DR4-mediated CCL20 release via NF-κB pathway
DS Wang, D Liu, J Gao, M Liu, SL Liu, YX Liu, DX Zheng
Chinese Science Bulletin 2012
Increase in resistance of A431 cancer cells to TRAIL-induced apoptosis in confluent cultures
RS Fadeev, AV Chekanov, NV Dolgikh, VS Akatov
Biophysics 2012
Human Umbilical Cord Mesenchymal Stem Cells as Vehicles of CD20-specific TRAIL Fusion Protein Delivery: a Double-target Therapy against non-Hodgkin’s Lymphoma
D Xiong, S Li, Z Li, H Peng, X Yuan, L Jiang, Y Zhang, D Fan, X Hu, D Xiong, M Yang
Molecular Pharmaceutics 2012
Bax is Essential for Death Receptor-Mediated Apoptosis in Human Colon Cancer Cells
S Zhu, T Li, J Tan, X Yan, D Zhang, C Zheng, Y Chen, Z Xiang, H Cui
Cancer Biotherapy & Radiopharmaceuticals 2012
Synergistic induction of TRAIL-mediated apoptosis by anisomycin in human hepatoma cells via the BH3-only protein Bid and c-Jun/AP-1 signaling pathway
CY Jin, C Park, SH Hong, MH Han, JW Jeong, HD Xu, HM Liu, GY Kim, WJ Kim, YH Yoo, YH Choi
Biomedicine & Pharmacotherapy 2012
Anisomycin treatment enhances TRAIL-mediated apoptosis in renal carcinoma cells through the down-regulation of Bcl-2, c-FLIP(L) and Mcl-1
BR Seo, K Min, S Kim, JW Park, WK Park, TJ Lee, TK Kwon
Biochimie 2012
Lipoxygenase inhibitor MK886 potentiates TRAIL-induced apoptosis through CHOP- and p38 MAPK-mediated up-regulation of death receptor 5 in malignant glioma
JS Woo, SM Kim, CH Jeong, CH Ryu, SS Jeun
Biochemical and Biophysical Research Communications 2012
Inhibition of SIRT1 Sensitizes TRAIL-Resistant MCF-7 Cells by Upregulation of DR5 and Inhibition of c-FLIP
SH Lee, HB Kim, MJ Kim, JW Lee, JH Bae, DW Kim, CD Kang, SH Kim
Journal of Life Science 2012
Hyperthermia Promotes Apoptosis and Suppresses Invasion in C6 Rat Glioma Cells
DC Wang, Y Zhang, HY Chen, XL Li, LJ Qin, YJ Li, HY Zhang, S Wang
Asian Pacific Journal of Cancer Prevention 2012
A Novel Role of IGF1 in Apo2L/TRAIL-Mediated Apoptosis of Ewing Tumor Cells
F Valen, H Harrer, M Hotfilder, U Dirksen, T Pap, G Gosheger, HU Humpf, H Jürgens
Sarcoma 2012
HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells
DM Pineda, DW Rittenhouse, CC Valley, JA Cozzitorto, RA Burkhart, B Leiby, JM Winter, MC Weber, ER Londin, I Rigoutsos, CJ Yeo, M Gorospe, AK Witkiewicz, JN Sachs, JR Brody
Cancer biology & therapy 2012
Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies
EW Duiker, EC Dijkers, HL Heerspink, S Jong, AG van der Zee, PL Jager, JG Kosterink, EG de Vries, MN Hooge
British Journal of Pharmacology 2012
Cardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins
VR Yadav, S Prasad, BB Aggarwal
British Journal of Pharmacology 2012
ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2
R Martín-Pérez, M Niwa, A López-Rivas
Apoptosis 2012
Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells
JJ Chen, HC Shen, LA Rosado, Y Zhang, X Di, B Zhang
Oncotarget 2012
TRAIL apoptotic pathway-targeted therapies for NSCLC
Anita C Bellail, Chunhai Hao
Translational Lung Cancer Research 2012
Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo
S Vitovski, AD Chantry, MA Lawson, PI Croucher, C Bunce
PloS one 2012
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to TRAIL-Induced Apoptosis
S Mamaghani, CD Simpson, PM Cao, M Cheung, S Chow, B Bandarchi, AD Schimmer, DW Hedley, SB Bratton
PloS one 2012
Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL
E Szegezdi, AM van der Sloot, D Mahalingam, L O'Leary, RH Cool, IG Muñoz, G Montoya, WJ Quax, S Jong, A Samali, L Serrano
Molecular & cellular proteomics : MCP 2012
Differential susceptibility of gastric cancer cells to TRAIL-induced apoptosis
NM Song, S Jun, DY Zang, SG Kim, HR Park, D Kang
Oncology reports 2012
Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo
H Zhang, A Sui, Z Wang, S Liu, R Yao
International journal of molecular medicine 2012
Tagged and untagged TRAIL show different activity against tumor cells
K Zhao, Y Wang, X Wang, Y Wang, Y Ma
Oncology Letters 2012
Information Technology and Agricultural Engineering
E Zhu, S Sambath
2012
Nutrition, Diet and Cancer
S Shankar, RK Srivastava
2012
TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4(+)CD25 (+) Treg apoptosis.
Diao Z, Shi J, Zhu J, Yuan H, Ru Q, Liu S, Liu Y, Zheng D
Cancer Immunology, Immunotherapy 2012
2A Peptide-based, Lentivirus-mediated Anti-death Receptor 5 Chimeric Antibody Expression Prevents Tumor Growth in Nude Mice
M Li, Y Wu, Y Qiu, Z Yao, S Liu, Y Liu, J Shi, D Zheng
Molecular Therapy 2011
Osteoprotegerin (OPG) and Related Proteins (RANK, RANKL and TRAIL) in Thyroid Disease
SK Sood, S Balasubramanian, S Higham, M Fernando, B Harrison
World Journal of Surgery 2011
KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP Levels
D Llobet, N Eritja, M Domingo, L Bergada, C Mirantes, M Santacana, J Pallares, A Macià, A Yeramian, M Encinas, G Moreno-Bueno, J Palacios, RE Lewis, X Matias-Guiu, X Dolcet
The American Journal of Pathology 2011
Role of TLR2-dependent inflammation in metastatic progression
S Kim, M Karin
Annals of the New York Academy of Sciences 2011
Volatile Anesthetics Protect Cancer Cells against Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis via Caveolins
Y Kawaraguchi, YT Horikawa, AN Murphy, F Murray, A Miyanohara, SS Ali, BP Head, PM Patel, DM Roth, HH Patel
Anesthesiology 2011
Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis
V Kedinger, S Muller, H Gronemeyer
Molecular Cancer 2011
TNF related apoptosis-inducing ligand and its receptors in ocular tumors
Q Ning, L Hou, M Meng, BR Pan, XH Zhao
International Journal of Ophthalmology 2011
Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
S Shirley, A Morizot, O Micheau
Recent Patents on Anti-Cancer Drug Discovery 2011
The therapeutic potential of TRAIL receptor signalling in cancer cells
R Yerbes, C Palacios, A López-Rivas
Clinical and Translational Oncology 2011
Combined modality therapy with TRAIL or agonistic death receptor antibodies
HM Amm, PG Oliver, CH Lee, Y Li, DJ Buchsbaum
Cancer biology & therapy 2011
Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells
HM Amm, T Zhou, AD Steg, H Kuo, Y Li, DJ Buchsbaum
Molecular cancer research : MCR 2011
Modulation of CCAAT/Enhancer Binding Protein Homologous Protein (CHOP)-dependent DR5 Expression by Nelfinavir Sensitizes Glioblastoma Multiforme Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)*
X Tian, J Ye, M Alonso-Basanta, SM Hahn, C Koumenis, JF Dorsey
The Journal of biological chemistry 2011
Encyclopedia of Life Sciences
B Dahlbäck
Encyclopedia of Life Sciences 2011
Oxidative Stress and Disease
I Paur, M Carlsen, B Halvorsen, R Blomhoff
Herbal Medicine 2011
The scavenging of superoxide radicals promotes apoptosis induced by a novel cell-permeable fusion protein, sTRAIL:FeSOD, in tumor necrosis factor-related apoptosis-inducing ligand-resistant leukemia cells
H Tang, Y Qin, J Li, X Gong
BMC Biology 2011
Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts
Y Liu, F Lang, X Xie, S Prabhu, J Xu, D Sampath, K Aldape, G Fuller, VK Puduvalli
Cell Death and Disease 2011
Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5
CM van Geelen, B Pennarun, PT Le, EG de Vries, S Jong
BMC Cancer 2011
Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis
MS Beausoleil, EB Schulze, D Goodale, CO Postenka, AL Allan
BMC Cancer 2011
Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis
EW Duiker, A Meijer, AR van der Bilt, GJ Meersma, N Kooi, AG van der Zee, EG de Vries, S Jong
British Journal of Cancer 2011
Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway
CE Badr, T Wurdinger, J Nilsson, JM Niers, M Whalen, A Degterev, BA Tannous
Neuro-Oncology 2011
Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector
BC Ahn, JA Ronald, YI Kim, R Katzenberg, A Singh, R Paulmurugan, S Ray, LV Hofmann, SS Gambhir
Gene Therapy 2011
Heterogeneity of primary glioblastoma cells in the expression of caspase-8 and the response to TRAIL-induced apoptosis
L Qi, AC Bellail, MR Rossi, Z Zhang, H Pang, S Hunter, C Cohen, CS Moreno, JJ Olson, S Li, C Hao
Apoptosis 2011
Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo
I Zinonos, A Labrinidis, M Lee, V Liapis, S Hay, V Ponomarev, P Diamond, DM Findlay, AC Zannettino, A Evdokiou
Journal of Bone and Mineral Research 2011
Targeting AML through DR4 with a novel variant of rhTRAIL
E Szegezdi, CR Reis, AM van der Sloot, A Natoni, A O’Reilly, J Reeve, RH Cool, M O’Dwyer, S Knapper, L Serrano, WJ Quax, A Samali
Journal of Cellular and Molecular Medicine 2011
TRAIL and DR5 Promote Thyroid Follicular Cell Apoptosis in Iodine Excess-Induced Experimental Autoimmune Thyroiditis in NOD Mice
X Yu, L Li, Q Li, X Zang, Z Liu
Biological Trace Element Research 2011
SOCS-3 antagonizes pro-apoptotic effects of TRAIL and resveratrol in prostate cancer cells
M Horndasch, Z Culig
The Prostate 2011
Guggulsterone sensitizes hepatoma cells to TRAIL-induced apoptosis through the induction of CHOP-dependent DR5: Involvement of ROS-dependent ER-stress
DO Moon, SY Park, YH Choi, JS Ahn, GY Kim
Biochemical Pharmacology 2011
Augmenting the Antitumor Effect of TRAIL by SOCS3 with Double-Regulated Replicating Oncolytic Adenovirus in Hepatocellular Carcinoma
RC Wei, X Cao, JH Gui, XM Zhou, D Zhong, QL Yan, WD Huang, QJ Qian, FL Zhao, XY Liu
Human Gene Therapy 2011
Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2
ES Yang, SM Woo, KS Choi, TK Kwon
Experimental Cell Research 2011
CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells
JC Lee, LC Chou, CH Huang, JG Chung, LJ Huang, KH Lee, MC Hung, TD Way, SC Kuo
European Journal of Pharmacology 2011
Biotherapeutic bioanalysis: a multi-indication case study review
HA Myler, A Given, K Kolz, JR Mora, G Hristopoulos
Bioanalysis 2011
Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma
C Röder, A Trauzold, H Kalthoff
European Journal of Cell Biology 2011
Preclinical toxicity of DATR, a recombinant soluble human TRAIL mutant, in rats and cynomolgus monkeys
X Zhang, Y Zou, Y Mao, M Huang, B Yuan, G Lu
Regulatory Toxicology and Pharmacology 2011
PEGylated TNF-Related Apoptosis-Inducing Ligand (TRAIL) Analogues: Pharmacokinetics and Antitumor Effects
TH Kim, YS Youn, HH Jiang, S Lee, X Chen, KC Lee
Bioconjugate Chemistry 2011
Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma
S Huang, J Li, L Han, S Liu, H Ma, R Huang, C Jiang
Biomaterials 2011
Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery
F Fay, KM McLaughlin, DM Small, DA Fennell, PG Johnston, DB Longley, CJ Scott
Biomaterials 2011
Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis
X Zhang, T Inukai, K Akahane, K Hirose, I Kuroda, H Honna, K Goi, K Kagami, T Tauchi, H Yagita, K Sugita
Leukemia Research 2011
Chrysin promotes tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced apoptosis in human cancer cell lines
X Li, JN Wang, JM Huang, XK Xiong, MF Chen, CN Ong, HM Shen, XF Yang
Toxicology in Vitro 2011
Growth Inhibition and Apoptosis Induced by Lupeol, a Dietary Triterpene, in Human Hepatocellular Carcinoma Cells
Y He, F Liu, L Zhang, Y Wu, B Hu, Y Zhang, Y Li, H Liu
Biological & Pharmaceutical Bulletin 2011
Role of Cell-Death Ligand-Receptor System of Granulosa Cells in Selective Follicular Atresia in Porcine Ovary
N INOUE, F MATSUDA, Y GOTO, N MANABE
Journal of Reproduction and Development 2011
Effect of β-Phenylethyl Isothiocyanate from Cruciferous Vegetables on Growth Inhibition and Apoptosis of Cervical Cancer Cells through the Induction of Death Receptors 4 and 5
LD Huong, JH Shim, KH Choi, JA Shin, ES Choi, HS Kim, SJ Lee, SJ Kim, NP Cho, SD Cho
Journal of Agricultural and Food Chemistry 2011
TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes
L Guo, L Fan, Z Pang, J Ren, Y Ren, J Li, J Chen, Z Wen, X Jiang
Journal of Controlled Release 2011
PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy
HH Jiang, TH Kim, S Lee, X Chen, YS Youn, KC Lee
Biomaterials 2011
Emerging roles of cathepsin E in host defense mechanisms
K Yamamoto, T Kawakubo, A Yasukochi, T Tsukuba
Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 2011
Radiotherapy and TRAIL for cancer therapy
OM Niemoeller, C Belka
Cancer Letters 2011
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
Y Pan, R Xu, M Peach, CP Huang, D Branstetter, W Novotny, RS Herbst, SG Eckhardt, PM Holland
British Journal of Cancer 2011
Tissue Factor/ FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1)
M Åberg, M Johnell, M Wickström, A Siegbahn
Thrombosis Research 2011
Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin
MJ Yoon, SS Park, YJ Kang, IY Kim, JA Lee, JS Lee, EG Kim, CW Lee, KS Choi
Carcinogenesis 2011
Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis
D Vindrieux, M Réveiller, J Chantepie, S Yakoub, C Deschildre, A Ruffion, M Devonec, M Benahmed, R Grataroli
Cancer Cell International 2011
Advances in Cancer Research
M Lemaire, S Deleu, ED Bruyne, EV Valckenborgh, E Menu, K Vanderkerken
Advances in Cancer Research Volume 110 2011
ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein
G Wang, Y Zhan, H Wang, W Li
Cancer Chemotherapy and Pharmacology 2011
Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL
L Piggott, N Omidvar, SM Pérez, M Eberl, RW Clarkson
Breast Cancer Research 2011
J7, a methyl jasmonate derivative, enhances TRAIL-mediated apoptosis through up-regulation of reactive oxygen species generation in human hepatoma HepG2 cells
C Park, CY Jin, HJ Hwang, GY Kim, JH Jung, WJ Kim, YH Yoo, YH Choi
Toxicology in Vitro 2011
An intermittent approach for cancer chemoprevention
X Wu, SM Lippman
Nature Reviews Cancer 2011
B Lymphocytes Are Resistant to Death Receptor 5-induced Apoptosis
RN Crowder, H Zhao, WW Chatham, T Zhou, RH Carter
Clinical Immunology 2011
Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy
CY Kim, SH Park, M Jeong, OS Kwon, H Doh, SH Kang, PD Robbins, BM Kim, DW Seol, BG Kim
Experimental & molecular medicine 2011
Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB signaling pathway
EP Jane, DR Premkumar, IF Pollack
Molecular cancer therapeutics 2011
Targeting Apoptosis Signaling Pathways for Anticancer Therapy
S Fulda
Frontiers in Oncology 2011
Cisplatin Restores TRAIL apoptotic pathway in Glioblastoma-Derived Stem Cells through Up-regulation of DR5 and Down-regulation of c-FLIP
L Ding, C Yuan, F Wei, G Wang, J Zhang, AC Bellail, Z Zhang, JJ Olson, C Hao
Cancer Investigation 2011
p53-independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: A mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis
DW Seol
Biochemical and Biophysical Research Communications 2011
IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells
CK Büneker, R Yu, L Deedigan, A Mohr, RM Zwacka
Cancer Letters 2011
Expression of Human Soluble Trail Protein in Transgenic Tobacco Nc89
D Wang, X Bai, C Ren, Y Bai, Y Wang
Procedia Environmental Sciences 2011
Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation
M Horinaka, T Yoshida, S Nakata, T Shiraishi, M Tomosugi, S Yoshikawa, M Wakada, T Sakai
Cancer Science 2011
Luteolin enhances TNF-related apoptosis-inducing ligand’s anticancer activity in a lung cancer xenograft mouse model
J Yan, Q Wang, X Zheng, H Sun, Y Zhou, D Li, Y Lin, X Wang
Biochemical and Biophysical Research Communications 2011
Enhancement of TRAIL-Mediated Apoptosis by Genistein in Human Hepatocellular Carcinoma Hep3B Cells: Roles of p38 MAPK Signaling Pathway
CY Jin, C Park, SE Park, SH Hong, YH Choi
Journal of Life Science 2011
Targeted ovarian cancer treatment: the TRAILs of resistance
NG Khaider, D Lane, I Matte, C Rancourt, A Piché
American journal of cancer research 2011
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment
G Picarda, V Trichet, S Téletchéa, D Heymann, F Rédini
American journal of cancer research 2011
Screening of genetic parameters for soluble protein expression in Escherichia coli
E Vernet, A Kotzsch, B Voldborg, M Sundström
Protein Expression and Purification 2011
Delivery of intracellular-acting biologics in pro-apoptotic therapies
H Li, CE Nelson, BC Evans, CL Duvall
Current pharmaceutical design 2011
Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer
L Norian, B James, T Griffith
Cancers 2011
Gomisin N enhances TRAIL-induced apoptosis via reactive oxygen species-mediated up-regulation of death receptors 4 and 5
H Inoue, P Waiwut, I Saiki, Y Shimada, H Sakurai
International journal of oncology 2011
WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis
SV Garimella, A Rocca, S Lipkowitz
Molecular cancer research : MCR 2011
EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis
F Xu, Y Tian, Y Huang, LL Zhang, ZZ Guo, JJ Huang, TY Lin
Chinese journal of cancer 2011
miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma
N Razumilava, SF Bronk, RL Smoot, CD Fingas, NW Werneburg, LR Roberts, JL Mott
Hepatology 2011
Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells
LC Li, S Jayaram, L Ganesh, L Qian, J Rotmensch, AV Maker, BS Prabhakar
American Journal of Obstetrics and Gynecology 2011
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts
IV Balyasnikova, SD Ferguson, Y Han, F Liu, MS Lesniak
Cancer Letters 2011
Cytokines, inflammation and colon cancer
L Klampfer
Current cancer drug targets 2011
Efficient In Vitro TRAIL-Gene Delivery in Drug-Resistant A2780/DDP Ovarian Cancer Cell Line via Magnetofection
F Li, S Niu, J Sun, H Zhu, Q Ba, Y Guo, D Shi
Journal of Nanomaterials 2011
Induction of Apoptosis in Lung Cancer Cells by TRAIL and L-leucyl-L-leucine Methyl Ester
XS Sun, L Bandura-Morgan, W Zacharias
Journal of Cancer Therapy 2011
Naturally occurring, tumor-specific, therapeutic proteins
K Argiris, C Panethymitaki, M Tavassoli
Experimental biology and medicine (Maywood, N.J.) 2011
Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
JC Soria, Z Márk, P Zatloukal, B Szima, I Albert, E Juhász, JL Pujol, J Kozielski, N Baker, D Smethurst, Y Hei, A Ashkenazi, H Stern, L Amler, Y Pan, F Blackhall
Journal of Clinical Oncology 2011
Modulation of CCAAT/Enhancer Binding Protein Homologous Protein (CHOP)-dependent DR5 Expression by Nelfinavir Sensitizes Glioblastoma Multiforme Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)
X Tian, J Ye, M Alonso-Basanta, SM Hahn, C Koumenis, JF Dorsey
The Journal of biological chemistry 2011
Implicación de NF-κB y p53 en la expresión de receptores de muerte-TRAIL y apoptosis por procianidinas en células metastásicas humanas SW620
ME Maldonado, S Bousserouel, F Gossé, A Lobstein, F Raul
Biomédica 2011
Tumors of the Central Nervous System, Volume 1
MA Hayat
2011
Attenuated, Oncolytic, but Not Wild-Type Measles Virus Infection Has Pleiotropic Effects on Human Neutrophil Function
Y Zhang, B Patel, A Dey, E Ghorani, L Rai, M Elham, AZ Castleton, AK Fielding
Journal of immunology (Baltimore, Md. : 1950) 2011
Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL
B Pennarun, JH Kleibeuker, T Oenema, JH Stegehuis, EG de Vries, S de Jong
Cellular Oncology 2011
An intermittent approach for cancer chemoprevention.
Wu X, Lippman SM
Nature reviews. Cancer 2011
Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3'-UTR microRNA
J Zhang, S Huang, H Zhang, H Wang, H Guo, G Qian, X Fan, J Lu, AR Hoffman, JF Hu, S Ge
International Journal of Cancer 2010
Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and Bid
S Schneider-Jakob, N Corazza, A Badmann, D Sidler, R Stuber-Roos, A Keogh, S Frese, M Tschan, T Brunner
Cell Death and Disease 2010
Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo
M Nagane, S Shimizu, E Mori, S Kataoka, Y Shiokawa
Neuro-Oncology 2010
Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature
C Lavazza, C Carlo-Stella, A Giacomini, L Cleris, M Righi, D Sia, MD Nicola, M Magni, P Longoni, M Milanesi, M Francolini, A Gloghini, A Carbone, F Formelli, AM Gianni
Blood 2010
Ursolic Acid, a Pentacyclin Triterpene, Potentiates TRAIL-induced Apoptosis through p53-independent Up-regulation of Death Receptors
S Prasad, VR Yadav, R Kannappan, BB Aggarwal
The Journal of biological chemistry 2010
“Combination-oriented molecular-targeting prevention” of cancer: a model involving the combination of TRAIL and a DR5 inducer
T Yoshida, M Horinaka, T Sakai
Environmental Health and Preventive Medicine 2010
Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells
P Kaler, V Galea, L Augenlicht, L Klampfer
PloS one 2010
Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL
R Yerbes, A López-Rivas
Investigational New Drugs 2010
Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo
CH Lee, KJ Park, ES Sung, A Kim, JD Choi, JS Kim, SH Kim, MH Kwon, YS Kim
Proceedings of the National Academy of Sciences 2010
Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins
B Schneider, S Münkel, A Krippner-Heidenreich, I Grunwald, WS Wels, H Wajant, K Pfizenmaier, J Gerspach
Cell Death and Disease 2010
Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin
TS Jani, J DeVecchio, T Mazumdar, A Agyeman, JA Houghton
The Journal of biological chemistry 2010
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy
NL Fox, R Humphreys, TA Luster, J Klein, G Gallant
Expert Opinion on Biological Therapy 2010
Improved Antitumor Activity and Tumor Targeting of NH 2 -Terminal–Specific PEGylated Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand
SY Chae, TH Kim, K Park, CH Jin, S Son, S Lee, YS Youn, K Kim, DG Jo, IC Kwon, X Chen, KC Lee
Molecular cancer therapeutics 2010
New insights into apoptosis signaling by Apo2L/TRAIL
F Gonzalvez, A Ashkenazi
Oncogene 2010
TRAIL-Rezeptor-Agonisten, eine neue Klasse proapoptotischer Krebstherapeutika
K Papenfuss, S Prieske, H Walczak
Onkopipeline 2010
TRAILing death in cancer
G Mellier, S Huang, K Shenoy, S Pervaiz
Molecular Aspects of Medicine 2010
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms
D Llobet, N Eritja, A Yeramian, J Pallares, A Sorolla, M Domingo, M Santacana, FJ Gonzalez-Tallada, X Matias-Guiu, X Dolcet
European Journal of Cancer 2010
APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo
G Eisele, P Roth, K Hasenbach, S Aulwurm, F Wolpert, G Tabatabai, W Wick, M Weller
Neuro-Oncology 2010
Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective
M Verheij, C Vens, B Triest
Drug Resistance Updates 2010
Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics
C Krakstad, M Chekenya
Molecular Cancer 2010
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants
CR Reis, AM van der Sloot, A Natoni, E Szegezdi, R Setroikromo, M Meijer, K Sjollema, F Stricher, RH Cool, A Samali, L Serrano, WJ Quax
Cell Death and Disease 2010
Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5
YJ Kang, IY Kim, EH Kim, MJ Yoon, SU Kim, TK Kwon, KS Choi
Experimental & molecular medicine 2010
NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL
C Aydin, AD Sanlioglu, A Bisgin, B Yoldas, L Dertsiz, B Karacay, TS Griffith, S Sanlioglu
BMC Cancer 2010
Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis
D Finlay, RD Richardson, LK Landberg, AL Howes, K Vuori
PloS one 2010
Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis
R Tiwary, W Yu, J Li, SK Park, BG Sanders, K Kline
PloS one 2010
TRAIL treatment provokes mutations in surviving cells
MM Lovric, CJ Hawkins
Oncogene 2010
Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors
MA Alcala, K Park, J Yoo, DH Lee, BH Park, BC Lee, DL Bartlett, YJ Lee
Journal of Cellular Biochemistry 2010
Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL
A Vaculova, V Kaminskyy, E Jalalvand, O Surova, B Zhivotovsky
Molecular Cancer 2010
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)
A Forero-Torres, J Shah, T Wood, J Posey, R Carlisle, C Copigneaux, FR Luo, S Wojtowicz-Praga, I Percent, M Saleh
Cancer Biotherapy & Radiopharmaceuticals 2010
FasL gene-deficient mice display a limited disruption in spermatogenesis and inhibition of mono-(2-ethylhexyl) phthalate-induced germ cell apoptosis
YC Lin, PL Yao, JH Richburg
Toxicological sciences : an official journal of the Society of Toxicology 2010
Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5
YH Jung, J Heo, YJ Lee, TK Kwon, YH Kim
Life Sciences 2010
Tumor-targeted delivery of biologically active TRAIL protein
HY Zhang, JH Man, B Liang, T Zhou, CH Wang, T Li, HY Li, WH Li, BF Jin, PJ Zhang, J Zhao, X Pan, K He, WL Gong, XM Zhang, AL Li
Cancer Gene Therapy 2010
Gliomagenesis and the use of neural stem cells in brain tumor treatment
P Achanta, NI Roman, A Quiñones-Hinojosa
Anti-cancer agents in medicinal chemistry 2010
Resveratrol: Biological and pharmaceutical properties as anticancer molecule
T Hsieh, JM Wu
BioFactors 2010
Plumbagin enhances TRAIL-mediated apoptosis through up-regulation of death receptor in human melanoma A375 cells
J Li, Q Shen, R Peng, R Chen, P Jiang, Y Li, L Zhang, J Lu
Journal of Huazhong University of Science and Technology [Medical Sciences] 2010
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development
AB Lee-Sherick, RM Linger, L Gore, AK Keating, DK Graham
British Journal of Haematology 2010
The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma
Y Wang, F Huang, H Cai, Y Wu, G He, WS Tan
Journal of Cancer Research and Clinical Oncology 2010
Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis
PL Chen, AS Easton
Biochemical and Biophysical Research Communications 2010
Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines
K Bräutigam, J Biernath-Wüpping, DO Bauerschlag, CS Kaisenberg, W Jonat, N Maass, N Arnold, I Meinhold-Heerlein
Journal of Cancer Research and Clinical Oncology 2010
Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles
SA Cillessen, CJ Meijer, M Notoya, GJ Ossenkoppele, JJ Oudejans
The Journal of Pathology 2010
TRAIL receptor targeting therapies for non-small cell lung cancer: Current status and perspectives
JH Stegehuis, LH Wilt, EG Vries, HJ Groen, S Jong, FA Kruyt
Drug Resistance Updates 2010
Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus
W Zhou, H Zhu, W Chen, X Hu, X Pang, J Zhang, X Huang, B Fang, C He
Cancer Gene Therapy 2010
Bortezomib Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells
J Liu, XJ Qu, L Xu, Y Zang, JL Qu, KZ Hou, YP Liu
Digestive Diseases and Sciences 2010
Synthetic constrained peptide selectively binds and antagonizes death receptor 5
J Vrielink, MS Heins, R Setroikromo, E Szegezdi, MM Mullally, A Samali, WJ Quax
FEBS Journal 2010
Down-regulation of RIP expression by 17-dimethylaminoethylamino-17-demethoxygeldanamycin promotes TRAIL-induced apoptosis in breast tumor cells
C Palacios, AI López-Pérez, A López-Rivas
Cancer Letters 2010
Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis
H Zhuang, W Jiang, W Cheng, K Qian, W Dong, L Cao, Q Huang, S Li, F Dou, JF Chiu, XX Fang, M Lu, ZC Hua
Lung Cancer 2010
Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells
Y Hagiwara, T Kasukabe, Y Kaneko, N Niitsu, J Okabe-Kado
International Journal of Hematology 2010
Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer
M Grimm, M Kim, A Rosenwald, B Rahden, I Tsaur, E Meier, U Heemann, CT Germer, M Gasser, AM Waaga-Gasser
European Journal of Cancer 2010
Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?
G Jacquemin, S Shirley, O Micheau
Cellular and Molecular Life Sciences 2010
Synergistic Anti-Cancer Activity by the Combination of TRAIL/APO-2L and Celastrol
H Zhu, WJ Ding, R Wu, QJ Weng, JS Lou, RJ Jin, W Lu, B Yang, QJ He
Cancer Investigation 2010
Emerging Non-transplant-based Strategies in Treating Pediatric Non-Hodgkin’s Lymphoma
L Gore, TM Trippett
Current Hematologic Malignancy Reports 2010
Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation
K Mizrahi, J Stein, M Pearl-Yafe, O Kaplan, I Yaniv, N Askenasy
Leukemia 2010
Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression
W Wang, J Zhao, H Wang, Y Sun, Z Peng, G Zhou, L Fan, X Wang, S Yang, R Wang, D Fang
Experimental Cell Research 2010
Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors
T Doi, H Murakami, A Ohtsu, N Fuse, T Yoshino, N Yamamoto, N Boku, Y Onozawa, CP Hsu, KS Gorski, G Friberg, T Kawaguchi, T Sasaki
Cancer Chemotherapy and Pharmacology 2010
Targeting of XIAP Combined with Systemic Mesenchymal Stem Cell-Mediated Delivery of sTRAIL Ligand Inhibits Metastatic Growth of Pancreatic Carcinoma Cells
A Mohr, SM Albarenque, L Deedigan, R Yu, M Reidy, S Fulda, RM Zwacka
Stem Cells 2010
Role of elevated pressure in TRAIL-induced apoptosis in human lung carcinoma cells
S Oh, D Kwon, HJ Lee, J Kim, E Lee
Apoptosis 2010
Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5
M Frese-Schaper, JA Schardt, T Sakai, GL Carboni, RA Schmid, S Frese
FEBS Letters 2010
Dryopteris crassirhizoma has anti-cancer effects through both extrinsic and intrinsic apoptotic pathways and G0/G1 phase arrest in human prostate cancer cells
SH Chang, JH Bae, DP Hong, KD Choi, SC Kim, E Her, SH Kim, CD Kang
Journal of Ethnopharmacology 2010
Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo
W Ding, T Cai, H Zhu, R Wu, C Tu, L Yang, W Lu, Q He, B Yang
Cancer Letters 2010
TRAIL and IFNα act synergistically to induce renal cell carcinoma apoptosis
PE Clark, DA Polosukhina, K Gyabaah, HL Moses, A Thorburn, R Zent
The Journal of Urology 2010
TRAIL protein expression in breast cancer cells correlates with nuclear grade
A Bilski, G Pasz-Walczak, R Kubiak, P Sek, J Chalubinska, W Fendler, K Wronski, A Piekarska, P Pluta, P Potemski, A Jeziorski, J Piekarski
Archives of Medical Science : AMS 2010
ROS and CHOP are Critical for Dibenzylideneacetone to Sensitize Tumor Cells to TRAIL Through Induction of Death Receptors and Downregulation of Cell Survival Proteins
S Prasad, VR Yadav, J Ravindran, BB Aggarwal
Cancer research 2010
HIV increases HCV-induced hepatocyte apoptosis
JY Jang, RX Shao, W Lin, E Weinberg, WJ Chung, WL Tsai, H Zhao, K Goto, L Zhang, J Mendez-Navarro, N Jilg, LF Peng, MA Brockman, RT Chung
Journal of Hepatology 2010
Programmed Cell Death 4 (PDCD4) Enhances the Sensitivity of Gastric Cancer Cells to TRAIL-Induced Apoptosis by Inhibiting the PI3K/Akt Signaling Pathway
WQ Wang, H Zhang, HB Wang, YG Sun, ZH Peng, G Zhou, SM Yang, RQ Wang, DC Fang
Molecular diagnosis & therapy 2010
Vitamins & Hormones
KJ Hare, FK Knop
Vitamins & Hormones 2010
Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells
M Horinaka, T Yoshida, A Kishi, K Akatani, T Yasuda, J Kouhara, M Wakada, T Sakai
FEBS Letters 2010
Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis
K Akahane, T Inukai, X Zhang, K Hirose, I Kuroda, K Goi, H Honna, K Kagami, S Nakazawa, K Endo, T Kubota, H Yagita, T Koyama-Okazaki, K Sugita
Experimental Hematology 2010
Exploring death receptor pathways as selective targets in cancer therapy
M Russo, A Mupo, C Spagnuolo, GL Russo
Biochemical Pharmacology 2010
Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma
KA Clawson, D Borja-Cacho, MB Antonoff, AK Saluja, SM Vickers
The Journal of surgical research 2010
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model
NV Rajeshkumar, ZA Rasheed, E García-García, F López-Ríos, K Fujiwara, WH Matsui, M Hidalgo
Molecular cancer therapeutics 2010
Targets for cancer therapy in childhood sarcomas
M Wachtel, BW Schäfer
Cancer Treatment Reviews 2010
TLR4 through IFN-  Promotes Low Molecular Mass Hyaluronan-Induced Neutrophil Apoptosis
SW Leu, L Shi, C Xu, Y Zhao, B Liu, Y Li, A Shiedlin, C Xiang, H Shen, DA Quinn, CA Hales, H Zhao
Journal of immunology (Baltimore, Md. : 1950) 2010
PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors
E Benedetti, R Galzio, B D'Angelo, MP Cerù, A Cimini
PPAR Research 2010
Tumor Associated Macrophages Protect Colon Cancer Cells from TRAIL-Induced Apoptosis through IL-1β- Dependent Stabilization of Snail in Tumor Cells
P Kaler, V Galea, L Augenlicht, L Klampfer, DY Jin
PloS one 2010
Novel HTS Strategy Identifies TRAIL-Sensitizing Compounds Acting Specifically Through the Caspase-8 Apoptotic Axis
D Finlay, RD Richardson, LK Landberg, AL Howes, K Vuori, AL Gartel
PloS one 2010
Role of Endoplasmic Reticulum Stress in α-TEA Mediated TRAIL/DR5 Death Receptor Dependent Apoptosis
R Tiwary, W Yu, J Li, SK Park, BG Sanders, K Kline, MV Blagosklonny
PloS one 2010
Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
JC Soria, E Smit, D Khayat, B Besse, X Yang, CP Hsu, D Reese, J Wiezorek, F Blackhall
Journal of Clinical Oncology 2010
Ursolic Acid, a Pentacyclin Triterpene, Potentiates TRAIL-induced Apoptosis through p53-independent Up-regulation of Death Receptors: EVIDENCE FOR THE ROLE OF REACTIVE OXYGEN SPECIES AND JNK
S Prasad, VR Yadav, R Kannappan, BB Aggarwal
The Journal of biological chemistry 2010
Inhibition of NF-κB Signaling by Quinacrine Is Cytotoxic to Human Colon Carcinoma Cell Lines and Is Synergistic in Combination with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) or Oxaliplatin
TS Jani, J DeVecchio, T Mazumdar, A Agyeman, JA Houghton
The Journal of biological chemistry 2010
Acute toxicity of a single dose DATR, recombinant soluble human TRAIL mutant, in rodents and crab-eating macaques
YX Zou, XD Zhang, Y Mao, GC Lu, M Huang, BJ Yuan
Human & Experimental Toxicology 2010
Nitric Oxide (NO) and Cancer
B Bonavida
2010
BCL-2 Protein Family
C Hetz
2010
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
RS Herbst, R Kurzrock, DS Hong, M Valdivieso, CP Hsu, L Goyal, G Juan, YC Hwang, S Wong, JS Hill, G Friberg, PM LoRusso
Clinical cancer research 2010
Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer
A El-Gazzar, P Perco, E Eckelhart, M Anees, V Sexl, B Mayer, Y Liu, W Mikulits, R Horvat, T Pangerl, D Zheng, M Krainer
Molecular cancer therapeutics 2010
TRAIL and Doxorubicin Combination Induces Proapoptotic and Antiangiogenic Effects in Soft Tissue Sarcoma In vivo
S Wang, W Ren, J Liu, G Lahat, K Torres, G Lopez, AJ Lazar, A Hayes-Jordan, K Liu, J Bankson, JD Hazle, D Lev
Clinical cancer research 2010
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
M de Bruyn, AA Rybczynska, Y Wei, M Schwenkert, GH Fey, RA Dierckx, A van Waarde, W Helfrich, E Bremer
Molecular Cancer 2010
6-Dehydrogingerdione Sensitizes Human Hepatoblastoma Hep G2 Cells to TRAIL-Induced Apoptosis via Reactive Oxygen Species-Mediated Increase of DR5
CY Chen, CJ Tai, JT Cheng, JJ Zheng, YZ Chen, TZ Liu, SJ Yiin, CL Chern
Journal of Agricultural and Food Chemistry 2010
Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells.
Liu J, Qu XJ, Xu L, Zang Y, Qu JL, Hou KZ, Liu YP
Digestive Diseases and Sciences 2010
Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells.
Hagiwara Y, Kasukabe T, Kaneko Y, Niitsu N, Okabe-Kado J
International Journal of Hematology 2010
Emerging non-transplant-based strategies in treating pediatric non-Hodgkin's lymphoma.
Gore L, Trippett TM
Current Hematologic Malignancy Reports 2010
Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.
Bräutigam K, Biernath-Wüpping J, Bauerschlag DO, von Kaisenberg CS, Jonat W, Maass N, Arnold N, Meinhold-Heerlein I
Journal of Cancer Research and Clinical Oncology 2010
Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing
TR Wilson, KM Redmond, KM McLaughlin, N Crawford, K Gately, K O'Byrne, C Le-Clorrenec, C Holohan, DA Fennell, PG Johnston, DB Longley
Cell Death and Differentiation 2009
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009
Therapeutic Targets of the TNF Superfamily
IS Grewal
2009
Therapeutic Targets of the TNF Superfamily
IS Grewal
2009
Therapeutic Targets of the TNF Superfamily
IS Grewal
2009
Therapeutic Targets of the TNF Superfamily
IS Grewal
2009
Therapeutic Targets of the TNF Superfamily
IS Grewal
2009
Therapeutic Targets of the TNF Superfamily
IS Grewal
2009
Therapeutic Targets of the TNF Superfamily
IS Grewal
2009
Therapeutic Targets of the TNF Superfamily
IS Grewal
2009
Therapeutic Targets of the TNF Superfamily
IS Grewal
2009
Therapeutic Targets of the TNF Superfamily
IS Grewal
2009
Therapeutic Targets of the TNF Superfamily
IS Grewal
2009
Regulation of CLU gene expression by oncogenes and epigenetic factors: Implications for tumorigenesis
A Sala, S Bettuzzi, S Pucci, O Chayka, M Dews, A Thomas-Tikhonenko
Advances in cancer research 2009
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma
A Labrinidis, P Diamond, S Martin, S Hay, V Liapis, I Zinonos, NA Sims, GJ Atkins, C Vincent, V Ponomarev, DM Findlay, AC Zannettino, A Evdokiou
Clinical cancer research 2009
Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1
P Moretto, SJ Hotte
Expert Opinion on Investigational Drugs 2009
Death Receptors and Cognate Ligands in Cancer
H Kalthoff
2009
Death Receptors and Cognate Ligands in Cancer
H Kalthoff
2009
Death Receptors and Cognate Ligands in Cancer
H Kalthoff
2009
Death Receptors and Cognate Ligands in Cancer
H Kalthoff
2009
Death Receptors and Cognate Ligands in Cancer
H Kalthoff
2009
Death Receptors and Cognate Ligands in Cancer
H Kalthoff
2009
Death Receptors and Cognate Ligands in Cancer
H Kalthoff
2009
Death Receptors and Cognate Ligands in Cancer
H Kalthoff
2009
Gene Therapy of Cancer
W Walther, US Stein
Gene Therapy of Cancer 2009
Gene Therapy of Cancer
W Walther, US Stein
Gene Therapy of Cancer 2009
Gene Therapy of Cancer
W Walther, US Stein
Gene Therapy of Cancer 2009
Gene Therapy of Cancer
W Walther, US Stein
Gene Therapy of Cancer 2009
Following TRAIL’s path in the immune system
C Falschlehner, U Schaefer, H Walczak
Immunology 2009
Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice
S Ganai, RB Arenas, NS Forbes
British Journal of Cancer 2009
Applications of neural and mesenchymal stem cells in the treatment of gliomas
T Kosztowski, HA Zaidi, A Quiñones-Hinojosa
Expert Review of Anticancer Therapy 2009
Life and death by death receptors
ME Guicciardi, GJ Gores
The FASEB Journal 2009
Cell death pathways – potential therapeutic targets
M MacFarlane
Xenobiotica 2009
Apoptosis in cancer: Key molecular signaling pathways and therapy targets
C Burz, I Berindan-Neagoe, O Balacescu, A Irimie
Acta Oncologica 2009
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B
W Tang, W Wang, Y Zhang, S Liu, Y Liu, D Zheng
FEBS Journal 2009
TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner
W Tang, W Wang, Y Zhang, S Liu, Y Liu, D Zheng
Cell Research 2009
Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence
J Luetzkendorf, LP Mueller, T Mueller, H Caysa, K Nerger, HJ Schmoll
Journal of Cellular and Molecular Medicine 2009
Programmed cell death pathways and current antitumor targets.
Tan ML, Ooi JP, Ismail N, Moad AI, Muhammad TS
Pharmaceutical Research 2009
Is TRAIL the holy grail of cancer therapy?
T Newsom-Davis, S Prieske, H Walczak
Apoptosis 2009
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
D Mahalingam, E Szegezdi, M Keane, S Jong, A Samali
Cancer Treatment Reviews 2009
Cell death in hematological tumors
S Fulda
Apoptosis 2009
Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia
S Fulda
British Journal of Haematology 2009
Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5
ME Gasparian, BV Chernyak, DA Dolgikh, AV Yagolovich, EN Popova, AM Sycheva, SA Moshkovskii, MP Kirpichnikov
Apoptosis 2009
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies
PA Holoch, TS Griffith
European Journal of Pharmacology 2009
Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents
KM Moxley, S Chengedza, DM Benbrook
Gynecologic Oncology 2009
Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL
JA Jiménez, X Li, YP Zhang, KH Bae, Y Mohammadi, P Pandya, C Kao, TA Gardner
Cancer Gene Therapy 2009
Gene expression profiling of dengue infected human primary cells identifies secreted mediators in vivo
A Becerra, RV Warke, K Martin, K Xhaja, N Bosch, AL Rothman, I Bosch
Journal of Medical Virology 2009
Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer
MR Loebinger, A Eddaoudi, D Davies, SM Janes
Cancer research 2009
The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells
G Guidicelli, B Chaigne-Delalande, MS Dilhuydy, B Pinson, W Mahfouf, JM Pasquet, FX Mahon, P Pourquier, JF Moreau, P Legembre
PloS one 2009
Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells
S Senthivinayagam, P Mishra, SK Paramasivam, S Yallapragada, M Chatterjee, L Wong, A Rana, B Rana
The Journal of biological chemistry 2009
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL
M Jeong, YS Kwon, SH Park, CY Kim, SS Jeun, KW Song, Y Ko, PD Robbins, TR Billiar, BM Kim, DW Seol
PloS one 2009
TRAIL gene therapy: from preclinical development to clinical application
TS Griffith, B Stokes, TA Kucaba, JK Earel, RL VanOosten, EL Brincks, LA Norian
Current gene therapy 2009
Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines
H Meng, L Li, H Liu, Y Wang, G Li, W Qian
Acta Pharmacologica Sinica 2009
Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs
JA Bauer, G Frye, A Bahr, J Gieg, P Brofman
Investigational New Drugs 2009
Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents
T Sánchez-Pérez, G Ortiz-Ferrón, A López-Rivas
Cell Death and Differentiation 2009
Serum soluble tumor necrosis factor-related apoptosis-inducing ligand level after allogeneic hematopoietic cell transplantation
T Toubai, Y Shono, S Tone, M Ibata, N Kato, C Malter, KP Lowler, S Ota, J Tanaka, M Asaka, M Imamura
Leukemia & Lymphoma 2009
Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy
LG Menon, K Kelly, HW Yang, SK Kim, PM Black, RS Carroll
Stem Cells 2009
Death receptor 5 targeting activity-guided isolation of isoflavones from Millettia brandisiana and Ardisia colorata and evaluation of ability to induce TRAIL-mediated apoptosis
H Kikuchi, T Ohtsuki, T Koyano, T Kowithayakorn, T Sakai, M Ishibashi
Bioorganic & Medicinal Chemistry 2009
Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1
S Huerta-Yepez, M Vega, SE Escoto-Chavez, B Murdock, T Sakai, S Baritaki, B Bonavida
Nitric Oxide 2009
Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation
JY Kim, EH Kim, SU Kim, TK Kwon, KS Choi
Carcinogenesis 2009
TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells
E Szliszka, B Mazur, G Żydowicz, ZP Czuba, W Król
Folia Histochemica et Cytobiologica 2009
Trimeric coiled-coil domain of human pulmonary surfactant protein D enhances zinc-binding ability and biologic activity of soluble TRAIL
X Wu, P Li, C Qian, O Li, Y Zhou
Molecular Immunology 2009
Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots toin vitroassays using TOP15 charts
J Petrak, O Toman, T Simonova, P Halada, R Cmejla, P Klener, J Zivny
PROTEOMICS 2009
Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells
M Li, H Li, C Li, S Zhou, L Guo, H Liu, W Jiang, X Liu, P Li, MA McNutt, G Li
International Journal of Cancer 2009
Efficacy of a Triple Treatment with Irradiation, Agonistic TRAIL Receptor Antibodies and EGFR Blockade
M Niyazi, P Marini, PT Daniel, R Humphreys, V Jendrossek, C Belka
Strahlentherapie und Onkologie 2009
Delivery of apoptotic signal to rolling cancer cells: A novel biomimetic technique using immobilized TRAIL and E-selectin
K Rana, JL Liesveld, MR King
Biotechnology and Bioengineering 2009
Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma
KH Lee, SW Lim, HG Kim, DY Kim, SY Ryu, JK Joo, JC Kim, JH Lee
Langenbeck's Archives of Surgery 2009
Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP
TJ Lee, HJ Um, DS Min, JW Park, KS Choi, TK Kwon
Free radical biology & medicine 2009
Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-κB signalling pathway in thyroid cancer cells
S Morello, R Sorrentino, A Porta, G Forte, A Popolo, A Petrella, A Pinto
Journal of Cellular Physiology 2009
Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth
B Hu, L Kou, C Li, LP Zhu, YR Fan, ZW Wu, JJ Wang, GX Xu
Cancer Gene Therapy 2009
Programmed Cell Death Pathways and Current Antitumor Targets
ML Tan, JP Ooi, N Ismail, AI Moad, TS Muhammad
Pharmaceutical Research 2009
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
B Cate, E Bremer, M Bruyn, T Bijma, D Samplonius, M Schwemmlein, G Huls, G Fey, W Helfrich
Leukemia 2009
The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis
A Dieterle, R Orth, M Daubrawa, A Grotemeier, S Alers, S Ullrich, R Lammers, S Wesselborg, B Stork
International Journal of Cancer 2009
TNF-related apoptosis-inducing ligand: Signalling of a ‘smart’ molecule
F Manzo, A Nebbioso, M Miceli, M Conte, FD Bellis, V Carafa, G Franci, FP Tambaro, L Altucci
The International Journal of Biochemistry & Cell Biology 2009
Esculetin enhances TRAIL-induced apoptosis through DR5 upregulation in human oral cancer SAS cells
SH Kok, CC Yeh, ML Chen, MY Kuo
Oral Oncology 2009
The significance ofTP53in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target
KJ Cheung, DE Horsman, RD Gascoyne
British Journal of Haematology 2009
TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors
E Oikonomou, V Kosmidou, A Katseli, K Kothonidis, D Mourtzoukou, G Kontogeorgos, L Andera, G Zografos, A Pintzas
International Journal of Cancer 2009
Cell survival and apoptosis-related molecules in cancer cells in effusions: A comprehensive review
L Kleinberg, B Davidson, Z Baloch
Diagnostic Cytopathology 2009
Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage
CY Jin, C Park, SK Moon, GY Kim, TK Kwon, SJ Lee, WJ Kim, YH Choi
Anti-Cancer Drugs 2009
DUAL-TARGETED ANTITUMOR EFFECTS AGAINST BRAINSTEM GLIOMA BY INTRAVENOUS DELIVERY OF TUMOR NECROSIS FACTOR-RELATED, APOPTOSIS-INDUCING, LIGAND-ENGINEERED HUMAN MESENCHYMAL STEM CELLS
B Yang, X Wu, Y Mao, W Bao, L Gao, P Zhou, R Xie, L Zhou, J Zhu
Neurosurgery 2009
Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells
CY Jin, C Park, GY Kim, SJ Lee, WJ Kim, YH Choi
Chemico-Biological Interactions 2009
PDTC enables type I TRAIL signaling in type II follicular lymphoma cells
U Nuutinen, N Simelius, A Ropponen, J Eeva, M Mättö, M Eray, R Pellinen, J Wahlfors, J Pelkonen
Leukemia Research 2009
The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases
BD Shepard, AD Badley
Anti-infective agents in medicinal chemistry 2009
Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
RC Elders, SJ Baines, B Catchpole
Veterinary Immunology and Immunopathology 2009
Forcing Cancer Cells to Commit Suicide
C Vangestel, CV de Wiele, G Mees, M Peeters
Cancer Biotherapy & Radiopharmaceuticals 2009
Pharmacology and Therapeutics
BL Clarke, S Khosla
Pharmacology & Therapeutics 2009
TNF-related apoptosis-inducing ligand suppresses PRDX4 expression
HQ Wang, ZX Du, BQ Liu, YY Gao, X Meng, Y Guan, HY Zhang
FEBS Letters 2009
Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer
I Zinonos, A Labrinidis, M Lee, V Liapis, S Hay, V Ponomarev, P Diamond, AC Zannettino, DM Findlay, A Evdokiou
Molecular cancer therapeutics 2009
The expression of TRAIL and its receptors in osteosarcoma cells and the apoptosis effect of a combination of TRAIL, adriamycin and IFN-γ on MG-63 cells
C Deng, Z Shao, X Xiong, Z Liu, Z Zhang
Journal of Nanjing Medical University 2009
The Many Roles of FAS Receptor Signaling in the Immune System
A Strasser, PJ Jost, S Nagata
Immunity 2009
Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism
CL Dobson, S Main, P Newton, M Chodorge, K Cadwallader, RC Humphreys, V Albert, TJ Vaughan, RR Minter, BM Edwards
mAbs 2009
Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
S Leong, RB Cohen, DL Gustafson, CJ Langer, DR Camidge, K Padavic, L Gore, M Smith, LQ Chow, M Mehren, C O'Bryant, S Hariharan, S Diab, NL Fox, R Miceli, SG Eckhardt
Journal of Clinical Oncology 2009
The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells
G Guidicelli, B Chaigne-Delalande, MS Dilhuydy, B Pinson, W Mahfouf, JM Pasquet, FX Mahon, P Pourquier, JF Moreau, P Legembre, GC Jagetia
PloS one 2009
Possible Novel Therapy for Malignant Gliomas with Secretable Trimeric TRAIL
M Jeong, YS Kwon, SH Park, CY Kim, SS Jeun, KW Song, Y Ko, PD Robbins, TR Billiar, BM Kim, DW Seol, X Wu
PloS one 2009
Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7
DD Cui, Y Huang, SH Mao, SC Chen, M Qiu, LL Ji, C Yi
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 2009
Caspase-mediated Cleavage of β-Catenin Precedes Drug-induced Apoptosis in Resistant Cancer Cells
S Senthivinayagam, P Mishra, SK Paramasivam, S Yallapragada, M Chatterjee, L Wong, A Rana, B Rana
The Journal of biological chemistry 2009
Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer
I Zinonos, A Labrinidis, M Lee, V Liapis, S Hay, V Ponomarev, P Diamond, AC Zannettino, DM Findlay, A Evdokiou
Molecular cancer therapeutics 2009
Essentials of Apoptosis
Z Dong, XM Yin
2009
CNS Cancer
EG Meir
2009
Principles of Cancer Biotherapy
RK Oldham, RO Dillman
2009
Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease
D Satoh, N Inami, T Shimazu, T Kajiura, K Yamada, T Iwasaka, S Nomura
Journal of Thrombosis and Thrombolysis 2009
Pharmaceutical Perspectives of Cancer Therapeutics
Y Lu, RI Mahato
2009
Knockdown of IG20 Gene Expression Renders Thyroid Cancer Cells Susceptible to Apoptosis
M Subramanian, T Pilli, P Bhattacharya, F Pacini, YE Nikiforov, PV Kanteti, BS Prabhakar
The Journal of clinical endocrinology and metabolism 2009
Apoptosis in Carcinogenesis and Chemotherapy
GG Chen, PB Lai
2009
Enhancement of Antitumor Properties of rhTRAIL by Affinity Increase toward Its Death Receptors
CR Reis, AM van der Sloot, E Szegezdi, A Natoni, V Tur, RH Cool, A Samali, L Serrano, WJ Quax
Biochemistry 2009
Activity of Mangosteen Xanthones and Teleocidin A-2 in Death Receptor Expression Enhancement and Tumor Necrosis Factor Related Apoptosis-Inducing Ligand Assays
H Kikuchi, T Ohtsuki, T Koyano, T Kowithayakorn, T Sakai, M Ishibashi
Journal of Natural Products 2009
Targeted Quantitative Mass Spectrometric Identification of Differentially Expressed Proteins between Bax-Expressing and Deficient Colorectal Carcinoma Cells
P Wang, A Lo, JB Young, JH Song, R Lai, NM Kneteman, C Hao, L Li
Journal of Proteome Research 2009
2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2
H Liu, CC Jiang, CJ Lavis, A Croft, L Dong, HY Tseng, F Yang, KH Tay, P Hersey, XD Zhang
Molecular Cancer 2009
Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells
DV Rozanov, AY Savinov, VS Golubkov, OL Rozanova, TI Postnova, EA Sergienko, S Vasile, AE Aleshin, MF Rega, M Pellecchia, AY Strongin
Molecular cancer therapeutics 2009
Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade.
Niyazi M, Marini P, Daniel PT, Humphreys R, Jendrossek V, Belka C
2009
Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma.
Lee KH, Lim SW, Kim HG, Kim DY, Ryu SY, Joo JK, Kim JC, Lee JH
Langenbeck's Archives of Surgery 2009
To Kill a Tumor Cell: the Potential of Pro-apoptotic Receptor Agonists
Avi Ashkenazi1, Roy S. Herbst2
Journal of Clinical Investigation 2008
Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression
J Du, X Liang, Y Liu, Z Qu, L Gao, L Han, S Liu, M Cui, Y Shi, Z Zhang, L Yu, L Cao, C Ma, L Zhang, Y Chen, W Sun
Cell Death and Differentiation 2008
TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse
A Kahraman, FJ Barreyro, SF Bronk, NW Werneburg, JL Mott, Y Akazawa, HC Masuoka, CL Howe, GJ Gores
Hepatology 2008
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White
2008
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White
2008
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White
2008
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White
2008
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White
2008
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White
2008
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced mitochondrial pathway to apoptosis and caspase activation is potentiated by phospholipid scramblase-3
K Ndebele, P Gona, TG Jin, N Benhaga, A Chalah, M Degli-Esposti, R Khosravi-Far
Apoptosis : an international journal on programmed cell death 2008
Targeted Therapies in Cancer
F Colotta, A Mantovani
2008
Targeted Therapies in Cancer
F Colotta, A Mantovani
2008
Targeted Therapies in Cancer
F Colotta, A Mantovani
2008
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
K Takeda, Y Kojima, K Ikejima, K Harada, S Yamashina, K Okumura, T Aoyama, S Frese, H Ikeda, NM Haynes, E Cretney, H Yagita, N Sueyoshi, N Sato, Y Nakanuma, MJ Smyth, K Okumura
Proceedings of the National Academy of Sciences 2008
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5
JB Fiveash, GY Gillespie, PG Oliver, T Zhou, ML Belenky, DJ Buchsbaum
International journal of radiation oncology, biology, physics 2008
Neutralization of tumor-derived soluble Glucocorticoid-Induced TNFR-Related Protein ligand increases NK cell anti-tumor reactivity
KM Baltz, M Krusch, T Baessler, BJ Schmiedel, A Bringmann, P Brossart, HR Salih
Blood 2008
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
AJ Frew, RK Lindemann, BP Martin, CJ Clarke, J Sharkey, DA Anthony, KM Banks, NM Haynes, P Gangatirkar, K Stanley, JE Bolden, K Takeda, H Yagita, JP Secrist, MJ Smyth, RW Johnstone
Proceedings of the National Academy of Sciences 2008
ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis
JH Song, K Kandasamy, AS Kraft
The Journal of biological chemistry 2008
Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells
T Yoshida, M Horinaka, M Takara, M Tsuchihashi, N Mukai, M Wakada, T Sakai
Environmental Health and Preventive Medicine 2008
The TRAIL apoptotic pathway in cancer onset, progression and therapy
RW Johnstone, AJ Frew, MJ Smyth
Nature Reviews Cancer 2008
The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway
S Wang
Oncogene 2008
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
A Ashkenazi
Nature Reviews Drug Discovery 2008
Wiley Encyclopedia of Chemical Biology
R Bittman
Wiley Encyclopedia of Chemical Biology 2008
Molecular targeted therapies for pancreatic cancer
D Borja-Cacho, EH Jensen, AK Saluja, DJ Buchsbaum, SM Vickers
The American Journal of Surgery 2008
Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts
K Sugamura, JF Gibbs, A Belicha-Villanueva, C Andrews, EA Repasky, BL Hylander
Oncology 2008
Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody
H Kim, DE Morgan, H Zeng, WE Grizzle, JM Warram, CR Stockard, D Wang, KR Zinn
Radiology 2008
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells
H Schulze-Bergkamen, R Ehrenberg, L Hickmann, B Vick, T Urbanik, CC Schimanski, MR Berger, A Schad, A Weber, S Heeger, PR Galle, M Moehler
World journal of gastroenterology : WJG 2008
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
DM Ashley, CD Riffkin, MM Lovric, T Mikeska, A Dobrovic, JA Maxwell, HS Friedman, KJ Drummond, AH Kaye, HK Gan, TG Johns, CJ Hawkins
British Journal of Cancer 2008
Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells
TE Fandy, S Shankar, RK Srivastava
Molecular Cancer 2008
Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission
O Sordet, A Goldman, C Redon, S Solier, VA Rao, Y Pommier
The Journal of biological chemistry 2008
Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells
E Bremer, M Bruyn, DF Samplonius, T Bijma, B Cate, LF de Leij, W Helfrich
Journal of Molecular Medicine 2008
TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5
CH Wu, CH Kao, AR Safa
Human Gene Therapy 2008
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
A Shanker, AD Brooks, CA Tristan, JW Wine, PJ Elliott, H Yagita, K Takeda, MJ Smyth, WJ Murphy, TJ Sayers
Journal of the National Cancer Institute 2008
Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11
PG Oliver, AF LoBuglio, KR Zinn, H Kim, L Nan, T Zhou, W Wang, DJ Buchsbaum
Clinical cancer research 2008
Turning the gene tap off; implications of regulating gene expression for cancer therapeutics
JF Curtin, M Candolfi, W Xiong, PR Lowenstein, MG Castro
Molecular cancer therapeutics 2008
Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production
V Levina, AM Marrangoni, R DeMarco, E Gorelik, AE Lokshin
Experimental Cell Research 2008
FLIP as an anti-cancer therapeutic target
JK Yang
Yonsei Medical Journal 2008
Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
S Shankar, S Ganapathy, Q Chen, RK Srivastava
Molecular Cancer 2008
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5
BZ Carter, DH Mak, WD Schober, MF Dietrich, C Pinilla, LT Vassilev, JC Reed, M Andreeff
Blood 2008
Targeting cell death in tumors by activating caspases
SH MacKenzie, AC Clark
Current cancer drug targets 2008
Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
E Szliszka, ZP Czuba, K Jernas, W Król
International journal of molecular sciences 2008
Peripheral blood serum markers for apoptosis and liver fibrosis: Are they trustworthy indicators of liver realness?
F Torre, L Bellis, A Delfino, N Pelli, P Contini, M Basso, C Puoti, A Picciotto
Digestive and Liver Disease 2008
Death receptors as targets for anti-cancer therapy
K Papenfuss, SM Cordier, H Walczak
Journal of Cellular and Molecular Medicine 2008
Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update
SH Beachy, EA Repasky
Cancer Immunology, Immunotherapy 2008
Targeting the extrinsic apoptosis pathway in cancer
A Ashkenazi
Cytokine & Growth Factor Reviews 2008
Targeted manipulation of apoptosis in cancer treatment
JA Call, SG Eckhardt, DR Camidge
The Lancet Oncology 2008
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
C Adams, K Totpal, D Lawrence, S Marsters, R Pitti, S Yee, S Ross, L Deforge, H Koeppen, M Sagolla, D Compaan, H Lowman, S Hymowitz, A Ashkenazi
Cell Death and Differentiation 2008
Role and prognostic significance of tumor necrosis factor‐related apoptosis‐inducing ligand death receptor DR5 in nonsmall‐cell lung cancer and precursor lesions
WA Cooper, MR Kohonen‐Corish, L Zhuang, B McCaughan, C Kennedy, G Screaton, RL Sutherland, CS Lee
Cancer 2008
Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis
T Yoshida, M Konishi, M Horinaka, T Yasuda, AE Goda, H Taniguchi, K Yano, M Wakada, T Sakai
Biochemical and Biophysical Research Communications 2008
Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
DR Camidge
Expert Opinion on Biological Therapy 2008
β-Sitosterol sensitizes MDA-MB-231 cells to TRAIL-induced apoptosis
C PARK, D MOON, C RYU, B CHOI, W LEE, G KIM, Y CHOI
Acta Pharmacologica Sinica 2008
Expression, regulation and function of trail in atherosclerosis
MM Kavurma, MR Bennett
Biochemical Pharmacology 2008
Blockade of processing/activation of caspase-3 by hypoxia
SH Han, M Kim, K Park, TH Kim, DW Seol
Biochemical and Biophysical Research Communications 2008
Stem and progenitor cell-mediated tumor selective gene therapy
KS Aboody, J Najbauer, MK Danks
Gene Therapy 2008
Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism
G Ortiz-Ferrón, R Yerbes, A Eramo, AI López-Pérez, RD Maria, A López-Rivas
Cell Research 2008
Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway
S Shamimi-Noori, WS Yeow, MF Ziauddin, H Xin, TL Tran, J Xie, A Loehfelm, P Patel, J Yang, DS Schrump, BL Fang, DM Nguyen
Cancer Gene Therapy 2008
Cytoskeleton inhibitors combined with TRAIL induce apoptosis in HeLa carcinoma cells overexpressing antiapoptotic protein Bcl-2
ME Gasparian, LV Domnina, OY Ivanova, DS Izyumov, AY Lomakin, EN Popova, AV Yagolovich, OY Pletjushkina, DA Dolgikh, BV Chernyak
Biochemistry (Moscow) 2008
Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling
YJ Jeon, IK Kim, SH Hong, H Nan, HJ Kim, HJ Lee, ES Masuda, O Meyuhas, BH Oh, YK Jung
Oncogene 2008
Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells
J Yoo, SS Park, YJ Lee
Journal of Cellular Biochemistry 2008
Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL
J Rieger, D Lemke, G Maurer, M Weiler, B Frank, G Tabatabai, M Weller, W Wick
Journal of Neurochemistry 2008
Apoptotic Phenotype Alters the Capacity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand to Induce Human Vascular Endothelial Activation
PL Chen, A Easton
Journal of Vascular Research 2008
Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model
JE Kendrick, JM Straughn, PG Oliver, W Wang, L Nan, WE Grizzle, CR Stockard, RD Alvarez, DJ Buchsbaum
Gynecologic Oncology 2008
Adriamycin sensitizes adriamycin-resistant HL-60/ADR cells to TRAIL-mediated apoptosis
H Ke, Y Wang, D Ren, L Wang
Chinese Journal of Clinical Oncology 2008
Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPSdown-regulation
JY Kim, EH Kim, SS Park, JH Lim, TK Kwon, KS Choi
Journal of Cellular Biochemistry 2008
TRAIL and cancer therapy
FA Kruyt
Cancer Letters 2008
Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2
J Li, MG Anderson, LA Tucker, Y Shen, KB Glaser, OJ Shah
Cell Death and Differentiation 2008
Immunohistochemical Analysis for the Expression of DR5 TRAIL Receptor and p53 in Non-small Cell Lung Cancer
KY Lee, JH Lee, SJ Kim, KH Yoo
Tuberculosis and Respiratory Diseases 2008
TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8
LL Belyanskaya, A Ziogas, S Hopkins-Donaldson, S Kurtz, HU Simon, R Stahel, U Zangemeister-Wittke
Lung Cancer 2008
Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC  -independent mechanism in human malignant tumor cells
JH Lim, JW Park, KS Choi, YB Park, TK Kwon
Carcinogenesis 2008
The role of TRAIL death receptors in the treatment of hematological malignancies
ES Henson, JB Johnston, SB Gibson
Leukemia & Lymphoma 2008
Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein
E Bremer, GM van Dam, M Bruyn, M Riezen, M Dijkstra, G Kamps, W Helfrich, H Haisma
Molecular Therapy 2008
Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole
AE Goda, T Yoshida, M Horinaka, T Yasuda, T Shiraishi, M Wakada, T Sakai
Oncogene 2008
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
FA Greco, P Bonomi, J Crawford, K Kelly, Y Oh, W Halpern, L Lo, G Gallant, J Klein
Lung Cancer 2008
Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand
SJ Na, SY Chae, S Lee, K Park, K Kim, JH Park, IC Kwon, SY Jeong, KC Lee
International Journal of Pharmaceutics 2008
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas
V Granci, F Bibeau, A Kramar, F Boissière-Michot, S Thézénas, A Thirion, C Gongora, P Martineau, MD Rio, M Ychou
European Journal of Cancer 2008
New Drugs for the Treatment of Lymphoma
L Paoluzzi, Y Kitagawa, M Kalac, J Zain, OA O'Connor
Hematology/Oncology Clinics of North America 2008
A cell-based high-throughput screen to identify synergistic TRAIL sensitizers
NL Booth, TJ Sayers, AD Brooks, CL Thomas, K Jacobsen, EI Goncharova, JB McMahon, CJ Henrich
Cancer Immunology, Immunotherapy 2008
Noninvasive Imaging of Therapeutic Gene Expression Using a Bi-directional Transcriptional Amplification Strategy
S Ray, R Paulmurugan, MR Patel, BC Ahn, L Wu, M Carey, SS Gambhir
Molecular Therapy 2008
A dual-step fluorescence resonance energy transfer-based quenching assay for screening of caspase-3 inhibitors
A Valanne, P Malmi, H Appelblom, P Niemelä, T Soukka
Analytical Biochemistry 2008
ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis
JH Song, K Kandasamy, AS Kraft
The Journal of biological chemistry 2008
TRAIL Stimulates Proliferation of Vascular Smooth Muscle Cells via Activation of NF-κB and Induction of Insulin-like Growth Factor-1 Receptor
MM Kavurma, M Schoppet, YV Bobryshev, LM Khachigian, MR Bennett
The Journal of biological chemistry 2008
DR4-selective Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Variants Obtained by Structure-based Design
V Tur, AM van der Sloot, CR Reis, E Szegezdi, RH Cool, A Samali, L Serrano, WJ Quax
The Journal of biological chemistry 2008
Topoisomerase I Requirement for Death Receptor-induced Apoptotic Nuclear Fission
O Sordet, A Goldman, C Redon, S Solier, VA Rao, Y Pommier
The Journal of biological chemistry 2008
Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells
H Schulze-Bergkamen, R Ehrenberg, L Hickmann, B Vick, T Urbanik, CC Schimanski, MR Berger, A Schad, A Weber, S Heeger, PR Galle, M Moehler
World journal of gastroenterology : WJG 2008
Transforming Growth Factor-β in Cancer Therapy, Volume I
SB Jakowlew
2008
Principles of Molecular Oncology
MH Bronchud, MA Foote, G Giaccone, O Olopade, P Workman
2008
Myeloma Therapy
S Lonial
2008
RETRACTED ARTICLE: A single chain (scFv425):sTRAIL fusion protein with specificity for the EGF receptor is effective in vitro but not in an in vivo brain tumor animal model
JM Kuijlen, JJ Mooij, W Helfrich, WF den Dunnen
Journal of Neuro-Oncology 2008
Targeted Cancer Therapy
R Kurzrock, M Markman
2008
Molecular Targeting in Oncology
HL Kaufman, S Wadler, K Antman
2008
Apoptosis and Cancer
G Mor, AB Alvero
2008
Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy
B Bonavida
2008
Targeted Therapies in Cancer
F Colotta, A Mantovani
2008
Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL
SV Schaeybroeck, DM Kelly, J Kyula, S Stokesberry, DA Fennell, PG Johnston, DB Longley
Cancer research 2008
CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF-κB Activation and Up-Regulation of c-FLIP and Bcl-x L
M Travert, P Ame-Thomas, C Pangault, A Morizot, O Micheau, G Semana, T Lamy, T Fest, K Tarte, T Guillaudeux
Journal of immunology (Baltimore, Md. : 1950) 2008
Early Therapy Evaluation of Combined Anti–Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging
H Kim, DE Morgan, DJ Buchsbaum, H Zeng, WE Grizzle, JM Warram, CR Stockard, LR McNally, JW Long, JC Sellers, A Forero, KR Zinn
Cancer research 2008
Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update.
Beachy SH, Repasky EA
Cancer Immunology, Immunotherapy 2008
TRAIL-R deficiency enhances lymph node metastasis without affecting primary tumor development
Anne Grosse-Wilde, Oksana Voloshanenko, S. Lawrence Bailey, Gary M. Longton, Uta Schaefer, Andreea I. Csernok, Günther Schütz, Erich F. Greiner, Christopher J. Kemp, and Henning Walczak
Journal of Clinical Investigation 2007
On the TRAIL to therapeutic intervention in liver disease
I Herr, P Schemmer, MW Büchler
Hepatology 2007
Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax
X Liang, Y Liu, Q Zhang, L Gao, L Han, C Ma, L Zhang, YH Chen, W Sun
Journal of immunology (Baltimore, Md. : 1950) 2007
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
D Daniel, B Yang, DA Lawrence, K Totpal, I Balter, WP Lee, A Gogineni, MJ Cole, SF Yee, S Ross, A Ashkenazi
Blood 2007
Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling
JA Bauer, JA Lupica, H Schmidt, BH Morrison, RM Haney, RK Masci, RM Lee, JA Didonato, DJ Lindner
PloS one 2007
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage
C Dunn, M Brunetto, G Reynolds, T Christophides, PT Kennedy, P Lampertico, A Das, AR Lopes, P Borrow, K Williams, E Humphreys, S Afford, DH Adams, A Bertoletti, MK Maini
Journal of Experimental Medicine 2007
NK Cells and Cancer
L Zamai, C Ponti, P Mirandola, G Gobbi, S Papa, L Galeotti, L Cocco, M Vitale
Journal of immunology (Baltimore, Md. : 1950) 2007
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity
H Malhi, FJ Barreyro, H Isomoto, SF Bronk, GJ Gores
Gut 2007
The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2
X Liang, J Du, Y Liu, M Cui, C Ma, L Han, Z Qu, Z Zhang, Z Sun, L Zhang, YH Chen, W Sun
Apoptosis 2007
TRAIL in cancer therapy: present and future challenges
D Mérino, N Lalaoui, A Morizot, E Solary, O Micheau
Expert Opinion on Therapeutic Targets 2007
RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL)
M Tarrus, AM van der Sloot, K Temming, M Lacombe, F Opdam, WJ Quax, G Molema, K Poelstra, RJ Kok
Apoptosis : an international journal on programmed cell death 2007
Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis
S Shankar, Q Chen, K Sarva, I Siddiqui, RK Srivastava
Journal of molecular signaling 2007
Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential
S Shankar, Q Chen, I Siddiqui, K Sarva, RK Srivastava
Journal of molecular signaling 2007
Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression
N Vigneswaran, DC Baucum, J Wu, Y Lou, J Bouquot, S Muller, W Zacharias
BMC Cancer 2007
Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo
E Oikonomou, K Kothonidis, E Taoufik, E Probert, G Zografos, G Nasioulas, L Andera, A Pintzas
British Journal of Cancer 2007
Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells
D Lane, V Robert, R Grondin, C Rancourt, A Piché
International Journal of Cancer 2007
Apoptosis and chemo-resistance in colorectal cancer
SG Prabhudesai, S Rekhraj, G Roberts, AW Darzi, P Ziprin
Journal of Surgical Oncology 2007
Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms
K Ishiguro, T Ando, O Maeda, N Ohmiya, Y Niwa, K Kadomatsu, H Goto
Biochemical and Biophysical Research Communications 2007
Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells
MS Lippa, LD Strockbine, TT Le, DG Branstetter, CA Strathdee, PM Holland
Apoptosis 2007
The promise of TRAIL—potential and risks of a novel anticancer therapy
R Koschny, H Walczak, TM Ganten
Journal of Molecular Medicine 2007
Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis
T Yoshida, T Shiraishi, M Horinaka, S Nakata, T Yasuda, AE Goda, M Wakada, Y Mizutani, T Miki, A Nishikawa, T Sakai
Cancer Science 2007
Cutting-Edge Apoptosis-Based Therapeutics
U Fischer, K Janssen, K Schulze-Osthoff
BioDrugs 2007
Increased hepatotoxicity of tumor necrosis factor–related apoptosis-inducing ligand in diseased human liver
X Volkmann, U Fischer, MJ Bahr, M Ott, F Lehner, M MacFarlane, GM Cohen, MP Manns, K Schulze-Osthoff, H Bantel
Hepatology 2007
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Pathway Signaling
A Thorburn
Journal of Thoracic Oncology 2007
Inducing rigid local structure around the zinc-binding region by hydrophobic interactions enhances the homotrimerization and apoptotic activity of zinc-free TRAIL
HW Lee, TI Kim, KH Chan, MH Kwon, JS Kim, M Jin, YS Kim
Biochemical and Biophysical Research Communications 2007
Profiling of Apoptotic Changes in Human Breast Cancer Cells Using SELDI-TOF Mass Spectrometry
S Leong, R Christopherson, R Baxter
Cellular Physiology and Biochemistry 2007
Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase
ME Gasparian, VG Ostapchenko, AV Yagolovich, IN Tsygannik, BV Chernyak, DA Dolgikh, MP Kirpichnikov
Biotechnology Letters 2007
Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor–related apoptosis-inducing ligand
M Nagane, WK Cavenee, Y Shiokawa
Journal of Neurosurgery 2007
Interferon-γ is produced by another player of innate immune responses: The interferon-producing killer dendritic cell (IKDC)
M Bonmort, E Ullrich, G Mignot, B Jacobs, N Chaput, L Zitvogel
Biochimie 2007
15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation
H Han, SW Shin, CY Seo, HC Kwon, JY Han, IH Kim, JY Kwak, JI Park
Apoptosis 2007
Enhanced proapoptotic effects of tumor necrosis factor–related apoptosis-inducing ligand on temozolomide-resistant glioma cells
M Uzzaman, G Keller, IM Germano
Journal of Neurosurgery 2007
Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells
J Wei, J Wahl, H Knauss, S Zeller, G Jarmy, G Fitze, KM Debatin, C Beltinger
Cancer Gene Therapy 2007
Targeting death-inducing receptors in cancer therapy
K Takeda, J Stagg, H Yagita, K Okumura, MJ Smyth
Oncogene 2007
Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
YS Youn, MJ Shin, SY Chae, CH Jin, TH Kim, KC Lee
Biotechnology Letters 2007
Treatment with IFN?in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients
H Tanaka, T Ito, T Kyo, A Kimura
European Journal of Haematology 2007
Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors
H Tsurushima, X Yuan, LE Dillehay, KW Leong
Cancer Gene Therapy 2007
Quercetin enhances CD95- and TRAIL-induced apoptosis in leukemia cell lines
M Russo, P Nigro, R Rosiello, R D'Arienzo, GL Russo
Leukemia 2007
Recombinant adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene suppresses human pancreatic cancer growth
R Tian, R Qin, Z Du, W Xia, C Shi
The Chinese-German Journal of Clinical Oncology 2007
TRAILs and tribulation
H Malhi
Hepatology 2007
Construction and characterization of two versions of bifunctional EGFP–sTRAIL fusion proteins
J Shen, Y Wu, L Shi, J Liu, S Liu, Z Guan, Z Yin
Applied Microbiology and Biotechnology 2007
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
KW Wagner, EA Punnoose, T Januario, DA Lawrence, RM Pitti, K Lancaster, D Lee, M Goetz, SF Yee, K Totpal, L Huw, V Katta, G Cavet, SG Hymowitz, L Amler, A Ashkenazi
Nature Medicine 2007
Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms
C Gill, SE Walsh, C Morrissey, JM Fitzpatrick, RW Watson
The Prostate 2007
Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas
S Heikaus, E Casliskan, C Mahotka, HE Gabbert, U Ramp
Apoptosis 2007
Screening of a novel octamer peptide, CNSCWSKD, that induces caspase-dependent cell death
C Kaga, M Okochi, M Nakanishi, H Hayashi, R Kato, H Honda
Biochemical and Biophysical Research Communications 2007
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers
JE Kendrick, JM Estes, JM Straughn, RD Alvarez, DJ Buchsbaum
Gynecologic Oncology 2007
α-Fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand
M Li, S Zhou, X Liu, P Li, MA McNutt, G Li
Cancer Letters 2007
Sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis by hyperthermia
M Moulin, C Dumontet, AP Arrigo
Cancer Letters 2007
Vitamin E analogues as a novel group of mitocans: Anti-cancer agents that act by targeting mitochondria
J Neuzil, LF Dong, L Ramanathapuram, T Hahn, M Chladova, XF Wang, R Zobalova, L Prochazka, M Gold, R Freeman, J Turanek, ET Akporiaye, JC Dyason, SJ Ralph
Molecular Aspects of Medicine 2007
TRAIL-receptor antibodies as a potential cancer treatment
DJ Buchsbaum, A Forero-Torres, AF LoBuglio
Future Oncology 2007
A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy- 12, 14 prostaglandin J2 production
H Hasegawa, Y Yamada, K Komiyama, M Hayashi, M Ishibashi, T Sunazuka, T Izuhara, K Sugahara, K Tsuruda, M Masuda, N Takasu, K Tsukasaki, M Tomonaga, S Kamihira
Blood 2007
Cancer: Novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway
E Cretney, K Takeda, MJ Smyth
The International Journal of Biochemistry & Cell Biology 2007
Emerging Approaches in Hepatocellular Carcinoma
LM Kulik, MF Mulcahy, RA Omary, R Salem
Journal of Clinical Gastroenterology 2007
Enhancement of Cell Death by TNF α-related Apoptosis-inducing Ligand (TRAIL) in Human Lung Carcinoma A549 Cells Exposed to X Rays under Hypoxia
M TAKAHASHI, O INANAMI, N KUBOTA, M TSUJITANI, H YASUI, A OGURA, M KUWABARA
Journal of Radiation Research 2007
The State of the Art in the Pathogenesis of ATL and New Potential Targets Associated with HTLV-1 and ATL
K Murata, Y Yamada
International Reviews of Immunology 2007
Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway
I Verbrugge, E Vries, SW Tait, EH Wissink, H Walczak, M Verheij, J Borst
Oncogene 2007
CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells
D Llobet, N Eritja, M Encinas, N Llecha, A Yeramian, J Pallares, A Sorolla, FJ Gonzalez-Tallada, X Matias-Guiu, X Dolcet
Oncogene 2007
Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver
M Ishii, M Iwai, Y Harada, T Kishida, H Asada, M Shin-Ya, Y Itoh, J Imanishi, T Okanoue, O Mazda
Cancer Letters 2007
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein
J Stieglmaier, E Bremer, C Kellner, TM Liebig, B Cate, M Peipp, H Schulze-Koops, M Pfeiffer, HJ Bühring, J Greil, F Oduncu, B Emmerich, GH Fey, W Helfrich
Cancer Immunology, Immunotherapy 2007
Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane
Š Šímová, M Klíma, L Cermak, V Šourková, L Anděra
Apoptosis 2007
MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release
A Mohr, C Büneker, RP Gough, RM Zwacka
Oncogene 2007
Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentrations after stem cell transplantation
S Nomura, K Ishii, N Inami, N Uoshima, H Ishida, T Yoshihara, H Kitayama, K Hayashi
Transplant Immunology 2007
Species-dependent serum interference in a sandwich ELISA for Apo2L/TRAIL
LE DeForge, DH Shih, D Kennedy, K Totpal, A Chuntharapai, GL Bennett, JH Drummond, P Siguenza, WL Wong
Journal of Immunological Methods 2007
Cytogenetic and molecular biological characterization of an adult medulloblastoma
H Holland, R Koschny, W Krupp, J Meixensberger, M Bauer, R Schober, H Kirsten, TM Ganten, P Ahnert
Cancer Genetics and Cytogenetics 2007
P60-c-src suppresses apoptosis through inhibition of caspase 8 activation in hepatoma cells, but not in primary hepatocytes
EN de Toni, C Kuntzen, AL Gerbes, WE Thasler, N Sonuc, SR Mucha, P Camaj, C Bruns, B Göke, ST Eichhorst
Journal of Hepatology 2007
Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis
M Kusaba, K Nakao, T Goto, D Nishimura, H Kawashimo, H Shibata, Y Motoyoshi, N Taura, T Ichikawa, K Hamasaki, K Eguchi
Journal of Hepatology 2007
Actinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cells
MJ Wang, S Liu, Y Liu, D Zheng
Neuroscience Research 2007
Cutting-Edge Apoptosis-Based Therapeutics: A Panacea for Cancer?
U Fischer, K Janssen, K Schulze-Osthoff
BioDrugs 2007
NEURAL STEM CELLS AND ARMED DERIVATIVES: FATE AND THERAPEUTIC POTENTIAL IN THE BRAIN
K Shah
Gene Therapy and Regulation 2007
Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells
VN Ivanov, H Zhou, TK Hei
Cancer research 2007
The Potential of Death Receptor 4– and 5–Directed Therapies in the Treatment of Lung Cancer
DR Camidge
Clinical Lung Cancer 2007
Targeted Therapies in Oncology
L Ellis
Targeted Therapies in Oncology 2007
Brandisianins A−F, Isoflavonoids Isolated from Millettia brandisiana in a Screening Program for Death-Receptor Expression Enhancement Activity
H Kikuchi, T Ohtsuki, T Koyano, T Kowithayakorn, T Sakai, M Ishibashi
Journal of Natural Products 2007
Synergistic Effects in Apoptosis Induction by Taurolidine and TRAIL in HCT-15 Colon Carcinoma Cells
AM Chromik, A Daigeler, C Hilgert, D Bulut, A Geisler, V Liu, JM Otte, W Uhl, U Mittelkötter
Journal of Investigative Surgery 2007
Nitrosylcobalamin Potentiates the Anti-Neoplastic Effects of Chemotherapeutic Agents via Suppression of Survival Signaling
JA Bauer, JA Lupica, H Schmidt, BH Morrison, RM Haney, RK Masci, RM Lee, JA DiDonato, DJ Lindner, E Grimm
PloS one 2007
Tumor Necrosis Factor-related Apoptosis-inducing Ligand Activates a Lysosomal Pathway of Apoptosis That Is Regulated by Bcl-2 Proteins
NW Werneburg, ME Guicciardi, SF Bronk, SH Kaufmann, GJ Gores
The Journal of biological chemistry 2007
MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis: A MECHANISTIC BASIS FOR SORAFENIB (BAY 43-9006)-INDUCED TRAIL SENSITIZATION
XW Meng, SH Lee, H Dai, D Loegering, C Yu, K Flatten, P Schneider, NT Dai, SK Kumar, BD Smith, JE Karp, AA Adjei, SH Kaufmann
The Journal of biological chemistry 2007
Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding
L Bin, J Thorburn, LR Thomas, PE Clark, R Humphreys, A Thorburn
The Journal of biological chemistry 2007
Investigating the Interaction between Osteoprotegerin and Receptor Activator of NF-κB or Tumor Necrosis Factor-related Apoptosis-inducing Ligand: EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS
S Vitovski, JS Phillips, J Sayers, PI Croucher
The Journal of biological chemistry 2007
Apoptosis, Senescence, and Cancer
DA Gewirtz, SE Holt, S Grant
2007
The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies
DM Nguyen, M Hussain
Journal of Bioenergetics and Biomembranes 2007
Apoptosis, Cell Signaling, and Human Diseases
R Srivastava
2007
Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents:
J SUN, Z FU, C FANG, J LI
Chinese Medical Journal 2007
Inhibition of Trail Gene Expression by Cyclopentenonic Prostaglandin 15-Deoxy-Δ 12,14 -Prostaglandin J 2 in T Lymphocytes
C Fionda, F Nappi, M Piccoli, L Frati, A Santoni, M Cippitelli
Molecular pharmacology 2007
Silibinin Sensitizes Human Glioma Cells to TRAIL-Mediated Apoptosis via DR5 Up-regulation and Down-regulation of c-FLIP and Survivin
Y Son, EH Kim, JY Kim, SU Kim, TK Kwon, AR Yoon, CO Yun, KS Choi
Cancer research 2007
Combination Treatment with TRA-8 Anti–Death Receptor 5 Antibody and CPT-11 Induces Tumor Regression in an Orthotopic Model of Pancreatic Cancer
LC DeRosier, DJ Buchsbaum, PG Oliver, ZQ Huang, JC Sellers, WE Grizzle, W Wang, T Zhou, KR Zinn, JW Long, SM Vickers
Clinical cancer research 2007
Curcumin [1,7-Bis(4-hydroxy-3-methoxyphenyl)-1–6-heptadine-3,5-dione; C 21 H 20 O 6 ] Sensitizes Human Prostate Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand/Apo2L-Induced Apoptosis by Suppressing Nuclear Factor-κB via Inhibition of the Prosurvival Akt Signaling Pathway
D Deeb, H Jiang, X Gao, S Al-Holou, AL Danyluk, SA Dulchavsky, SC Gautam
The Journal of pharmacology and experimental therapeutics 2007
Aspirin Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Hormone-Refractory Prostate Cancer Cells through Survivin Down-Regulation
J Yoo, YJ Lee
Molecular pharmacology 2007
Selective Inhibition of IκB Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level
G Roué, P Pérez-Galán, M López-Guerra, N Villamor, E Campo, D Colomer
Journal of immunology (Baltimore, Md. : 1950) 2007
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.
Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Bühring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W
Cancer Immunology, Immunotherapy 2007
Lipoxygenase inhibitors induce death receptor 5/TRAIL‐R2 expression and sensitize malignant tumor cells to TRAIL‐induced apoptosis
Yoshida T, Shiraishi T, Horinaka M, Nakata S, Yasuda T, Goda AE, Wakada M, Mizutani Y, Miki T, Nishikawa A, Sakai T
Cancer Science 2007
TRAIL receptor-mediated Jun kinase activation and Bim phosphorylation critically regulate Fas (CD95)-mediated liver damage and lethality
Nadia Corazza, Sabine Jakob, Corinne Schaer, Steffen Frese, Adrian Keogh, Deborah Stroka, Daniela Kassahn, Ralph Torgler, Christoph Mueller, Pascal Schneider, Thomas Brunner
Journal of Clinical Investigation 2006
TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque
K Sato, A Niessner, SL Kopecky, RL Frye, JJ Goronzy, CM Weyand
Journal of Experimental Medicine 2006
cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis
ME Guicciardi, SF Bronk, NW Werneburg, GJ Gores
AJP Gastrointestinal and Liver Physiology 2006
TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors
K Tateishi, M Ohta, B Guleng, F Kanai, Y Tanaka, Y Asaoka, A Jazag, J Imamura, T Imamura, H Ijichi, T Ikenoue, T Kawakami, Y Fukushima, M Washida, M Sata, M Miyagishi, K Taira, H Yoshida, T Kawabe, M Omata
International Journal of Cancer 2006
Antitumor Activity of Human CD34+ Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
C Carlo-Stella, C Lavazza, MD Nicola, L Cleris, P Longoni, M Milanesi, M Magni, D Morelli, A Gloghini, A Carbone, AM Gianni
Human Gene Therapy 2006
Chemotherapeutic approaches for targeting cell death pathways
MS Ricci, WX Zong
The oncologist 2006
Modulating apoptosis as a target for effective therapy
A Fleischer, A Ghadiri, F Dessauge, M Duhamel, MP Rebollo, F Alvarez-Franco, A Rebollo
Molecular Immunology 2006
Shared biology of GVHD and GVT effects: Potential methods of separation
DH Fowler
Critical Reviews in Oncology/Hematology 2006
Apoptosis: mechanisms and implications for cancer therapeutics
MM Mita, AC Mita, AW Tolcher
Targeted Oncology 2006
Tnfsf10
E Kratz, A Ashkenazi
AfCS-Nature Molecule Pages 2006
Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis
P Clarke, KL Tyler
Apoptosis : an international journal on programmed cell death 2006
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2
D Mérino, N Lalaoui, A Morizot, P Schneider, E Solary, O Micheau
Molecular and cellular biology 2006
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor
AM van der Sloot, V Tur, E Szegezdi, MM Mullally, RH Cool, A Samali, L Serrano, WJ Quax
Proceedings of the National Academy of Sciences 2006
Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis
TO Garnett, M Filippova, PJ Duerksen-Hughes
Cell Death and Differentiation 2006
The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells
E Choi, Y Kim, K Kim
Yonsei Medical Journal 2006
The proteasome is required for rapid initiation of death receptor-induced apoptosis
D Sohn, G Totzke, F Essmann, K Schulze-Osthoff, B Levkau, RU Jänicke
Molecular and cellular biology 2006
Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation
MF Ziauddin, WS Yeow, JB Maxhimer, A Baras, A Chua, RM Reddy, W Tsai, GW Cole, DS Schrump, DM Nguyen
Neoplasia (New York, N.Y.) 2006
Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines
K Miyazaki, T Shibahara, D Sato, K Uchida, H Suzuki, H Matsui, A Yanaka, A Nakahara, Y Matsuzaki
Journal of Gastroenterology 2006
Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells
S Gillespie, J Borrow, XD Zhang, P Hersey
Apoptosis 2006
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL
A Pathil, S Armeanu, S Venturelli, P Mascagni, TS Weiss, M Gregor, UM Lauer, M Bitzer
Hepatology 2006
Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation
A Hamaï, C Richon, F Meslin, F Faure, A Kauffmann, Y Lecluse, A Jalil, L Larue, MF Avril, S Chouaib, M Mehrpour
Oncogene 2006
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma
A Trauzold, D Siegmund, B Schniewind, B Sipos, J Egberts, D Zorenkov, D Emme, C Röder, H Kalthoff, H Wajant
Oncogene 2006
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
S Fulda, KM Debatin
Oncogene 2006
The mitogen-activated protein kinase pathway can inhibit TRAIL-induced apoptosis by prohibiting association of truncated Bid with mitochondria
G Ortiz-Ferrón, SW Tait, G Robledo, E Vries, J Borst, A López-Rivas
Cell Death and Differentiation 2006
Antitumor Activity of Human CD34+Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
C Carlo-Stella, C Lavazza, MD Nicola, L Cleris, P Longoni, M Milanesi, M Magni, D Morelli, A Gloghini, A Carbone, AM Gianni
Human Gene Therapy 2006
Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer
FA Sinicrope
Molecular Carcinogenesis 2006
Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain
K Taylor, D Micha, M Ranson, C Dive
Expert Opinion on Investigational Drugs 2006
Caspase-8 dependent trail-induced apoptosis in cancer cell lines is inhibited by vitamin C and catalase
I Perez-Cruz, JM Cárcamo, DW Golde
Apoptosis 2006
Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade
RM Reddy, WS Yeow, A Chua, DM Nguyen, A Baras, MF Ziauddin, SM Shamimi-Noori, JB Maxhimer, DS Schrump, DM Nguyen
Apoptosis 2006
Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases
JN Shin, SY Park, JH Cha, JY Park, BR Lee, SA Jung, ST Lee, CW Yun, DW Seol, TH Kim
Experimental Cell Research 2006
Long lasting heat shock stimulation of TRAIL-induced apoptosis in transformed T lymphocytes
M Moulin, AP Arrigo
Experimental Cell Research 2006
TRAIL-R4-β: A new splice variant of TRAIL-receptor 4 lacking the cysteine rich domain 1
A Krieg, JS 2nd, U Ramp, SB Hosch, WT Knoefel, HE Gabbert, C Mahotka
Biochemical and Biophysical Research Communications 2006
Soluble Tumor Necrosis Factor-Related Ligand (sTRAIL) Levels and Kinetics During Antiviral Treatment in Chronic Hepatitis C
N Pelli, F Torre, A Delfino, M Basso, A Picciotto
Journal of Interferon & Cytokine Research 2006
Functional solubilization of aggregation-prone TRAIL protein facilitated by coexpressing with protein isoaspartate methyltranferase
H Zhu, RJ Pan, TW Wang, YL Shen, DZ Wei
Applied Microbiology and Biotechnology 2006
TRAIL receptor-targeted therapy
DJ Buchsbaum, T Zhou, AF LoBuglio
Future Oncology 2006
Implication of TNF-Related Apoptosis-Inducing Ligand in Inflammatory Intestinal Epithelial Lesions
B Begue, H Wajant, JC Bambou, L Dubuquoy, D Siegmund, JF Beaulieu, D Canioni, D Berrebi, N Brousse, P Desreumaux, J Schmitz, MJ Lentze, O Goulet, N Cerf–Bensussan, FM Ruemmele
Gastroenterology 2006
The Essential Role of the Mitochondria-Dependent Death-Signaling Cascade in Chemotherapy-Induced Potentiation of Apo2L/TRAIL Cytotoxicity in Cultured Thoracic Cancer Cells
DM Nguyen, WS Yeow, MF Ziauddin, A Baras, W Tsai, RM Reddy, A Chua, GW Cole, DS Schrump
The Cancer Journal 2006
Gene Therapy Strategies for Hepatocellular Carcinoma
LH Hwang
Journal of Biomedical Science 2006
Testicular germ cell sensitivity to TRAIL-induced apoptosis is dependent upon p53 expression and is synergistically enhanced by DR5 agonistic antibody treatment
CM McKee, Y Ye, JH Richburg
Apoptosis 2006
The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer
A Dutton, LS Young, PG Murray
Expert Opinion on Therapeutic Targets 2006
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL
LM Butler, V Liapis, S Bouralexis, K Welldon, S Hay, LM Thai, A Labrinidis, WD Tilley, DM Findlay, A Evdokiou
International Journal of Cancer 2006
Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo
P Liu, H Mao, P Hou
International Journal of Gynecological Cancer 2006
Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model
J Yoo, S Choi, KS Hwang, WK Cho, CR Jung, ST Kwon, DS Im
The Journal of Gene Medicine 2006
Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis
BM Hougardy, JH Maduro, AG van der Zee, DJ de Groot, FA van Heuvel, EG de Vries, S Jong
International Journal of Cancer 2006
Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay
SA Cillessen, CJ Meijer, GJ Ossenkoppele, KC Castricum, AH Westra, P Niesten, JJ Muris, HF Nijdam, KG van der Hem, M Flens, E Hooijberg, JJ Oudejans
British Journal of Haematology 2006
TRAIL gene reorganizes the cytoskeleton and decreases the motility of human leukemic Jurkat cells
Y Jiang, K Chen, Z Tang, Z Zeng, W Yao, D Sun, W Ka, D He, Z Wen, S Chien
Cell Motility and the Cytoskeleton 2006
The Role of Death Receptor Signaling in Testicular Germ-Cell Apoptosis Triggered by Mono-(2-ethylhexyl) Phthalate (MEHP)-Induced Sertoli Cell Injury and Its Implications for Risk Assessment
JH Richburg
Journal of Toxicology and Environmental Health, Part A 2006
Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma
T Azuhata, D Scott, TS Griffith, M Miller, AD Sandler
Journal of Pediatric Surgery 2006
Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo
P Marini, S Denzinger, D Schiller, S Kauder, S Welz, R Humphreys, PT Daniel, V Jendrossek, W Budach, C Belka
Oncogene 2006
Over-expressed estrogen receptor-α up-regulates hTNF-α gene expression and down-regulates β-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells
HH Hsu, SF Cheng, LM Chen, JY Liu, CH Chu, YJ Weng, ZY Li, CS Lin, SD Lee, WW Kuo, CY Huang
Molecular and Cellular Biochemistry 2006
Expression of TNF-related Apoptosis-inducing Ligand (TRAIL) and TRAIL Receptor 1 on Cancer and Normal Tissues in Patients with Non-small Cell Lung Cancer
T Kawashima, R Matsumura, K Umemiya, S Kawashima, K Kikkawa, Y Nishi, T Goto, Y Matsuzawa, H Tomioka, H Yamakawa
Haigan 2006
TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis
CA Dumitru, E Gulbins
Oncogene 2006
Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-κB
AC Williams, H Smartt, AM H-Zadeh, M MacFarlane, C Paraskeva, TJ Collard
Cell Death and Differentiation 2006
Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors
T Wenger, J Mattern, R Penzel, N Gassler, TL Haas, MR Sprick, H Walczak, PH Krammer, KM Debatin, I Herr
Cell Death and Differentiation 2006
Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin
K Schultze, B Böck, A Eckert, L Oevermann, D Ramacher, O Wiestler, W Roth
Apoptosis 2006
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity
RL VanOosten, JK Earel, TS Griffith
Apoptosis 2006
Adenoviral-mediated interferon α overcomes resistance to the interferon protein in various cancer types and has marked bystander effects
X Zhang, Z Yang, L Dong, A Papageorgiou, DJ McConkey, WF Benedict
Cancer Gene Therapy 2006
The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors
JM Kuijlen, BJ Haan, W Helfrich, JF Boer, D Samplonius, JJ Mooij, P Vos
Journal of Neuro-Oncology 2006
Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy
A Crijns, E Duiker, S JONG, P Willemse, AG der ZEE, EG VRIES
International Journal of Gynecological Cancer 2006
TRAIL-mediated Cytotoxicity: Impacts of sTRAIL and vTRAIL Microvesicles
AF ., SJ ., YY ., YA ., TA ., TK .
Journal of Biological Sciences 2006
Cancer gene-therapy: clinical trials
DH Palmer, LS Young, V Mautner
Trends in Biotechnology 2006
Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model
JM Straughn, PG Oliver, T Zhou, W Wang, RD Alvarez, WE Grizzle, DJ Buchsbaum
Gynecologic Oncology 2006
TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme
JM Kuijlen, JJ Mooij, I Platteel, EW Hoving, WT Graaf, MM Span, H Hollema, WF Dunnen
Journal of Neuro-Oncology 2006
TRAIL, caspases and maturation of normal and leukemic myeloid precursors
F Corallini, D Milani, V Nicolin, P Secchiero
Leukemia & Lymphoma 2006
Immunomodulatory neural stem cells for brain tumour therapy
JJ Yu, X Sun, X Yuan, JW Lee, EY Snyder, JS Yu
Expert Opinion on Biological Therapy 2006
Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor–related apoptosis-inducing ligand
WS Yeow, A Baras, A Chua, DM Nguyen, SS Sehgal, DS Schrump, DM Nguyen
The Journal of Thoracic and Cardiovascular Surgery 2006
A CD40–CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95
C Assohou-Luty, J Gerspach, D Siegmund, N Müller, B Huard, G Tiegs, K Pfizenmaier, H Wajant
Journal of Molecular Medicine 2006
Targeting Death Receptors in Bladder, Prostate and Renal Cancer
HF O’Kane, CJ Watson, SR Johnston, I Petak, R William, G Watson, KE Williamson
The Journal of Urology 2006
Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor–related apoptosis-inducing ligand
L Zhuang, CS Lee, RA Scolyer, SW McCarthy, XD Zhang, JF Thompson, G Screaton, P Hersey
Human Pathology 2006
In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma
JQ Tian, ZP Wang, R Rodriguez, JS Fu, JZ Lu, BL Ma
Urology 2006
Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis
S Boehrer, D Nowak, E Puccetti, M Ruthardt, N Sattler, B Trepohl, B Schneider, D Hoelzer, PS Mitrou, KU Chow
Leukemia Research 2006
Activation of the Proapoptotic Death Receptor DR5 by Oligomeric Peptide and Antibody Agonists
B Li, SJ Russell, DM Compaan, K Totpal, SA Marsters, A Ashkenazi, AG Cochran, SG Hymowitz, SS Sidhu
Journal of Molecular Biology 2006
TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway
A Jurewicz, M Matysiak, S Andrzejak, K Selmaj
Glia 2006
TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy
EH Wissink, I Verbrugge, SR Vink, MB Schader, U Schaefer, H Walczak, J Borst, M Verheij
Radiotherapy and Oncology 2006
Death ligands and autoimmune demyelination
O Aktas, T Prozorovski, F Zipp
The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry 2006
The clinical trail of TRAIL
EW Duiker, CH Mom, S Jong, PH Willemse, JA Gietema, AG der Zee, EG Vries
European Journal of Cancer 2006
Differential response of neuroblastoma cells to TRAIL is independent of PI3K/AKT
PA Efron, MK Chen, M Iyengar, W Dai, A Nagaram, EA Beierle
Journal of Pediatric Surgery 2006
Immunoplacental therapy, a potential multi-epitope cancer vaccine
A Harandi
Medical Hypotheses 2006
Colorectal Cancer
G Chong, D Cunningham
Colorectal Cancer 2006
Hyperthermia enhances tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human cancer cells
J Yoo, HR Kim, YJ Lee
International Journal of Hyperthermia 2006
Gene Expression Analysis on the Dicyclanil-Induced Hepatocellular Tumors in Mice
M Moto, M Okamura, M Muguruma, T Ito, M Jin, Y Kashida, K Mitsumori
Toxicologic pathology 2006
Prognostic Significance of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand and Its Receptors in Adjuvantly Treated Stage III Colon Cancer Patients
CM van Geelen, JL Westra, EG de Vries, WB Ek, N Zwart, H Hollema, HM Boezen, NH Mulder, JT Plukker, S Jong, JH Kleibeuker, JJ Koornstra
Journal of Clinical Oncology 2006
Perspectivas de novos tratamentos para o carcinoma tireoidiano avançado
A Rodrigues
Revista do Colégio Brasileiro de Cirurgiões 2006
Evidence for Two Modes of Development of Acquired Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance: INVOLVEMENT OF Bcl-xL
JJ Song, JY An, YT Kwon, YJ Lee
The Journal of biological chemistry 2006
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells
N Ishimura, H Isomoto, SF Bronk, GJ Gores
AJP Gastrointestinal and Liver Physiology 2006
TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression
NJ Clemons, RL Anderson
Cell Stress and Chaperones 2006
The Link Between Inflammation and Cancer
AG Dalgleish, B Haefner
2006
TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract
A Sadarangani, S Kato, N Espinoza, S Lange, C Llados, M Espinosa, M Villalón, S Lipkowitz, M Cuello, GI Owen
Apoptosis 2006
Breast Cancer and Molecular Medicine
MJ Piccart, MC Hung, LJ Solin, F Cardoso, WC Wood
2006
Selective TRAIL-Induced Apoptosis in Dysplastic Neoplasia of the Colon May Lead to New Neoadjuvant or Adjuvant Therapies
N Finnberg, WS El-Deiry
Clinical cancer research 2006
Inducible Resistance of Tumor Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 2–Mediated Apoptosis by Generation of a Blockade at the Death Domain Function
Y Li, H Wang, Z Wang, S Makhija, D Buchsbaum, A LoBuglio, R Kimberly, T Zhou
Cancer research 2006
Eliminating Established Tumor in nu/nu Nude Mice by a Tumor Necrosis Factor-α-Related Apoptosis-Inducing Ligand–Armed Oncolytic Adenovirus
F Dong, L Wang, JJ Davis, W Hu, L Zhang, W Guo, F Teraishi, L Ji, B Fang
Clinical cancer research 2006
A Novel Selective Progesterone Receptor Modulator Asoprisnil Activates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Signaling Pathway in Cultured Human Uterine Leiomyoma Cells in the Absence of Comparable Effects on Myometrial Cells
H Sasaki, N Ohara, Q Xu, J Wang, DA DeManno, K Chwalisz, S Yoshida, T Maruo
The Journal of clinical endocrinology and metabolism 2006
Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma
MM McCarthy, KA DiVito, M Sznol, D Kovacs, R Halaban, AJ Berger, KT Flaherty, RL Camp, R Lazova, DL Rimm, HM Kluger
Clinical cancer research 2006
Wogonin sensitizes resistant malignant cells to TNFα- and TRAIL-induced apoptosis
SC Fas, S Baumann, JY Zhu, M Giaisi, MK Treiber, U Mahlknecht, PH Krammer, M Li-Weber
Blood 2006
Transduction of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand into Hematopoietic Cells Leads to Inhibition of Syngeneic Tumor Growth In vivo
K Song, N Benhaga, RL Anderson, R Khosravi-Far
Cancer research 2006
TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme.
Kuijlen JM, Mooij JJ, Platteel I, Hoving EW, van der Graaf WT, Span MM, Hollema H, den Dunnen WF
Journal of Neuro-Oncology 2006
The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors.
Kuijlen JM, de Haan BJ, Helfrich W, de Boer JF, Samplonius D, Mooij JJ, de Vos P
Journal of Neuro-Oncology 2006
Over-expressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells.
Hsu HH, Cheng SF, Chen LM, Liu JY, Chu CH, Weng YJ, Li ZY, Lin CS, Lee SD, Kuo WW, Huang CY
Molecular and Cellular Biochemistry 2006
Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC).
Yang F, Shi P, Xi X, Yi S, Li H, Sun Q, Sun M
Medical Oncology 2006
A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95.
Assohou-Luty C, Gerspach J, Siegmund D, Müller N, Huard B, Tiegs G, Pfizenmaier K, Wajant H
Journal of Molecular Medicine 2006
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells
P Secchiero, M Tiribelli, E Barbarotto, C Celeghini, A Michelutti, P Masolini, R Fanin, G Zauli
Journal of Cellular Physiology 2005
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma
TR Singh, S Shankar, RK Srivastava
Oncogene 2005
New Approaches and Therapeutics Targeting Apoptosis in Disease
U Fischer, K Schulze-Osthoff
Pharmacological reviews 2005
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Alters Mitochondrial Membrane Lipids
F Sandra, MD Esposti, K Ndebele, P Gona, D Knight, M Rosenquist, R Khosravi-Far
Cancer research 2005
Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells
LY Dimberg, AI Dimberg, K Ivarsson, T Strömberg, A Österborg, K Nilsson, F Öberg, HJ Wiklund
Blood 2005
Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake
B Mundt, T Wirth, L Zender, M Waltemathe, C Trautwein, MP Manns, F Kühnel, S Kubicka
Gut 2005
Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL
O Aktas, A Smorodchenko, S Brocke, C Infante-Duarte, US Topphoff, J Vogt, T Prozorovski, S Meier, V Osmanova, E Pohl, I Bechmann, R Nitsch, F Zipp
Neuron 2005
Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer
M Jalving, JJ Koornstra, S Jong, EG Vries, JH Kleibeuker
Alimentary Pharmacology and Therapeutics 2005
A novel apoptosis-inducing monoclonal antibody (anti-LHK) against a cell surface antigen on colon cancer cells
H Matsukawa, T Kanai, M Naganuma, N Kamada, T Hisamatsu, H Takaishi, H Ogata, M Mukai, H Ishii, T Mimori, M Watanabe, T Hibi
Journal of Gastroenterology 2005
Increased Expression and a Potential Anti-Inflammatory Role of TRAIL in Atopic Dermatitis
E Vassina, M Leverkus, S Yousefi, LR Braathen, HU Simon, D Simon
Journal of Investigative Dermatology 2005
Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease
B Fadeel, S Orrenius
Journal of Internal Medicine 2005
Angiogenesis and apoptosis in glioma: Two arenas for promising new therapies
O Bögler, T Mikkelsen
Journal of Cellular Biochemistry 2005
Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells
KU Kim, SY Seo, KY Heo, YH Yoo, HJ Kim, HS Lee, SS Choi, TH Hwang, HJ Lee
Journal of Korean Medical Science 2005
Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis
L Clancy, K Mruk, K Archer, M Woelfel, J Mongkolsapaya, G Screaton, MJ Lenardo, FK Chan
Proceedings of the National Academy of Sciences 2005
Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8
S Shin, Y Lee, W Kim, H Ko, H Choi, K Kim
The EMBO Journal 2005
A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance
KU Kim, SM Wilson, KS Abayasiriwardana, R Collins, L Fjellbirkeland, Z Xu, DM Jablons, SL Nishimura, VC Broaddus
American journal of respiratory cell and molecular biology 2005
The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
BL Hylander, R Pitoniak, RB Penetrante, JF Gibbs, D Oktay, J Cheng, EA Repasky
Journal of Translational Medicine 2005
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
L Pukac, P Kanakaraj, R Humphreys, R Alderson, M Bloom, C Sung, T Riccobene, R Johnson, M Fiscella, A Mahoney, J Carrell, E Boyd, XT Yao, L Zhang, L Zhong, A Kerczek, L Shepard, T Vaughan, B Edwards, C Dobson, T Salcedo, V Albert
British Journal of Cancer 2005
Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes
D Campioni, P Secchiero, F Corallini, E Melloni, S Capitani, F Lanza, G Zauli
The American Journal of Pathology 2005
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis
P Marini, A Schmid, V Jendrossek, H Faltin, PT Daniel, W Budach, C Belka
BMC Cancer 2005
Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines
T Matsuda, A Almasan, M Tomita, J Uchihara, M Masuda, K Ohshiro, N Takasu, H Yagita, T Ohta, N Mori
Journal of virology 2005
Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts
A El-Zawahry, J McKillop, C Voelkel-Johnson
BMC Cancer 2005
Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development
E Melloni, P Secchiero, C Celeghini, D Campioni, V Grill, L Guidotti, G Zauli
Journal of Cellular Physiology 2005
Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis
A Hague, DJ Hicks, F Hasan, H Smartt, GM Cohen, C Paraskeva, M MacFarlane
British Journal of Cancer 2005
Apoptosis: mechanisms and relevance in cancer
K Vermeulen, DR Bockstaele, ZN Berneman
Annals of Hematology 2005
Chronic Lymphocytic Leukemia
N Chiorazzi, KR Rai, M Ferrarini
New England Journal of Medicine 2005
Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors Part 5: apoptosis and cell cycle
HB Newton
Expert Review of Anticancer Therapy 2005
Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors
HW Lee, SH Lee, HW Lee, YW Ryu, MH Kwon, YS Kim
Biochemical and Biophysical Research Communications 2005
The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells
M Horinaka, T Yoshida, T Shiraishi, S Nakata, M Wakada, R Nakanishi, H Nishino, T Sakai
Biochemical and Biophysical Research Communications 2005
Death squads enlisted by the tumour suppressor p53
E Michalak, A Villunger, M Erlacher, A Strasser
Biochemical and Biophysical Research Communications 2005
Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand
H Hasegawa, Y Yamada, H Harasawa, T Tsuji, K Murata, K Sugahara, K Tsuruda, S Ikeda, Y Imaizumi, M Tomonaga, M Masuda, N Takasu, S Kamihira
British Journal of Haematology 2005
Requirement of c-Jun NH2-terminal kinase activation in interferon-α-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells
N Yanase, K Hata, K Shimo, M Hayashida, BM Evers, J Mizuguchi
Experimental Cell Research 2005
Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice
H Ma, Y Liu, S Liu, R Xu, D Zheng
Hepatology 2005
Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand1
F FANG, A WANG, S YANG
Acta Pharmacologica Sinica 2005
Other Compounds and Targets in Non–Small Cell Lung Cancer
V Villaflor, P Bonomi
Seminars in Oncology 2005
Cancer gene therapy using a novel secretable trimeric TRAIL
CY Kim, M Jeong, H Mushiake, BM Kim, WB Kim, JP Ko, MH Kim, M Kim, TH Kim, PD Robbins, TR Billiar, DW Seol
Gene Therapy 2005
In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL
A El-Zawahry, P Lu, SJ White, C Voelkel-Johnson
Cancer Gene Therapy 2005
Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors
H Ma, Y Liu, S Liu, HF Kung, X Sun, D Zheng, R Xu
International Journal of Cancer 2005
On the TRAIL of a new therapy for leukemia
SH Kaufmann, DP Steensma
Leukemia 2005
Initiation factor modifications in the preapoptotic phase
SJ Morley, MJ Coldwell, MJ Clemens
Cell Death and Differentiation 2005
Extensive regions of the FADD death domain are required for binding to the TRAIL receptor DR5
LR Thomas, LM Bender, MJ Morgan, A Thorburn
Cell Death and Differentiation 2005
TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway
J Wendt, C Haefen, P Hemmati, C Belka, B Dörken, PT Daniel
Oncogene 2005
TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-β in cervical carcinoma cells
S Vannucchi, MV Chiantore, G Fiorucci, ZA Percario, S Leone, E Affabris, G Romeo
Oncogene 2005
Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas
H Kumamoto, K Ooya
Journal of Oral Pathology and Medicine 2005
Relationships between tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and hematopoietic activity in healthy adults
JW Choi
Annals of Hematology 2005
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
M MacFarlane, S Inoue, SL Kohlhaas, A Majid, N Harper, DB Kennedy, MJ Dyer, GM Cohen
Cell Death and Differentiation 2005
A new TRAIL to therapy of hepatocellular carcinoma: Blocking the proteasome
A Anan, GJ Gores
Hepatology 2005
Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?
BM Reipert, S Tanneberger, A Pannetta, M Bedosti, M Poell, K Zimmermann, MT Stellamor
Cancer Immunology, Immunotherapy 2005
TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice
E Cretney, JL McQualter, N Kayagaki, H Yagita, CC Bernard, IS Grewal, A Ashkenazi, MJ Smyth
Immunology and Cell Biology 2005
Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP
EH Kim, HS Kim, SU Kim, EJ Noh, JS Lee, KS Choi
Oncogene 2005
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL
TM Ganten, R Koschny, TL Haas, J Sykora, M Li-Weber, K Herzer, H Walczak
Hepatology 2005
Transforming growth factor β can mediate apoptosis via the expression of TRAIL in human hepatoma cells
K Herzer, TM Ganten, H Schulze-Bergkamen, A Grosse-Wilde, R Koschny, PH Krammer, H Walczak
Hepatology 2005
Promoting apoptosis as a strategy for cancer drug discovery
SW Fesik
Nature Reviews Cancer 2005
Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity
SA Kaliberov, S Chiz, LN Kaliberova, V Krendelchtchikova, DD Manna, T Zhou, DJ Buchsbaum
Cancer Gene Therapy 2005
Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor
S Ray, O Bucur, A Almasan
Apoptosis 2005
Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells
T Abdollahi, NM Robertson, A Abdollahi, G Litwack
Apoptosis 2005
Caspase 8 is absent or low in many ex vivo gliomas
DM Ashley, CD Riffkin, AM Muscat, MJ Knight, AH Kaye, U Novak, CJ Hawkins
Cancer 2005
Parenchymal regression in chronic pancreatitis spares islets reprogrammed for the expression of NFκB and IAPs
C Hasel, UK Bhanot, R Heydrich, J Sträter, P Möller
Laboratory Investigation 2005
Death Receptor Apoptosis Signaling Mediated by FADD in CD30-Positive Lymphoproliferative Disorders Involving the Skin
LE Clarke, MG Bayerl, RD Bruggeman, D Mauger, MD Ioffreda, A Abou-Elella, KF Helm
The American Journal of Surgical Pathology 2005
Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells
M Horinaka, T Yoshida, T Shiraishi, S Nakata, M Wakada, R Nakanishi, H Nishino, H Matsui, T Sakai
Oncogene 2005
FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis
X Dolcet, D Llobet, J Pallares, M Rue, JX Comella, X Matias-Guiu
Laboratory Investigation 2005
Apoptosis-based therapies and drug targets
U Fischer, K Schulze-Osthoff
Cell Death and Differentiation 2005
Characterisation of monoclonal antibodies to the TNF and TNF receptor families
PF Ch’en, XG Xu, XS Liu, Y Liu, CJ Song, GR Screaton, BQ Jin, XN Xu
Cellular Immunology 2005
Embryonic stem cell–derived astrocytes: a novel gene therapy vector for brain tumors
M Uzzaman, RJ Benveniste, G Keller, IM Germano
Neurosurgical FOCUS 2005
Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice
FJ Salguero, MA Sánchez-Martín, FD Segundo, A Avila, N Sevilla
Virology 2005
Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study
N Reesink-Peters, BM Hougardy, FA Heuvel, KA Hoor, H Hollema, HM Boezen, EG Vries, S Jong, AG der Zee
Gynecologic Oncology 2005
Biology of plasma cells
S Chen-Kiang
Best Practice & Research Clinical Haematology 2005
Novel apoptosis inducing agents in cancer therapy
M Mita, AW Tolcher
Current Problems in Cancer 2005
Current status of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) targeting cancer therapy
E Mori, K Motoki, S Kataoka
Annals of Cancer Research and Therapy 2005
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
TJ Sayers, WJ Murphy
Cancer Immunology, Immunotherapy 2005
Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: Potential targets for apoptosis induction
JJ Koornstra, M Jalving, FE Rijcken, J Westra, N Zwart, H Hollema, EG de Vries, RW Hofstra, JT Plukker, S Jong, JH Kleibeuker
European Journal of Cancer 2005
Selection for TRAIL resistance results in melanoma cells with high proliferative potential
JJ Wu, XD Zhang, S Gillespie, P Hersey
FEBS Letters 2005
Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis
E Mori, M Thomas, K Motoki, S Kataoka
FEBS Letters 2005
1'-Acetoxychavicol acetate induces apoptosis of myeloma cells via induction of TRAIL
K Ito, T Nakazato, A Murakami, H Ohigashi, Y Ikeda, M Kizaki
Biochemical and Biophysical Research Communications 2005
Novel biological therapies for the treatment of multiple myeloma
PG Richardson, CS Mitsiades, T Hideshima, KC Anderson
Best practice & research. Clinical haematology 2005
Cell Death During HIV Infection
M Smith-Raska, M Lenardo, K Sakai
Cell Death During HIV Infection: gp120 2005
TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation
VK Puduvalli, D Sampath, JM Bruner, J Nangia, R Xu, AP Kyritsis
Apoptosis 2005
Bcl-xL/Bax ratio is altered by IFNγ in TNFα- but not in TRAIL-induced apoptosis in colon cancer cell line
G Baillat, F Garrouste, M Remacle-Bonnet, J Marvaldi, G Pommier
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2005
The Activation of ERK1/2 via a Tyrosine Kinase Pathway Attenuates Trail-Induced Apoptosis in HeLa Cells
MW Lee, JH Bach, HJ Lee, DY Lee, WS Joo, YS Kim, SC Park, KY Kim, WB Lee, SS Kim
Cancer Investigation 2005
Apoptosis and immaturity in acute myeloid leukemia
MI Principe, GD Poeta, A Venditti, F Buccisano, L Maurillo, C Mazzone, A Bruno, B Neri, MI Consalvo, FL Coco, S Amadori
Hematology 2005
Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Activating Agents
EK Rowinsky
Journal of Clinical Oncology 2005
Effective gene–virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5
XY Liu, SB Qiu, WG Zou, ZF Pei, JF Gu, CX Luo, HM Ruan, Y Chen, YP Qi, C Qian
Molecular Therapy 2005
Pretreatment of Acetylsalicylic Acid Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Down-regulating BCL-2 Gene Expression
KM Kim, JJ Song, JY An, YT Kwon, YJ Lee
The Journal of biological chemistry 2005
Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR
E Bremer, DF Samplonius, L Genne, MH Dijkstra, BJ Kroesen, LF de Leij, W Helfrich
The Journal of biological chemistry 2005
A Novel Anti-human DR5 Monoclonal Antibody with Tumoricidal Activity Induces Caspase-dependent and Caspase-independent Cell Death
Y Guo, C Chen, Y Zheng, J Zhang, X Tao, S Liu, D Zheng, Y Liu
The Journal of biological chemistry 2005
A Peroxisome Proliferator-activated Receptor-γ Agonist, Troglitazone, Facilitates Caspase-8 and -9 Activities by Increasing the Enzymatic Activity of Protein-tyrosine Phosphatase-1B on Human Glioma Cells
Y Akasaki, G Liu, HH Matundan, H Ng, X Yuan, Z Zeng, KL Black, JS Yu
The Journal of biological chemistry 2005
Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines
K Izeradjene, L Douglas, A Delaney, JA Houghton
Oncogene 2005
Death to the bad guys: Targeting cancer via Apo2L/TRAIL
S Bouralexis, DM Findlay, A Evdokiou
Apoptosis 2005
In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma
E Ciusani, D Croci, M Gelati, C Calatozzolo, F Sciacca, L Fumagalli, M Balzarotti, L Fariselli, A Boiardi, A Salmaggi
Journal of Neuro-Oncology 2005
Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases
M Los, SB Gibson
2005
Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP
L Galligan, DB Longley, M McEwan, TR Wilson, K McLaughlin, PG Johnston
Molecular cancer therapeutics 2005
E1A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis through Enhancement of Caspase Activation
R Shao, DF Lee, Y Wen, Y Ding, W Xia, B Ping, H Yagita, B Spohn, MC Hung
Molecular cancer research : MCR 2005
Perturbation of the Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Cascade in Ovarian Cancer: Overexpression of FLIP L and Deregulation of the Functional Receptors DR4 and DR5
P Horak, D Pils, A Kaider, A Pinter, K Elandt, C Sax, CC Zielinski, R Horvat, R Zeillinger, A Reinthaller, M Krainer
Clinical cancer research 2005
Target Cell–Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7
E Bremer, DF Samplonius, M Peipp, L van Genne, BJ Kroesen, GH Fey, M Gramatzki, LF de Leij, W Helfrich
Cancer research 2005
Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells
F Dicker, AP Kater, T Fukuda, TJ Kipps
Blood 2005
Caspase-10 Sensitizes Breast Carcinoma Cells to TRAIL-Induced but Not Tumor Necrosis Factor-Induced Apoptosis in a Caspase- 3-Dependent Manner
IH Engels, G Totzke, U Fischer, K Schulze-Osthoff, RU Jänicke
Molecular and cellular biology 2005
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
D Re, RK Thomas, K Behringer, V Diehl
Blood 2005
Apoptosis-based therapies for hematologic malignancies
JC Reed, M Pellecchia
Blood 2005
Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Non–Small Cell Lung Cancer
X Zhang, RM Cheung, R Komaki, B Fang, JY Chang
Clinical cancer research 2005
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Sayers TJ, Murphy WJ
Cancer Immunology, Immunotherapy 2005
Sensitization of human glioblastomas to tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) by NF‐κB inhibitors
Kasuga C, Ebata T, Kayagaki N, Yagita H, Hishii M, Aral H, Sato K, Okumura K
Cancer Science 2005
AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression
A Mohr, G Henderson, L Dudus, I Herr, T Kuerschner, KM Debatin, H Weiher, KJ Fisher, RM Zwacka
Gene Therapy 2004
PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes
L Larribere, M Khaled, S Tartare-Deckert, R Busca, F Luciano, K Bille, G Valony, A Eychene, P Auberger, JP Ortonne, R Ballotti, C Bertolotto
Cell Death and Differentiation 2004
Lysosomes in cell death
ME Guicciardi, M Leist, GJ Gores
Oncogene 2004
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF
G Zauli, E Rimondi, V Nicolin, E Melloni, C Celeghini, P Secchiero
Blood 2004
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis
M Chawla-Sarkar, SI Bae, FJ Reu, BS Jacobs, DJ Lindner, EC Borden
Cell Death and Differentiation 2004
Blasts from the past
PA Insel, S Kornfeld, PW Majerus, AR Marks, PA Marks, AS Relman, BF Scharschmidt, TP Stossel, AP Varki, SJ Weiss, JD Wilson
Journal of Clinical Investigation 2004
Sensitization of Cells to TRAIL-induced Apoptosis by Decoy Receptor 3
YY Wu, YC Chang, TL Hsu, SL Hsieh, MZ Lai
The Journal of biological chemistry 2004
Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy
K Takeda, N Yamaguchi, H Akiba, Y Kojima, Y Hayakawa, JE Tanner, TJ Sayers, N Seki, K Okumura, H Yagita, MJ Smyth
Journal of Experimental Medicine 2004
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
Y Shao, Z Gao, PA Marks, X Jiang
Proceedings of the National Academy of Sciences 2004
Critical roles of TRAIL in hepatic cell death and hepatic inflammation
SJ Zheng, P Wang, G Tsabary, YH Chen
Journal of Clinical Investigation 2004
Apoptosis in cancer—implications for therapy
H Schulze-Bergkamen, PH Krammer
Seminars in Oncology 2004
Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system
G Eissner, W Kolch, P Scheurich
Cytokine & Growth Factor Reviews 2004
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity
MS Ricci, Z Jin, M Dews, D Yu, A Thomas-Tikhonenko, DT Dicker, WS El-Deiry
Molecular and cellular biology 2004
Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL
MA el Hassan, DC Mastenbroek, WR Gerritsen, G Giaccone, FA Kruyt
British Journal of Cancer 2004
Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells
E Bremer, D Samplonius, BJ Kroesen, L Genne, L Leij, W Helfrich
Neoplasia (New York, N.Y.) 2004
Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand
P Secchiero, A Gonelli, E Carnevale, F Corallini, C Rizzardi, S Zacchigna, M Melato, G Zauli
Neoplasia (New York, N.Y.) 2004
Gene therapy strategies to improve the effectiveness of cancer radiotherapy
SO Freytag, JH Kim, SL Brown, K Barton, M Lu, M Chung
Expert Opinion on Biological Therapy 2004
eNOS protects prostate cancer cells from TRAIL-induced apoptosis
X Tong, H Li
Cancer Letters 2004
Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms
S Shankar, TR Singh, RK Srivastava
The Prostate 2004
Exploiting death receptor signaling pathways for tumor therapy
S Fulda, KM Debatin
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2004
Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression
JL Luo, S Maeda, LC Hsu, H Yagita, M Karin
Cancer Cell 2004
The secretable form of trimeric TRAIL, a potent inducer of apoptosis
MH Kim, TR Billiar, DW Seol
Biochemical and Biophysical Research Communications 2004
Down-regulation of procaspase-8 expression by focal adhesion kinase protects HL-60 cells from TRAIL-induced apoptosis
Y Tamagiku, Y Sonoda, M Kunisawa, D Ichikawa, Y Murakami, E Aizu-Yokota, T Kasahara
Biochemical and Biophysical Research Communications 2004
Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications
S Shankar, RK Srivastava
Drug Resistance Updates 2004
An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice
Z Pei, L Chu, W Zou, Z Zhang, S Qiu, R Qi, J Gu, C Qian, X Liu
Hepatology 2004
Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2
E Bremer, J Kuijlen, D Samplonius, H Walczak, L Leij, W Helfrich
International Journal of Cancer 2004
Quantification of tumor tissue populations by multispectral analysis
RA Carano, AL Ross, J Ross, SP Williams, H Koeppen, RH Schwall, NV Bruggen
Magnetic Resonance in Medicine 2004
Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L
RD Pietro, G Zauli
Journal of Cellular Physiology 2004
Monocytes Stimulated with Group B Streptococci or Interferons Release Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand
O Halaas, NB Liabakk, R Vik, C Beninati, P Henneke, A Sundan, T Espevik
Scandinavian Journal of Immunology 2004
Sensitization of human renal cell carcinoma cell lines to TRAIL-induced apoptosis by anthracyclines
XX Wu, O Ogawa, Y Kakehi
International Journal of Urology 2004
Following a TRAIL: Update on a ligand and its five receptors
FC KIMBERLEY, GR SCREATON
Cell Research 2004
Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitors
C Kasuga, T Ebata, N Kayagaki, H Yagita, M Hishii, H Aral, K Sato, K Okumura
Cancer Science 2004
TRAIL and its receptors as targets for cancer therapy
H Yagita, K Takeda, Y Hayakawa, MJ Smyth, K Okumura
Cancer Science 2004
Restricted expression of tumor necrosis factor-related apoptosis-inducing ligand receptor 4 in human peripheral blood lymphocytes
H Hasegawa, Y Yamada, H Harasawa, T Tsuji, K Murata, K Sugahara, K Tsuruda, M Masuda, N Takasu, S Kamihira
Cellular Immunology 2004
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy
CM van Geelen, EG de Vries, S Jong
Drug Resistance Updates 2004
Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs
S Tomek, P Horak, I Pribill, G Haller, M Rössler, CC Zielinski, D Pils, M Krainer
Gynecologic Oncology 2004
Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma
HJ Arts, S Jong, H Hollema, K Hoor, AG der Zee, EG Vries
Gynecologic Oncology 2004
Combination of Targeting Gene-ViroTherapy with 5-FU Enhances Antitumor Efficacy in Malignant Colorectal Carcinoma
S Qiu, H Ruan, Z Pei, B Hu, P Lan, J Wang, Z Zhang, J Gu, L Sun, C Qian, X Liu, Y Qi
Journal of Interferon & Cytokine Research 2004
Thapsigargin potentiates TRAIL-induced apoptosis in giant cell tumor of bone
L Huang, J Xu, K Li, MH Zheng, SM Kumta
Bone 2004
Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor–related apoptosis-inducing ligand
RM Reddy, WS Tsai, MF Ziauddin, JT Zuo, GW Cole, JB Maxhimer, BL Fang, DS Schrump, DM Nguyen
The Journal of Thoracic and Cardiovascular Surgery 2004
Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1
V Chopin, C Slomianny, H Hondermarck, XL Bourhis
Experimental Cell Research 2004
Influence of hypoxia on TRAIL-induced apoptosis in tumor cells
M Weinmann, P Marini, V Jendrossek, A Betsch, B Goecke, W Budach, C Belka
International journal of radiation oncology, biology, physics 2004
Apoptosis-modulating agents in combination with radiotherapy—current status and outlook
C Belka, V Jendrossek, M Pruschy, S Vink, M Verheij, W Budach
International journal of radiation oncology, biology, physics 2004
Development of Rationally Designed, Target-Based Agents for the Treatment of Advanced Colorectal Cancer
AC Mita, MM Mita, EK Rowinsky
Clinical Colorectal Cancer 2004
Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma
LP Bron, RA Scolyer, JF Thompson, P Hersey
Pathology 2004
Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects
C He
World journal of gastroenterology : WJG 2004
Induction of potent TRAIL-mediated tumoricidal activity by hFLEX/Furin/TRAIL recombinant DNA construct
X Wu, KM Hui
Molecular Therapy 2004
Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer
SA Kaliberov, LN Kaliberova, CR Stockard, WE Grizzle, DJ Buchsbaum
Molecular Therapy 2004
A Tumor-Targeted and Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL for Treatment of Liver Metastases
P Sova, XW Ren, S Ni, KM Bernt, J Mi, N Kiviat, A Lieber
Molecular Therapy 2004
The C-terminal Tails of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Fas Receptors Have Opposing Functions in Fas-associated Death Domain (FADD) Recruitment and Can Regulate Agonist-specific Mechanisms of Receptor Activation
LR Thomas, RL Johnson, JC Reed, A Thorburn
The Journal of biological chemistry 2004
Death Induction by Recombinant Native TRAIL and Its Prevention by a Caspase 9 Inhibitor in Primary Human Esophageal Epithelial Cells
SH Kim, K Kim, JG Kwagh, DT Dicker, M Herlyn, AK Rustgi, Y Chen, WS El-Deiry
The Journal of biological chemistry 2004
Direct Binding of Fas-associated Death Domain (FADD) to the Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptor DR5 Is Regulated by the Death Effector Domain of FADD
LR Thomas, A Henson, JC Reed, FR Salsbury, A Thorburn
The Journal of biological chemistry 2004
Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling
RF Kelley, K Totpal, SH Lindstrom, M Mathieu, K Billeci, L DeForge, R Pai, SG Hymowitz, A Ashkenazi
The Journal of biological chemistry 2004
Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL
KD Burroughs, DB Kayda, K Sakhuja, Y Hudson, J Jakubczak, JA Bristol, D Ennist, P Hallenbeck, M Kaleko, S Connelly
Cancer Gene Therapy 2004
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs
TM Ganten, TL Haas, J Sykora, H Stahl, MR Sprick, SC Fas, A Krueger, MA Weigand, A Grosse-Wilde, W Stremmel, PH Krammer, H Walczak
Cell Death and Differentiation 2004
Death receptors in chemotherapy and cancer
KM Debatin, PH Krammer
Oncogene 2004
Type I and type II reactions in TRAIL-induced apoptosis – results from dose–response studies
J Rudner, V Jendrossek, K Lauber, PT Daniel, S Wesselborg, C Belka
Oncogene 2004
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
S Nakata, T Yoshida, M Horinaka, T Shiraishi, M Wakada, T Sakai
Oncogene 2004
Targets and mechanisms for the regulation of translation in malignant transformation
MJ Clemens
Oncogene 2004
Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP
EH Kim, SU Kim, DY Shin, KS Choi
Oncogene 2004
Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-κB and inhibition of Bcl-xL expression
S Huerta-Yepez, M Vega, A Jazirehi, H Garban, F Hongo, G Cheng, B Bonavida
Oncogene 2004
Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway
C Haefen, B Gillissen, PG Hemmati, J Wendt, D Güner, A Mrozek, C Belka, B Dörken, PT Daniel
Oncogene 2004
Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells
S Kaliberov, MA Stackhouse, L Kaliberova, T Zhou, DJ Buchsbaum
Gene Therapy 2004
Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells
J Han, LA Goldstein, BR Gastman, A Rabinovitz, GQ Wang, B Fang, H Rabinowich
Leukemia 2004
Type I interferon and TNFα cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells
A Abadie, F Besançon, J Wietzerbin
Oncogene 2004
Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP
EH Kim, SU Kim, KS Choi
Oncogene 2004
Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas
J An, Y Sun, M Fisher, MB Rettig
Leukemia 2004
Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo
QL Fan, WY Zou, LH Song, W Wei
Cancer Chemotherapy and Pharmacology 2004
Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis
AD Brooks, TJ Sayers
Cancer Immunology, Immunotherapy 2004
ENDOTOXIN INCREASES PLASMA SOLUBLE TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND LEVEL MEDIATED BY THE p38 MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY:
MN Hooge, S de Jong, C Vermot-Desroches, JE Tulleken, EG de Vries, JG Zijlstra
Shock 2004
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
WD Figg, HL McLeod
2004
Proteasome Inhibitors in Cancer Therapy
J Adams
2004
N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines
M Cuello, AO Coats, I Darko, SA Ettenberg, GJ Gardner, MM Nau, JR Liu, MJ Birrer, S Lipkowitz
Cell Death and Differentiation 2004
Interleukin-1β and Tumor Necrosis Factor (TNF)-α Sensitize Human Thyroid Epithelial Cells to TNF-Related Apoptosis-Inducing Ligand-Induced Apoptosis through Increases in Procaspase-7 and Bid, and the Down-Regulation of p44/42 Mitogen-Activated Protein Kinase Activity
E Mezosi, SH Wang, S Utsugi, L Bajnok, JD Bretz, PG Gauger, NW Thompson, JR Baker
The Journal of clinical endocrinology and metabolism 2004
Signal Transduction in Cancer
DA Frank
2004
IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells
C Tecchio, V Huber, P Scapini, F Calzetti, D Margotto, G Todeschini, L Pilla, G Martinelli, G Pizzolo, L Rivoltini, MA Cassatella
Blood 2004
TISSUE DISTRIBUTION, STABILITY, AND PHARMACOKINETICS OF APO2 LIGAND/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND IN HUMAN COLON CARCINOMA COLO205 TUMOR-BEARING NUDE MICE
H Xiang, CB Nguyen, SK Kelley, N Dybdal, E Escandón
Drug Metabolism and Disposition 2004
Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells
F Guo, C Sigua, J Tao, P Bali, P George, Y Li, S Wittmann, L Moscinski, P Atadja, K Bhalla
Cancer research 2004
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells
A Ballestrero, A Nencioni, D Boy, I Rocco, A Garuti, GS Mela, LV Parijs, P Brossart, S Wesselborg, F Patrone
Clinical cancer research 2004
Sensitization for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by the Chemopreventive Agent Resveratrol
S Fulda, KM Debatin
Cancer research 2004
Bax Mediates the Apoptosis-Sensitizing Effect of Maspin
J Liu, S Yin, N Reddy, C Spencer, S Sheng
Cancer research 2004
TRAIL regulates normal erythroid maturation through an ERK-dependent pathway
P Secchiero, E Melloni, M Heikinheimo, S Mannisto, RD Pietro, A Iacone, G Zauli
Blood 2004
Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects.
He C, Lao WF, Hu XT, Xu XM, Xu J, Fang BL
World Journal of Gastroenterology 2004
Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL
M Chawla-Sarkar, JA Bauer, JA Lupica, BH Morrison, Z Tang, RK Oates, A Almasan, JA DiDonato, EC Borden, DJ Lindner
The Journal of biological chemistry 2003
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP
TJ Sayers, AD Brooks, CY Koh, W Ma, N Seki, A Raziuddin, BR Blazar, X Zhang, PJ Elliott, WJ Murphy
Blood 2003
Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice
QS Mi, D Ly, SE Lamhamedi-Cherradi, KV Salojin, L Zhou, M Grattan, C Meagher, P Zucker, YH Chen, J Nagle, D Taub, TL Delovitch
Diabetes 2003
Caspase- and Serine Protease-dependent Apoptosis by the Death Domain of FADD in Normal Epithelial Cells
J Thorburn, LM Bender, MJ Morgan, A Thorburn, M Raff
Molecular biology of the cell 2003
Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice
SE Lamhamedi-Cherradi, SJ Zheng, KA Maguschak, J Peschon, YH Chen
Nature Immunology 2003
Molecular pathology of tumor metastasis III: Target array and combinatorial therapies
J Tímár, A Ladányi, I Peták, A Jeney, L Kopper
Pathology & Oncology Research 2003
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival
B Zheng, P Fiumara, YV Li, G Georgakis, V Snell, M Younes, JN Vauthey, A Carbone, A Younes
Blood 2003
Apoptosis: targets in pancreatic cancer
S Westphal, H Kalthoff
Molecular Cancer 2003
Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells
E Ucur, J Mattern, T Wenger, S Okouoyo, A Schroth, KM Debatin, I Herr
British Journal of Cancer 2003
Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma
Q Chen, S Ray, MA Hussein, G Srkalovic, A Almasan
Leukemia & Lymphoma 2003
Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines
CM van Geelen, EG de Vries, TK Le, RP van Weeghel, S Jong
British Journal of Cancer 2003
Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy
S Bouralexis, DM Findlay, GJ Atkins, A Labrinidis, S Hay, A Evdokiou
British Journal of Cancer 2003
Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage
U Ramp, E Caliskan, C Mahotka, A Krieg, S Heikaus, HE Gabbert, CD Gerharz
British Journal of Cancer 2003
TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential
A Krieg, T Krieg, M Wenzel, M Schmitt, U Ramp, B Fang, HE Gabbert, CD Gerharz, C Mahotka
British Journal of Cancer 2003
Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2
IK Kim, YK Jung, DY Noh, YS Song, CH Choi, BH Oh, ES Masuda, YK Jung
British Journal of Cancer 2003
A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents
Y Arizono, H Yoshikawa, H Naganuma, Y Hamada, Y Nakajima, K Tasaka
British Journal of Cancer 2003
Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation
M Leverkus, MR Sprick, T Wachter, T Mengling, B Baumann, E Serfling, EB Bröcker, M Goebeler, M Neumann, H Walczak
Molecular and cellular biology 2003
Death receptors and their role in dermatology, with particular focus on tumor necrosis factor-related apoptosis-inducing ligand receptors
KJ Smith, H Diwan, H Skelton
International Journal of Dermatology 2003
Apoptosis and Plastic Surgery
BR Gastman, JW Futrell, EK Manders
Plastic and Reconstructive Surgery 2003
T-cell immune responses in the brain and their relevance for cerebral malignancies
PR Walker, T Calzascia, N Tribolet, PY Dietrich
Brain Research Reviews 2003
Cellular FLICE-inhibitory protein: an attractive therapeutic target?
O Micheau
Expert Opinion on Therapeutic Targets 2003
TRAIL Triggers Apoptosis in Human Malignant Glioma Cells Through Extrinsic and Intrinsic Pathways
JH Song, DK Song, B Pyrzynska, KC Petruk, EG Meir, C Hao
Brain Pathology 2003
Modulation of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Chemotherapy in Thyroid Cancer Cell Lines
JW Park, MG Wong, M Lobo, WC Hyun, QY Duh, OH Clark
Thyroid 2003
Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer
SH Lee, HS Kim, SY Kim, YS Lee, WS Park, SH Kim, JY Lee, NJ Yoo
APMIS 2003
Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design
M Los, CJ Burek, C Stroh, K Benedyk, H Hug, A Mackiewicz
Drug Discovery Today 2003
Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells
D Griffin, S Wittmann, F Guo, R Nimmanapalli, P Bali, HG Wang, K Bhalla
Gynecologic Oncology 2003
Nature's TRAIL—On a Path to Cancer Immunotherapy
MJ Smyth, K Takeda, Y Hayakawa, JJ Peschon, MR van Brink, H Yagita
Immunity 2003
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme
V Jendrossek, C Belka, M Bamberg
Expert Opinion on Investigational Drugs 2003
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand
DT Jones, K Ganeshaguru, WA Mitchell, L Foroni, RJ Baker, HG Prentice, AB Mehta, RG Wickremasinghe
British Journal of Haematology 2003
Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential
T Hotta, H Suzuki, S Nagai, K Yamamoto, A Imakiire, E Takada, M Itoh, J Mizuguchi
Journal of Orthopaedic Research 2003
Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas
NJ Yoo, HS Kim, SY Kim, WS Park, CH Park, HM Jeon, ES Jung, JY Lee, SH Lee
APMIS 2003
Etoposide upregulates Bax-enhancing tumour necrosis factor-related apoptosis inducing ligand-mediated apoptosis in the human hepatocellular carcinoma cell line QGY-7703
L Miao, P Yi, Y Wang, M Wu
European Journal of Biochemistry 2003
Upregulation of FLIPS by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers
SY Nam, GA Jung, GC Hur, HY Chung, WH Kim, DW Seol, BL Lee
Cancer Science 2003
Targeting the tumor necrosis factor-related apoptosis-inducing ligand path in neuroblastoma
X Yang, CJ Thiele
Cancer Letters 2003
Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas
JJ Koornstra, JH Kleibeuker, CM van Geelen, FE Rijcken, H Hollema, EG de Vries, S Jong
The Journal of Pathology 2003
Bcl-2 and apoptosis in chronic lymphocytic leukemia
AD Schimmer, I Munk-Pedersen, MD Minden, JC Reed
Current Treatment Options in Oncology 2003
Molecular targets in therapy for human soft-tissue and bone sarcomas
DM Steinert, LJ Blakely, J Salganick, JC Trent
Current Oncology Reports 2003
Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines
RR Siervo-Sassi, AM Marrangoni, X Feng, N Naoumova, M Winans, RP Edwards, A Lokshin
Cancer Letters 2003
Macrophages From Cancer Patients: Analysis of TRAIL, TRAIL Receptors, and Colon Tumor Cell Apoptosis
JP Herbeuval, C Lambert, O Sabido, M Cottier, P Fournel, M Dy, C Genin
JNCI Journal of the National Cancer Institute 2003
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
A Almasan, A Ashkenazi
Cytokine & Growth Factor Reviews 2003
Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature
JJ Koornstra, S Jong, H Hollema, EG Vries, JH Kleibeuker
Critical Reviews in Oncology/Hematology 2003
Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes
S Ehrlich, C Infante-Duarte, B Seeger, F Zipp
Cytokine 2003
Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential
M Itoh, T Noutomi, H Toyota, J Mizuguchi
Oral Oncology 2003
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines
A Mouzakiti, G Packham
British Journal of Haematology 2003
Handbook of Cell Signaling
MF White
Handbook of Cell Signaling 2003
Apoptosis and Plastic Surgery:
BR Gastman, JW Futrell, EK Manders
Plastic and Reconstructive Surgery 2003
Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines
S Tomek, W Koestler, P Horak, T Grunt, T Brodowicz, I Pribill, J Halaschek, G Haller, C Wiltschke, CC Zielinski, M Krainer
European Journal of Cancer 2003
Molecular requirements for the combined effects of TRAIL and ionising radiation
P Marini, V Jendrossek, E Durand, C Gruber, W Budach, C Belka
Radiotherapy and Oncology 2003
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Enhances Collagen Production by Human Lung Fibroblasts
VV Yurovsky
American journal of respiratory cell and molecular biology 2003
Utilisation de la molécule pro-apoptotique « TRAIL » dans de nouvelles stratégies thérapeutiques anticancéreuses. Exemple du cancer de la prostate
V Hesry, JJ Patard, T Guillaudeux
Pathologie Biologie 2003
Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders: A short review
A Younes, BB Aggarwall
Cancer 2003
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
SH Kaufmann, DL Vaux
Oncogene 2003
Apoptosis-targeted therapies for cancer
John C Reed
Cancer Cell 2003
Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29
Xiang-Ming Xu, Chao He, Xiao-Tong Hu, Bing-Liang Fang
World journal of gastroenterology : WJG 2003
Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480
Li-Hong Xu, Chang-Sheng Deng, You-Qing Zhu, Shi-Quan Liu, Dong-Zhou Liu
World journal of gastroenterology : WJG 2003
Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells: TRAIL/Apo2L + Chemotherapy in Bone Tumour
FV Valen, S Fulda, KL Schäfer, B Truckenbrod, M Hotfilder, C Poremba, KM Debatin, W Winkelmann
International Journal of Cancer 2003
Actinomycin D renders cultured synovial fibroblasts susceptible to tumour necrosis factor related apoptosis‐inducing ligand (TRAIL)‐induced apoptosis
YW Park, JD Ji, JS Lee, DW Ryang, DH Yoo
Scandinavian Journal of Rheumatology 2003
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
A Younes, ME Kadin
Journal of Clinical Oncology 2003
Chemotherapy-induced Apoptosis of S-type Neuroblastoma Cells Requires Caspase-9 and Is Augmented by CD95/Fas Stimulation
X Bian, TD Giordano, HJ Lin, G Solomon, VP Castle, AW Opipari
The Journal of biological chemistry 2003
c-Jun N-terminal Kinase Contributes to Apoptotic Synergy Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand plus DNA Damage in Chemoresistant, p53 Inactive Mesothelioma Cells
C Vivo, W Liu, VC Broaddus
The Journal of biological chemistry 2003
Protein Kinase C Modulates Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Targeting the Apical Events of Death Receptor Signaling
N Harper, MA Hughes, SN Farrow, GM Cohen, M MacFarlane
The Journal of biological chemistry 2003
NF-κB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells
M Hermisson, M Weller
Cell Death and Differentiation 2003
Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect
JY Seol, KH Park, CI Hwang, WY Park, CG Yoo, YW Kim, SK Han, YS Shim, CT Lee
Cancer Gene Therapy 2003
Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines
CM van Geelen, EG de Vries, TK Le, RP van Weeghel, S Jong
British Journal of Cancer 2003
Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2
IK Kim, YK Jung, DY Noh, YS Song, CH Choi, BH Oh, ES Masuda, YK Jung
British Journal of Cancer 2003
A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents
Y Arizono, H Yoshikawa, H Naganuma, Y Hamada, Y Nakajima, K Tasaka
British Journal of Cancer 2003
TRAIL-β and TRAIL-γ: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential
A Krieg, T Krieg, M Wenzel, M Schmitt, U Ramp, B Fang, HE Gabbert, CD Gerharz, C Mahotka
British Journal of Cancer 2003
A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells
I Petak, R Vernes, KS Szucs, M Anozie, K Izeradjene, L Douglas, DM Tillman, DC Phillips, JA Houghton
Cell Death and Differentiation 2003
International Hermelin Brain Tumor Center Symposium on Apoptosis
O Bögler, M Weller
Cell Death and Differentiation 2003
Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2
E Mori, M Thomas, K Motoki, K Nakazawa, T Tahara, K Tomizuka, I Ishida, S Kataoka
Cell Death and Differentiation 2003
Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line
DC Spierings, EG de Vries, E Vellenga, S Jong
Cell Death and Differentiation 2003
Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia
JB Johnston, AF Kabore, J Strutinsky, X Hu, JT Paul, DM Kropp, B Kuschak, A Begleiter, SB Gibson
Oncogene 2003
PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2
S Frese, F Pirnia, D Miescher, S Krajewski, MM Borner, JC Reed, RA Schmid
Oncogene 2003
Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis
Q He, JA Montalbano, C Corcoran, W Jin, Y Huang, MS Sheikh
Oncogene 2003
TRAIL and apoptosis induction by TNF-family death receptors
S Wang, WS El-Deiry
Oncogene 2003
Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells
S Lacour, O Micheau, A Hammann, V Drouineaud, J Tschopp, E Solary, MT Dimanche-Boitrel
Oncogene 2003
Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway
T Ohtsuka, D Buchsbaum, P Oliver, S Makhija, R Kimberly, T Zhou
Oncogene 2003
Interferon-α sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-κB inactivation
M Shigeno, K Nakao, T Ichikawa, K Suzuki, A Kawakami, S Abiru, S Miyazoe, Y Nakagawa, H Ishikawa, K Hamasaki, K Nakata, N Ishii, K Eguchi
Oncogene 2003
The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27Kip1 and control of cyclin D1 expression
A Cappellini, G Tabellini, M Zweyer, R Bortul, PL Tazzari, AM Billi, F Falà, L Cocco, AM Martelli
Leukemia 2003
Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIPL up-regulation
R Bortul, PL Tazzari, A Cappellini, G Tabellini, AM Billi, R Bareggi, L Manzoli, L Cocco, AM Martelli
Leukemia 2003
Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria
XD Zhang, JM Borrow, XY Zhang, T Nguyen, P Hersey
Oncogene 2003
Death receptors and melanoma resistance to apoptosis
VN Ivanov, A Bhoumik, Z Ronai
Oncogene 2003
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-α promote the NF-κB-dependent maturation of normal and leukemic myeloid cells
P Secchiero, D Milani, A Gonelli, E Melloni, D Campioni, D Gibellini, S Capitani, G Zauli
Journal of leukocyte biology 2003
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools
R Greil, G Anether, K Johrer, I Tinhofer
Journal of leukocyte biology 2003
Protein-based therapeutic approaches targeting death receptors
LE French, J Tschopp
Cell Death and Differentiation 2003
Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells
XX Wu, Y Kakehi, Y Mizutani, H Nishiyama, T Kamoto, Y Megumi, N Ito, O Ogawa
International Journal of Cancer 2003
Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells
Q He, Y Huang, MS Sheikh
Oncogene 2003
Apo2L/TRAIL and its death and decoy receptors
HN LeBlanc, A Ashkenazi
Cell Death and Differentiation 2003
Gene Therapy of Pancreatic Cancer With Green Fluorescent Protein and Tumor Necrosis Factor?Related Apoptosis-Inducing Ligand Fusion Gene Expression Driven by a Human Telomerase Reverse Transcriptase Promoter
MH Katz, DE Spivack, S Takimoto, B Fang, DW Burton, AR Moossa, RM Hoffman, M Bouvet
Annals of Surgical Oncology 2003
Allogeneic Stem Cell Transplantation
MJ Laughlin, HM Lazarus
2003
Grundlagen der Molekularen Medizin
D Ganten, K Ruckpaul
2003
Modification of Radiation Response
C Nieder, L Milas, KK Ang
2003
Molecular Mechanisms of Programmed Cell Death
Y Shi, JA Cidlowski, D Scott, JR Wu, YB Shi
2003
Pediatric Acute Lymphoblastic Leukemia
WL Carroll, D Bhojwani, DJ Min, E Raetz, M Relling, S Davies, JR Downing, CL Willman, JC Reed
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2003
Death receptors on reactive astrocytes: A key role in the fine tuning of brain inflammation?
PY Dietrich, PR Walker, P Saas
Neurology 2003
Monocytes Treated with Human Immunodeficiency Virus Tat Kill Uninfected CD4 + Cells by a Tumor Necrosis Factor-Related Apoptosis-Induced Ligand-Mediated Mechanism
Y Yang, I Tikhonov, TJ Ruckwardt, M Djavani, JC Zapata, CD Pauza, MS Salvato
Journal of virology 2003
Arsenic trioxide–induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL
Q Liu, S Hilsenbeck, Y Gazitt
Blood 2003
TRAIL Induces Apoptosis and Inflammatory Gene Expression in Human Endothelial Cells
JH Li, NC Kirkiles-Smith, JM McNiff, JS Pober
Journal of immunology (Baltimore, Md. : 1950) 2003
TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus
B Washburn, MA Weigand, A Grosse-Wilde, M Janke, H Stahl, E Rieser, MR Sprick, V Schirrmacher, H Walczak
Journal of immunology (Baltimore, Md. : 1950) 2003
Design, Construction, and In Vitro Analyses of Multivalent Antibodies
K Miller, G Meng, J Liu, A Hurst, V Hsei, WL Wong, R Ekert, D Lawrence, S Sherwood, L DeForge, J Gaudreault, G Keller, M Sliwkowski, A Ashkenazi, L Presta
Journal of immunology (Baltimore, Md. : 1950) 2003
Erythroid Differentiation Sensitizes K562 Leukemia Cells to TRAIL-Induced Apoptosis by Downregulation of c-FLIP
V Hietakangas, M Poukkula, KM Heiskanen, JT Karvinen, L Sistonen, JE Eriksson
Molecular and cellular biology 2003
Plasmacytoid Dendritic Cell-Derived IFN-α Induces TNF-Related Apoptosis-Inducing Ligand/Apo-2L-Mediated Antitumor Activity by Human Monocytes Following CpG Oligodeoxynucleotide Stimulation
TJ Kemp, BD Elzey, TS Griffith
Journal of immunology (Baltimore, Md. : 1950) 2003
Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma
Ulrike Naumann, Robert Waltereit, Jörg B Schulz, Michael Weller
Journal of Neuro-Oncology 2003
Genes and Genomics of Autoimmune Inflammation: From Rel to TRAIL
YH Chen
Immunologic Research 2003
Molecular targets in therapy for human soft-tissue and bone sarcomas.
Steinert DM, Blakely LJ, Salganick J, Trent JC
Current Oncology Reports 2003
TRAIL, Bim, and thymic-negative selection.
Zheng SJ, Chen YH
Immunologic research 2003
Bcl-2 and apoptosis in chronic lymphocytic leukemia.
Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC
Current Treatment Options in Oncology 2003
Upregulation of FLIPS by Akt, a possible inhibition mechanism of TRAIL‐induced apoptosis in human gastric cancers
Nam SY, Jung G, Hur G, Chung H, Kim WH, Seol D, Lee BL
Cancer Science 2003
Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P
Oncogene 2003
TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors
M Plasilova, J Zivny, J Jelinek, R Neuwirtova, J Cermak, E Necas, L Andera, T Stopka
Leukemia 2002
Wiley Encyclopedia of Molecular Medicine
WT Morgan
Wiley Encyclopedia of Molecular Medicine 2002
Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients
E Stylianou, A Yndestad, LI Sikkeland, V Bjerkeli, JK Damås, T Haug, HG Eiken, P Aukrust, SS Frøland
Clinical & Experimental Immunology 2002
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO
Y Deng, Y Lin, X Wu
Genes & development 2002
Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells
V Poulaki, CS Mitsiades, V Kotoula, S Tseleni-Balafouta, A Ashkenazi, DA Koutras, N Mitsiades
The American Journal of Pathology 2002
Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector
J Lee, M Hampl, P Albert, HA Fine
Neoplasia (New York, N.Y.) 2002
Encyclopedia of Cancer
G Sgouros
Encyclopedia of Cancer 2002
Life and Death Signaling Pathways Contributing to Skin Cancer
BJ Nickoloff, JZ Qin, V Chaturvedi, P Bacon, J Panella, MF Denning
Journal of Investigative Dermatology Symposium Proceedings 2002
Electroporation-Mediated Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)/Apo2L Gene Therapy for Hepatocellular Carcinoma
YI Yamashita, M Shimada, S Tanaka, M Okamamoto, JI Miyazaki, K Sugimachi
Human Gene Therapy 2002
T cells require TRAIL for optimal graft-versus-tumor activity
C Schmaltz, O Alpdogan, BJ Kappel, SJ Muriglan, JA Rotolo, J Ongchin, LM Willis, AS Greenberg, JM Eng, JM Crawford, GF Murphy, H Yagita, H Walczak, JJ Peschon, MR van Brink
Nature Medicine 2002
Death Receptor Ligands in Tumors
P Cappello, F Novelli, G Forni, M Giovarelli
Journal of Immunotherapy 2002
The biological role of the Fas/FasL system during tumor formation and progression
E Reichmann
Seminars in Cancer Biology 2002
Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL)
N Kayagaki, N Yamaguchi, M Abe, S Hirose, T Shirai, K Okumura, H Yagita
Cellular Immunology 2002
TRAIL-mediated apoptosis requires NF-kB inhibition and the mitochondrial permeability transition in human hepatoma cells
YS Kim, RF Schwabe, T Qian, JJ Lemasters, DA Brenner
Hepatology 2002
The RB and p53 pathways in cancer
CJ Sherr, F McCormick
Cancer Cell 2002
Focus on sarcomas
CL Mackall, PS Meltzer, LJ Helman
Cancer Cell 2002
Potential methods to circumvent blocks in apoptosis in lymphomas
R Ravi, A Bedi
Current Opinion in Oncology 2002
Induction of TRAIL-mediated glioma cell death by human T cells
J Dörr, S Waiczies, U Wendling, B Seeger, F Zipp
Journal of Neuroimmunology 2002
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail-induced apoptosis
A Evdokiou, S Bouralexis, GJ Atkins, F Chai, S Hay, M Clayer, DM Findlay
International Journal of Cancer 2002
Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study
SH Lee, HS Kim, WS Park, SY Kim, KY Lee, SH Kim, JY Lee, NJ Yoo
APMIS 2002
Combination therapy with imatinib mesylate (sti571): synopsis of in vitro studies
J Topaly, WJ Zeller, S Fruehauf
British Journal of Haematology 2002
Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers
JC Reed, S Kitada, Y Kim, J Byrd
Seminars in Oncology 2002
The involvement of oxidative stress in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in HeLa cells
MW Lee, SC Park, JH Kim, IK Kim, KS Han, KY Kim, WB Lee, YK Jung*, SS Kim
Cancer Letters 2002
Enhancement of Apo2L/TRAIL (tumor necrosis factor–related apoptosis-inducing ligand)–induced apoptosis in non–small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein
S Frese, T Brunner, M Gugger, A Uduehi, RA Schmid
The Journal of Thoracic and Cardiovascular Surgery 2002
On the TRAIL to apoptosis
TM Baetu, J Hiscott
Cytokine & Growth Factor Reviews 2002
Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis
GJ Atkins, S Bouralexis, A Evdokiou, S Hay, A Labrinidis, AC Zannettino, DR Haynes, DM Findlay
Bone 2002
Regulators of apoptosis as anticancer targets
AW Tolcher
Hematology/Oncology Clinics of North America 2002
Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma
TJ Zuzak, DF Steinhoff, LN Sutton, PC Phillips, A Eggert, MA Grotzer
European Journal of Cancer 2002
Evidence that the human death receptor 4 is regulated by activator protein 1
B Guan, P Yue, R Lotan, SY Sun
Oncogene 2002
Anticancer Drug Development
E Solary, N Droin, O Sordet, C Rebe, R Filomenko, A Wotawa, S Plenchette, P Ducoroy
Anticancer Drug Development 2002
The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis
L Bin, X Li, LG Xu, HB Shu
FEBS Letters 2002
Tumor necrosis factor-related, apoptosis-inducing ligand supports growth of mouse mastocytoma tumors by killing tumor-infiltrating macrophages
A Strebel, F Bachmann, M Wernli, P Erb
International Journal of Cancer 2002
The involvement of reactive oxygen species (ROS) and p38 mitogen-activated protein (MAP) kinase in TRAIL/Apo2L-induced apoptosis
MW Lee, SC Park, YG Yang, SO Yim, HS Chae, JH Bach, HJ Lee, KY Kim, WB Lee, SS Kim
FEBS Letters 2002
Gene Therapy of Cancer
IV Lebedeva, CA Stein
Gene Therapy of Cancer 2002
The Role of Apoptosis-Related Genes in non—small-Cell Lung Cancer
E Fokkema, HJ Groen, C Meijer, W Timens, S Jong, EG de Vries
Clinical Lung Cancer 2002
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi
Nature Reviews Cancer 2002
Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia
M MacFarlane, N Harper, RT Snowden, MJ Dyer, GA Barnett, JH Pringle, GM Cohen
Oncogene 2002
Antitumor Activity and Prolonged Expression from a TRAIL-Expressing Adenoviral Vector
J Lee, M Hampl, P Albert, HA Fine
Neoplasia (New York, N.Y.) 2002
Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations
Jian-Zhong Qin, Patricia E Bacon, Vijaya Chaturvedi, Brian Bonish, Brian J Nickoloff
Experimental Dermatology 2002
Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development
K Takeda, MJ Smyth, E Cretney, Y Hayakawa, N Kayagaki, H Yagita, K Okumura
Journal of Experimental Medicine 2002
Induction of apoptosis in cancer: new therapeutic opportunities
HF Ding, DE Fisher
Annals of Medicine 2002
Detection of soluble TRAIL in HBV infected patients and its clinical implications
LH Han
World journal of gastroenterology : WJG 2002
Regulation of TRAIL Expression by the Phosphatidylinositol 3-Kinase/Akt/GSK-3 Pathway in Human Colon Cancer Cells
Q Wang, X Wang, A Hernandez, MR Hellmich, Z Gatalica, BM Evers
The Journal of biological chemistry 2002
Identification of a New Murine Tumor Necrosis Factor Receptor Locus That Contains Two Novel Murine Receptors for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)
P Schneider, D Olson, A Tardivel, B Browning, A Lugovskoy, DH Gong, M Dobles, S Hertig, K Hofmann, HV Vlijmen, YM Hsu, LC Burkly, J Tschopp, TS Zheng
The Journal of biological chemistry 2002
An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis
Y Kim, N Suh, M Sporn, JC Reed
The Journal of biological chemistry 2002
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL
C Voelkel-Johnson, DL King, JS Norris
Cancer Gene Therapy 2002
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors
H Xiang, JA Fox, K Totpal, M Aikawa, K Dupree, D Sinicropi, J Lowe, E Escandón
Oncogene 2002
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
CS Mitsiades, N Mitsiades, V Poulaki, R Schlossman, M Akiyama, D Chauhan, T Hideshima, SP Treon, NC Munshi, PG Richardson, KC Anderson
Oncogene 2002
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells
A Nesterov, Y Ivashchenko, AS Kraft
Oncogene 2002
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
S Fulda, W Wick, M Weller, KM Debatin
Nature Medicine 2002
Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells
Q He, X Luo, Y Huang, MS Sheikh
Oncogene 2002
TRAIL-mediated apoptosis requires NF-κB inhibition and the mitochondrial permeability transition in human hepatoma cells
Y Kim
Hepatology 2002
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: Role of XIAP in resistance
CP Ng, A Zisman, B Bonavida
The Prostate 2002
Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
H LeBlanc, D Lawrence, E Varfolomeev, K Totpal, J Morlan, P Schow, S Fong, R Schwall, D Sinicropi, A Ashkenazi
Nature Medicine 2002
Apoptosis and cancer: When BAX is TRAILing away
W Roth, JC Reed
Nature Medicine 2002
Selective Inhibition of FLICE-like Inhibitory Protein (FLIP) Expression With Small Interfering RNA Oligonucleotides (siRNAs) Is Sufficient to Sensitize Tumor Cells for TRAIL-Induced Apoptosis
D Siegmund, P Hadwiger, K Pfizenmaier, HP Vornlocher, H Wajant
Molecular Medicine 2002
Neuroinflammation — From Bench to Bedside
H Kettenmann, GA Burton, UJ Moenning
2002
Cholestasis Increases Tumor Necrosis Factor-Related Apoptotis-Inducing Ligand (TRAIL)-R2/DR5 Expression and Sensitizes the Liver to TRAIL-Mediated Cytotoxicity
H Higuchi, SF Bronk, M Taniai, A Canbay, GJ Gores
The Journal of pharmacology and experimental therapeutics 2002
Molekulare Medizin in der Frauenheilkunde
MW Beckmann, PA Fasching, P Dall, JS Krüssel, D Niederacher, B Tutschek
2002
Molecular and Cellular Biology of Neuroprotection in the CNS
C Alzheimer
2002
Dysregulation of apoptosis genes in hematopoietic malignancies
S Kitada, IM Pedersen, AD Schimmer, JC Reed
Oncogene 2002
Tumor-Infiltrating CD4 + T Lymphocytes Express APO2 Ligand (APO2L)/TRAIL upon Specific Stimulation with Autologous Lung Carcinoma Cells: Role of IFN-α on APO2L/TRAIL Expression and -Mediated Cytotoxicity
G Dorothée, I Vergnon, J Menez, H Echchakir, D Grunenwald, M Kubin, S Chouaib, F Mami-Chouaib
Journal of immunology (Baltimore, Md. : 1950) 2002
Intracellular regulation of tumor necrosis factor–related apoptosis-inducing ligand–induced apoptosis in human multiple myeloma cells
N Mitsiades, CS Mitsiades, V Poulaki, KC Anderson, SP Treon
Blood 2002
Death Ligand TRAIL Induces No Apoptosis but Inhibits Activation of Human (Auto)antigen-Specific T Cells
JD Lünemann, S Waiczies, S Ehrlich, U Wendling, B Seeger, T Kamradt, F Zipp
Journal of immunology (Baltimore, Md. : 1950) 2002
Tumor necrosis factor–related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway
P Secchiero, A Gonelli, P Mirandola, E Melloni, L Zamai, C Celeghini, D Milani, G Zauli
Blood 2002
Involvement of TRAIL and its receptors in viral hepatitis
B Mundt, F Kühnel, L Zender, Y Paul, H Tillmann, C Trautwein, MP Manns, S Kubicka
The FASEB Journal 2002
Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice
E Cretney, K Takeda, H Yagita, M Glaccum, JJ Peschon, MJ Smyth
Journal of immunology (Baltimore, Md. : 1950) 2002
Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative–(BMS 247550) and Apo-2L/TRAIL–induced apoptosis
F Guo, R Nimmanapalli, S Paranawithana, S Wittman, D Griffin, P Bali, E O'Bryan, C Fumero, HG Wang, K Bhalla
Blood 2002
TRAIL/Apo-2 Ligand Induces Primary Plasma Cell Apoptosis
J Ursini-Siegel, W Zhang, A Altmeyer, EN Hatada, RK Do, H Yagita, S Chen-Kiang
Journal of immunology (Baltimore, Md. : 1950) 2002
IFN-β Pretreatment Sensitizes Human Melanoma Cells to TRAIL/Apo2 Ligand-Induced Apoptosis
M Chawla-Sarkar, DW Leaman, BS Jacobs, EC Borden
Journal of immunology (Baltimore, Md. : 1950) 2002
Immunobiology of Tumor Necrosis Factor Receptor Superfamily
T Zhou, JD Mountz, RP Kimberly
Immunologic Research 2002
Detection of soluble TRAIL in HBV infected patients and its clinical implications.
Han LH, Sun WS, Ma CH, Zhang LN, Liu SX, Zhang Q, Gao LF, Chen YH
World Journal of Gastroenterology 2002
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4
A Chuntharapai, K Dodge, K Grimmer, K Schroeder, SA Marsters, H Koeppen, A Ashkenazi, KJ Kim
Journal of immunology (Baltimore, Md. : 1950) 2001
Is Myelodysplastic Related Acute Myelogenous Leukemia a Distinct Entity from de novo Acute Myelogenous Leukemia? Potential for Targeted Therapies
C Rosenfeld, H Kantarjian
Leukemia & Lymphoma 2001
CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies
P Fiumara, A Younes
British Journal of Haematology 2001
Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes
AK Simon, O Williams, J Mongkolsapaya, B Jin, XN Xu, H Walczak, GR Screaton
Proceedings of the National Academy of Sciences 2001
TRAIL/Apo-2L: mechanisms and clinical applications in cancer
RK Srivastava
Neoplasia (New York, N.Y.) 2001
Targeting the Function of Mature Dendritic Cells by Human Cytomegalovirus
MJ Raftery, M Schwab, SM Eibert, Y Samstag, H Walczak, G Schönrich
Immunity 2001
Shared pathways: Death receptors and cytotoxic drugs in cancer therapy
I Petak, JA Houghton
Pathology & Oncology Research 2001
Mutations in apoptosis genes: a pathogenetic factor for human disease
L Müllauer, P Gruber, D Sebinger, J Buch, S Wohlfart, A Chott
Mutation Research/Reviews in Mutation Research 2001
Apoptosis and the response to anticancer therapy
BM Mow, AL Blajeski, J Chandra, SH Kaufmann
Current Opinion in Oncology 2001
Apoptosis and its clinical impact
BR Gastman
Head & Neck 2001
A Protective Role of PKCϵ against TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in Glioma Cells
H Shinohara, N Kayagaki, H Yagita, N Oyaizu, M Ohba, T Kuroki, Y Ikawa
Biochemical and Biophysical Research Communications 2001
IFN-?induces cell death in human hepatoma cells through a trail/death receptor-mediated apoptotic pathway
EC Shin, JM Ahn, CH Kim, Y Choi, YS Ahn, H Kim, SJ Kim, JH Park
International Journal of Cancer 2001
Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias
N Mitsiades, CS Mitsiades, V Poulaki, KC Anderson, SP Treon
Expert Opinion on Investigational Drugs 2001
Apoptosis: implications of basic research for clinical oncology
I Tamm, F Schriever, B Dörken
The Lancet Oncology 2001
Pancreatic Adenocarcinoma Cell Lines Show Variable Susceptibility to TRAIL-Mediated Cell Death
SM Ibrahim, J Ringel, C Schmidt, B Ringel, P Müller, D Koczan, HJ Thiesen, M Löhr
Pancreas 2001
Actinomycin D and Gemcitabine Synergistically Sensitize Androgen-Independent Prostate Cancer Cells to Apo2L/TRAIL-Mediated Apoptosis
A Zisman, CP Ng, AJ Pantuck, B Bonavida, AS Belldegrun
Journal of Immunotherapy 2001
Role of innate immunity in cancer
SJ Golby, J Spencer
Current Opinion in Gastroenterology 2001
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand and Its Receptor Expression and the Pathway of Apoptosis in Human Pancreatic Cancer
K Satoh, K Kaneko, M Hirota, A Masamune, A Satoh, T Shimosegawa
Pancreas 2001
Potential and caveats of TRAIL in cancer therapy
J Held, K Schulze-Osthoff
Drug Resistance Updates 2001
Apoptosis in oncology
XQ FAN, YJ GUO
Cell Research 2001
Molecular mechanisms of TRAIL-induced apoptosis of cancer cells
L Li, H Shu
Chinese Science Bulletin 2001
Recombinant soluble TRAIL induces apoptosis of cancer cells
L Lianyun, H Jiancheng, B Lianghua, L Lixia, Z Jikun, X Liangguo, Z Zhen, Z Zhonghe, S Hongbing
Chinese Science Bulletin 2001
Involvement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in NK Cell-Mediated and IFN-γ-Dependent Suppression of Subcutaneous Tumor Growth
K Takeda, MJ Smyth, E Cretney, Y Hayakawa, N Yamaguchi, H Yagita, K Okumura
Cellular Immunology 2001
Fas ligand and TRAIL augment the effect of photodynamic therapy on the induction of apoptosis in JURKAT cells
DJ Granville, H Jiang, BM McManus, DW Hunt
International Immunopharmacology 2001
Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene
T Yoshida, A Maeda, N Tani, T Sakai
FEBS Letters 2001
Hypericin photo-induced apoptosis involves the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and activation of caspase-8
CM Schempp, B Simon-Haarhaus, CC Termeer, JC Simon
FEBS Letters 2001
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand and Chemotherapy Cooperate to Induce Apoptosis in Mesothelioma Cell Lines
W Liu, E Bodle, JY Chen, M Gao, GD Rosen, VC Broaddus
American journal of respiratory cell and molecular biology 2001
The biology of apoptosis
FJ Geske, LE Gerschenson
Human Pathology 2001
TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer
RK Srivastava
Neoplasia (New York, N.Y.) 2001
Regression of Human Mammary Adenocarcinoma by Systemic Administration of a Recombinant Gene Encoding the hFlex-TRAIL Fusion Protein
X Wu, Y He, LD Falo, KM Hui, L Huang
Molecular Therapy 2001
Suppression of Tumor Growth Following Intralesional Therapy with TRAIL Recombinant Adenovirus
TS Griffith, EL Broghammer
Molecular Therapy 2001
Enhanced Apoptosis of Soft Tissue Sarcoma Cells with Chemotherapy: A Potential New Approach Using Trail
M Clayer, S Bouralexis, A Evdokiou, S Hay, GJ Atkins, DM Findlay
Journal of Orthopaedic Surgery 2001
Interferon-γ Sensitizes Human Myeloid Leukemia Cells to Death Receptor-mediated Apoptosis by a Pleiotropic Mechanism
N Varela, C Muñoz-Pinedo, C Ruiz-Ruiz, G Robledo, M Pedroso, A López-Rivas
The Journal of biological chemistry 2001
Molecular Cross-talk between the TRAIL and Interferon Signaling Pathways
C Kumar-Sinha, S Varambally, A Sreekumar, AM Chinnaiyan
The Journal of biological chemistry 2001
Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis
A Nesterov, X Lu, M Johnson, GJ Miller, Y Ivashchenko, AS Kraft
The Journal of biological chemistry 2001
Ultraviolet Light (UV) Regulation of the TNF Family Decoy Receptors DcR2 and DcR3 in Human Keratinocytes
T Maeda, C Hao, VA Tron
Journal of Cutaneous Medicine & Surgery 2001
Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene
B Guan, P Yue, GL Clayman, SY Sun
Journal of Cellular Physiology 2001
Cytotoxicity of Tumor Necrosis Factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines
A Kumar, A Jasmin, MT Eby, PM Chaudhary
Oncogene 2001
Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
X Chen, H Thakkar, F Tyan, S Gim, H Robinson, C Lee, SK Pandey, C Nwokorie, N Onwudiwe, RK Srivastava
Oncogene 2001
Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells
M Oya, M Ohtsubo, A Takayanagi, M Tachibana, N Shimizu, M Murai
Oncogene 2001
Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells
YJ Lee, KH Lee, HR Kim, JM Jessup, DW Seol, TH Kim, TR Billiar, YK Song
Oncogene 2001
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release
TA Röhn, B Wagenknecht, W Roth, U Naumann, E Gulbins, PH Krammer, H Walczak, M Weller
Oncogene 2001
The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels
CR de Almodóvar, C Ruiz-Ruiz, C Muñoz-Pinedo, G Robledo, A López-Rivas
Oncogene 2001
Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection
P Clarke, SM Meintzer, AC Spalding, GL Johnson, KL Tyler
Oncogene 2001
Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL
C Belka, B Schmid, P Marini, E Durand, J Rudner, H Faltin, M Bamberg, K Schulze-Osthoff, W Budach
Oncogene 2001
Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative
H Wajant, D Moosmayer, T Wüest, T Bartke, E Gerlach, U Schönherr, N Peters, P Scheurich, K Pfizenmaier
Oncogene 2001
Induction of Cell Death in Human Immunodeficiency Virus-Infected Macrophages and Resting Memory CD4 T Cells by TRAIL/Apo2L
JJ Lum, AA Pilon, J Sanchez-Dardon, BN Phenix, JE Kim, J Mihowich, K Jamison, N Hawley-Foss, DH Lynch, AD Badley
Journal of virology 2001
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
D Lawrence, Z Shahrokh, S Marsters, K Achilles, D Shih, B Mounho, K Hillan, K Totpal, L DeForge, P Schow, J Hooley, S Sherwood, R Pai, S Leung, L Khan, B Gliniak, J Bussiere, CA Smith, SS Strom, S Kelley, JA Fox, D Thomas, A Ashkenazi
Nature Medicine 2001
Avoiding premature apoptosis of normal epidermal cells
J Qin, V Chaturvedi, B Bonish, BJ Nickoloff
Nature Medicine 2001
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
K Takeda, Y Hayakawa, MJ Smyth, N Kayagaki, N Yamaguchi, S Kakuta, Y Iwakura, H Yagita, K Okumura
Nature Medicine 2001
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
K Ichikawa, W Liu, L Zhao, Z Wang, D Liu, T Ohtsuka, H Zhang, JD Mountz, WJ Koopman, RP Kimberly, T Zhou
Nature Medicine 2001
Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB
R Ravi, GC Bedi, LW Engstrom, Q Zeng, B Mookerjee, C Gélinas, EJ Fuchs, A Bedi
Nature Cell Biology 2001
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL
L Altucci, A Rossin, W Raffelsberger, A Reitmair, C Chomienne, H Gronemeyer
Nature Medicine 2001
The kiss of death: promises and failures of death receptors and ligands in cancer therapy
PT Daniel, T Wieder, I Sturm, K Schulze-Osthoff
Leukemia 2001
Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D
A Olsson, T Diaz, M Aguilar-Santelises, A Österborg, F Celsing, M Jondal, LM Osorio
Leukemia 2001
In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity
C Wuchter, D Krappmann, Z Cai, V Ruppert, C Scheidereit, B Dörken, WD Ludwig, L Karawajew
Leukemia 2001
TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy
LF Lincz, TX Yeh, A Spencer
Leukemia 2001
Activation of protein kinase C inhibits TRAIL-induced caspases activation, mitochondrial events and apoptosis in a human leukemic T cell line
M Sarker, C Ruiz-Ruiz, A López-Rivas
Cell Death and Differentiation 2001
Brain Tumor Immunotherapy
LM Liau, DP Becker, TF Cloughesy, DD Bigner
2001
Roles of TNF-Related Apoptosis-Inducing Ligand in Experimental Autoimmune Encephalomyelitis
B Hilliard, A Wilmen, C Seidel, TS Liu, R Göke, Y Chen
Journal of immunology (Baltimore, Md. : 1950) 2001
Identification of Inhibitors of TRAIL-induced Death (ITIDs) in the TRAIL-sensitive Colon Carcinoma Cell Line SW480 Using a Genetic Approach
TF Burns, WS El-Deiry
The Journal of biological chemistry 2001
Apo2L/TRAIL and Bcl-2–related proteins regulate type I interferon–induced apoptosis in multiple myeloma
Q Chen, B Gong, AS Mahmoud-Ahmed, A Zhou, ED Hsi, M Hussein, A Almasan
Blood 2001
Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor–related apoptosis-inducing ligand–mediated cytotoxicity on hematologic malignancies
P Secchiero, A Gonelli, C Celeghini, P Mirandola, L Guidotti, G Visani, S Capitani, G Zauli
Blood 2001
Expression of tumor necrosis factor–related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis
DY Zang, RG Goodwin, MR Loken, E Bryant, HJ Deeg
Blood 2001
CD99 Signals Caspase-Independent T Cell Death
RD Pettersen, G Bernard, MK Olafsen, M Pourtein, SO Lie
Journal of immunology (Baltimore, Md. : 1950) 2001
Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view
AD Schimmer, DW Hedley, LZ Penn, MD Minden
Blood 2001
Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)–mediated cytotoxicity by selective up-regulation of TRAIL-R1
RD Pietro, P Secchiero, R Rana, D Gibellini, G Visani, K Bemis, L Zamai, S Miscia, G Zauli
Blood 2001
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
CS Mitsiades, SP Treon, N Mitsiades, Y Shima, P Richardson, R Schlossman, T Hideshima, KC Anderson
Blood 2001
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
D Hanahan, G Bergers, E Bergsland
Journal of Clinical Investigation 2000
Apoptosis
S Afford, S Randhawa
Molecular pathology : MP 2000
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression
K Song, Y Chen, R Göke, A Wilmen, C Seidel, A Göke, B Hilliard, Y Chen
Journal of Experimental Medicine 2000
Functional analysis of tumour necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine
D Trabzuni, KS Famulski, M Ahmad
Biochemical Journal 2000
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
AM Chinnaiyan, U Prasad, S Shankar, DA Hamstra, M Shanaiah, TL Chenevert, BD Ross, A Rehemtulla
Proceedings of the National Academy of Sciences 2000
Genomic Organization and Transcriptional Regulation of Human Apo2/TRAIL Gene
B Gong, A Almasan
Biochemical and Biophysical Research Communications 2000
Significance of Fas Protein in Squamous Cell Carcinoma of the Larynx
Y Bayazit
Acta Oto-laryngologica 2000
FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2
MR Sprick, MA Weigand, E Rieser, CT Rauch, P Juo, J Blenis, PH Krammer, H Walczak
Immunity 2000
Isolation and Molecular Characterization of the 5′-Upstream Region of the Human TRAIL Gene
Q Wang, Y Ji, X Wang, BM Evers
Biochemical and Biophysical Research Communications 2000
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
FC Kischkel, DA Lawrence, A Chuntharapai, P Schow, KJ Kim, A Ashkenazi
Immunity 2000
T cell life and death signalling via TNF-receptor family members
G Screaton, XN Xu
Current Opinion in Immunology 2000
Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer
HS Ryu, KH Chang, SJ Chang, MS Kim, HJ Joo, KS Oh
International Journal of Gynecological Cancer 2000
Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis
S Hopkins-Donaldson, JL Bodmer, KB Bourloud, CB Brognara, J Tschopp, N Gross
Medical and Pediatric Oncology 2000
NF-?B kinetics predetermine TNF-? sensitivity of colorectal cancer cells
RM Zwacka, L Stark, MG Dunlop
The Journal of Gene Medicine 2000
Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells
K Clodi, D Wimmer, Y Li, R Goodwin, U Jaeger, G Mann, H Gadner, A Younes
British Journal of Haematology 2000
Pro-apoptotic treatment with an adenovirus encodingBax enhances the effect of chemotherapy in ovarian cancer
J Xiang, J G�mez-Navarro, W Arafat, B Liu, SD Barker, RD Alvarez, GP Siegal, DT Curiel
The Journal of Gene Medicine 2000
Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)
FV Valen, S Fulda, B Truckenbrod, V Eckervogt, J Sonnemann, A Hillmann, R Rödl, C Hoffmann, W Winkelmann, L Schäfer, B Dockhorn-Dworniczak, T Wessel, J Boos, KM Debatin, H Jürgens
International Journal of Cancer 2000
The Complexity of TNF-Related Apoptosis-Inducing Ligand
K Abe, A Kurakin, M Mohseni-Maybodi, B Kay, R Khosravi-Far
Annals of the New York Academy of Sciences 2000
Predicting human safety: screening and computational approaches
DE Johnson, GH Wolfgang
Drug Discovery Today 2000
Apoptosis in cancer: cause and cure
SH Kaufmann, GJ Gores
BioEssays 2000
Don't blaze the trailblazer TRAIL too early
EG Vries, WT der Graaf, FJ Heijenbrok, HJ Hoekstra, S Jong
The Lancet 2000
Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines
MM Keane, Y Rubinstein, M Cuello, SA Ettenberg, P Banerjee, MM Nau, S Lipkowitz
Breast Cancer Research and Treatment 2000
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression
K Song, Y Chen, R Goke, A Wilmen, C Seidel, A Goke, B Hilliard, Y Chen
Journal of Experimental Medicine 2000
Intracellular Mechanisms of TRAIL and Its Role in Cancer Therapy
RK Srivastava
Molecular Cell Biology Research Communications 2000
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems
H Walczak, PH Krammer
Experimental Cell Research 2000
Induction of Apoptosis in Glioma Cells by Recombinant Human Fas Ligand
S Kawaguchi, T Mineta, M Ichinose, J Masuoka, T Shiraishi, K Tabuchi
Neurosurgery 2000
Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL
JL Bodmer, P Meier, J Tschopp, P Schneider
The Journal of biological chemistry 2000
Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity
SS Cha, BJ Sung, YA Kim, YL Song, HJ Kim, S Kim, MS Lee, BH Oh
The Journal of biological chemistry 2000
The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation
F Mühlenbeck, P Schneider, JL Bodmer, R Schwenzer, A Hauser, G Schubert, P Scheurich, D Moosmayer, J Tschopp, H Wajant
The Journal of biological chemistry 2000
Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
M Déjosez, U Ramp, C Mahotka, A Krieg, H Walczak, HE Gabbert, CD Gerharz
Cell Death and Differentiation 2000
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis
S Hinz, A Trauzold, L Boenicke, C Sandberg, S Beckmann, E Bayer, H Walczak, H Kalthoff, H Ungefroren
Oncogene 2000
Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression
MA Grotzer, A Eggert, TJ Zuzak, AJ Janss, S Marwaha, BR Wiewrodt, N Ikegaki, GM Brodeur, PC Phillips
Oncogene 2000
Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells
SY Sun, P Yue, R Lotan
Oncogene 2000
Steering anti-cancer drugs away from the TRAIL
S Nagata
Nature Medicine 2000
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-relatedapoptosis-inducing ligand
M Jo, TH Kim, DW Seol, JE Esplen, K Dorko, TR Billiar, SC Strom
Nature Medicine 2000
Expression and Antitumor Effects of TRAIL in Human Cholangiocarcinoma
S Tanaka, K Sugimachi, K Shirabe, M Shimada, JR Wands, K Sugimachi
Hepatology 2000
From bench to clinic with apoptosis-based therapeutic agents
DW Nicholson
Nature 2000
Programmed cell death regulation: basic mechanisms and therapeutic opportunities
DE Johnson
Leukemia 2000
Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies
E Solary, N Droin, A Bettaieb, L Corcos, MT Dimanche-Boitrel, C Garrido
Leukemia 2000
Chirurgisches Forum 2000 für experimentelle und klinische Forschung
A Encke, M Rothmund, W Hartel, HG Beger
2000
The Death Domain Kinase RIP Is Essential for TRAIL (Apo2L)-Induced Activation of IκB Kinase and c-Jun N-Terminal Kinase
Y Lin, A Devin, A Cook, MM Keane, M Kelliher, S Lipkowitz, Z Liu
Molecular and cellular biology 2000
A Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL
SG Hymowitz, MP O'Connell, MH Ultsch, A Hurst, K Totpal, A Ashkenazi, AM de Vos, RF Kelley
Biochemistry 2000
Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis
TS Griffith, RD Anderson, BL Davidson, RD Williams, TL Ratliff
Journal of immunology (Baltimore, Md. : 1950) 2000
TNF-Related Apoptosis-Inducing Ligand-Induced Apoptosis of Melanoma Is Associated with Changes in Mitochondrial Membrane Potential and Perinuclear Clustering of Mitochondria
WD Thomas, XD Zhang, AV Franco, T Nguyen, P Hersey
Journal of immunology (Baltimore, Md. : 1950) 2000
Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of Neurotoxicity
W Roth, S Isenmann, U Naumann, S Kügler, M Bähr, J Dichgans, A Ashkenazi, M Weller
Biochemical and Biophysical Research Communications 1999
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5
SG Hymowitz, HW Christinger, G Fuh, M Ultsch, M O'Connell, RF Kelley, A Ashkenazi, AM de Vos
Molecular Cell 1999
Cytokines and Cancer
E Tartour, WH Fridman
International Reviews of Immunology 1998

← Previous 1 2 3 … 68 69 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 58 patents
387 readers on Mendeley
See more details